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A randomised clinical trial sought evidence as to whether leucocyte depleting arterial line 
filters had any effect on intra- operative cerebral microemboli and post- operative 
neuropsychological outcome in non emergency patients undergoing coronary artery 
bypass (CABG) surgery. 
Methods 
One hundred and ninety -two patients were randomised to the use of a Pall LG -6 
leucocyte depleting (test) filter or either an Avecor Affinity or Pall AV -6 control filter. 
Cerebral microemboli during surgery were recorded by transcranial Doppler monitor 
over the right middle cerebral artery. Evidence of cerebral impairment was obtained by 
comparing patients' performance in a neuropsychological test battery (9 tests) 
administered 6 -8 weeks post -operatively with their pre -operative scores. 
Results 
The groups proved well balanced in pre- operative variables. During cardiopulmonary 
bypass the median number and range of microemboli was 15 (3 -180) in the leucocyte 
depleting group compared to 67 (5 -846) and 55 (2 -773) for the Avecor and AV6 groups 
respectively (p <0.0001). One hundred and sixty -one patients completed all the 
neuropsychological tests. The leucocyte depleting group showed better post- operative 
performance in all but one of the nine tests although the difference in a total change score 
did not reach significance (p = 0.07, 1 tailed t test). 
Conclusion 
Leucocyte depleting filtration during CABG reduced the number of cerebral microemboli 
recorded by transcranial Doppler and showed a strong trend towards improving 
neuropsychological performance post -operatively. These findings suggest that the use of 
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Cardiac surgery accompanied by cardiopulmonary bypass (CPB) may in some patients result 
in a global cerebral injury manifest as a decline in post- operative neuropsychological (NP) 
performance. This decline is defined as an impairment of concentration, memory, learning or 
the speed of mental and visuomotor responses (although not necessarily all of these). NP 
testing is currently the best method of assessing global cerebral injury, although a clear 
relationship has not been established between decline on NP testing and everyday 
functioning and quality of life. One report suggests that there is impaired driving 
performance as well as cognitive impairment after CABG surgery'. It is important to 
distinguish diffuse cerebral injury resulting in NP deficits from a gross cerebral injury 
resulting in stroke. These separate phenomena probably have differing aetiologies. The 
incidence of strokes is reported as between 1.5 and 5.2 %2 but NP deficits are far commoner 
with incidences of between 15% and 80 %3 reported in the literature. With improvements in 
techniques to protect the brain, NP outcome has improved and is now accepted to occur in 
about 20% of cases. The incidence of such deficits is found to vary according to the 
methods and timing of measurement used in each study. Significantly, these deficits are not 
always a temporary problem but have been shown to persist in studies up to five years post 
surgery5. Although any resulting disability must be seen in the context of the overall benefits 
of cardiac surgery, there is certainly much scope for improvement. 
A considerable number of investigations have attempted to elucidate the causes of post- 
operative neuropsychological deficits, yet most theories for causes and mechanisms of 
cerebral injury remain unproven. Much of the literature suggests that CPB is the principal 
cause. However, cardiac surgical patients are inherently prone to neurological and 
neuropsychological insult6 and factors other than CPB, such as surgical trauma or 
anaesthesia, may be involved to a greater extent than is realised. Several recent studies 
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suggest that cerebral injury as measured by NP deterioration is similar in cardiac surgical 
patients whether they receive an operation with or without CPB6'7. Despite this, most 
evidence continues to implicate CPB and this thesis focuses on the cerebral injury associated 
with cardiac surgery and CPB. There are currently three inter -related causal theories of 
cardiopulmonary bypass induced global cerebral injury. These are altered cerebral perfusion, 
microembolism and the systemic inflammatory response4. Neutrophils have a pivotal role in 
the inflammatory response to bypass and may have a role in microemboli production. 
Despite a large body of evidence for this systemic inflammatory response, there are few 
studies of its relation to cerebral injury and so any link between the two is, at present, mainly 
speculative. 
The improvement in NP outcome seen in recent years results from a number of refinements 
in anaesthetic, perfusion and surgical practice3. The conventional arterial line filter has made 
an important contribution to this improvement. Most commonly used is the 401,t,m screen 
arterial line filter which is positioned in the tubing returning blood from the CPB machine to 
the patient with the aim of filtering out potentially harmful bubbles or particulate debris. 
This filter has been shown conclusively to simultaneously reduce the number of 
microembolic events and reduce NP deficit6°8. In addition to this "conventional" filter, a 
leucocyte- depleting (LD) filter has more recently been designed for clinical use. This LD 
filter consists of a screen filter with an additional polyester mesh, which has the ability to 
trap leucocytes. It is claimed that this LD filter attenuates the inflammatory response and 
may reduce CPB induced cardiopulmonary damage. However any effect of the LD filter on 
microemboli has not been studied. There are therefore two possible ways in which the LD 
filter could modulate cerebral injury and NP outcome: via the inflammatory response and 
microemboli. The aim of this thesis is to investigate the effects of using a LD arterial line 
filter during CPB on neuropsychological outcome as the primary endpoint. Microemboli and 
13 
the inflammatory response are secondary and potentially mediating outcomes. 
Original Hypothesis 
The null hypotheses tested were: - 
1) There will be no significant difference in the neuropsychological outcome when 
leucocyte -depleting filters are used. 
2) There will be no significant difference in the microemboli count or inflammatory response 
when leucocyte -depleting filters are used. 
Brief Outline of Methods Used 
The study was a prospective, randomised, controlled clinical trial conducted in the 
Department of Cardiothoracic Surgery at University College London Hospitals (Middlesex 
Hospital). Following local ethics committee approval selected patients scheduled for non 
emergency coronary artery bypass surgery were invited to participate. If patients consented 
they were randomised into two groups to either receive conventional or leucocyte depleting 
arterial line filtration. Other anaesthetic, perfusion and surgical variables were standardised. 
Patients received a pre- operative and post- operative neuropsychological assessment, 
measurement of inflammatory markers peri- operatively and intra- operative measurements of 
microemboli counts in the middle cerebral artery. 
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Review of the Relevant Literature 
The first six chapters of this thesis consist of a review of the relevant current literature. The 
specific areas discussed are: - 
1) The assessment of neuropsychological function after cardiac surgery 
2) Interventions which affect neuropsychological outcome following cardiac surgery 
3) Mechanisms of cerebral injury during cardiac surgery 
4) The role of neutrophils in the inflammatory response to cardiopulmonary bypass 
5) The use of conventional and leucocyte depleting arterial line filters to reduce CPB induced 
injury 
6) The role of S100b as a marker in cardiac surgery 
15 
Chapter 1 
The assessment of neuropsychological function 
after cardiac surgery 
16 
1.1 Historical Note 
The concept of brain injury has been a concern ever since cardiac surgery was first attempted by 
Souttar in 19259. Describing closed digital mitral valvotomy, Souttar wrote "In view of the 
extreme danger to the brain from even the shortest check to its blood supply, any manipulations 
which are carried out must therefore be executed in the full flow of the bloodstream, and they 
must not perceptibly interfere with the contractions of the heart ". However it is only since 
cardiac surgery became an extremely common and safer procedure10 in the 1970s that attention 
was able to shift from mortality rates to more subtle measures of outcome such as 
neuropsychological (NP) function. This chapter describes the development of NP testing. 
explains how it is best carried out, summarises the main findings relating to cardiac surgery and 
discusses some of the complex methodological issues involved. 
1.2 Methods of Testing 
In a clinical setting a psychologist conducts the standard clinical NP assessment of an individual 
patient over one or two test periods totalling between about two and five hours. The patient is 
given a comprehensive battery of up to 25 standardised tests with the aim of identifying and 
localising a brain lesion, assessing the degree of cognitive disturbance in patients with known 
brain lesions or in order to distinguish between neurological and psychiatric symptomsTM. The NP 
assessment of outcome following cardiac surgery differs from this standard assessment in several 
ways. 
Firstly, assessments must be performed both prior to and then following surgery, rather than the 
single assessment thus enabling comparisons to be made between the patients own baseline score 
pre- operatively to post- operative performance. The purpose is to measure change in 
performance over time. Time constraints only allow about one hour for each of the pre -operative 
and post- operative tests. Therefore, in order to perform as many tests as possible and so be as 
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comprehensive as possible in testing different cognitive domains, relatively short tests must be 
selected. Investigators have used between 1 and 14 tests in various studies. The fact that the test 
will be repeated shortly afterwards demands that the test should have a minimal learning effect. 
Parallel forms of the same test may be used to reduce learning effects. If the tests were too easily 
learnt this would decrease the sensitivity of post- operative testing. Some degree of learning is 
inevitable with most tests and it is expected that the majority of patients without impairment will 
show an improvement in neuropsychological test performance post -operatively. As learning is 
inevitable, it is best taken into account using Z change scores (see later). It can therefore be seen 
that the battery of tests one uses to assess patients before and after cardiac surgery is a 
compromise between wishing to be as comprehensive as possible while completing testing in 
about one hour. This one hour limit is arbitrary but considered practical and reasonable for 
patients awaiting surgery. 
The early incidence studies were designed to assess what affect cardiac surgery had on cognitive 
function. These early studies used a single group assessed on at least two separate occasions. 
This work established that a proportion of patients do show a post- operative neuropsychological 
decline but the incidence varied widely. While it has been suggested that such a variety of 
results could be due to an inherent problem of neuropsychological testing, the variability is no 
greater than that reported for post- operative strokes''- a related problem which is often perceived 
as a more reliable outcome measure as it has overt clinical signs and consequences. It is worth 
considering the reasons for variability between results of these incidence studies. The factors that 
will affect results are test, patient, study design and data analysis variables. 
1.3 Test Variables 
As has already been mentioned, NP testing in cardiac surgery is a compromise between being 
exhaustive in assessing cognition and being able to perform the tests in the time available. The 
18 
more tests that are used, the greater will be the probability of detecting a lesion because more 
domains are being tested. However the potential problem of using too many tests is that some 
may test the same domain and result in a deficit appearing worse than it actually is. The 
sensitivity of the tests used in neuropsychology test batteries has improved as the study of NP 
outcome has been refined. The early studies used intelligence tests or tests such as the Mini 
Mental State Exam. Although these are highly reliable they are relatively insensitive13 and a 
number of tests have now been specifically chosen for use in cardiac surgery'`'. 
The way in which tests are administered is highly important but it is rarely mentioned in 
publications. To ensure reliability of assessments it is preferable that the same psychologist does 
the pre- surgery and post- surgery tests in the same environment. Factors such as noise and 
lighting may have effects upon test results. Also it is important that the patient can practise tests 
and so be fully aware of what is expected with each test and perform to the best of his /her ability. 
1.4 Patient Variables 
In addition to these test variables there are also a number of patient variables that could explain 
the difference in incidence between studies. There is considerable evidence that age is 
associated with NP outcome following cardiac surgery. Older patients have a worse outcome's -18 
This may be because more microemboli are produced in older patients19 or because cerebral 
blood flow autoregulation on CPB is impaired in the elderly15. This will be discussed further in 
chapter 2. Therefore the age of study populations is significant when comparing studies from 
different centres and also over time because the average age of the cardiac surgical patient has 
risen over the last twenty years. 
Gender of patients may also be an issue. As CABG is much commoner in males, many studies 
have only had male participants but there is some evidence that women have a worse outcome. A 
relatively old study from 1981 involving forty nine valve replacement patients found that women 
had a poorer neuropsychological outcome20. A more recent study'' also suggests that women 
have a worse neuropsychological outcome after cardiac surgery. Di Carlo et al`'' studied 110 
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patients, 30% of whom were female, having any type of cardiac surgery requiring 
cardiopulmonary bypass. Di Carlo et al did not use the standard battery of NP tests14 which limits 
the validity of their results. However they found that female sex significantly predicted a greater 
cognitive decline six months after surgery. 
The separate issue of whether valve replacement heart surgery (true "open heart" surgery 
because the heart chambers are opened) carries a greater risk of neuropsychological impairment 
remains unresolved. In a relatively small study, Braekken et aí22 in 1998 compared 26 patients 
having valve replacement to 14 patients undergoing CABG. No difference in 
neuropsychological outcome was found between the two groups at two months after surgery. 
Braekken did however find that in valve replacement patients, those with deficits had higher 
microemboli counts whereas this relationship was not seen in the CABG group. Neville at al 
(2001)73 compared 193 patients undergoing CABG to 73 matched patients having valve 
replacement surgery. They measured neuropsychological performance with a standard battery of 
eleven tests and found no difference in outcome at five to seven days, one month and six months 
post surgery. This lack of difference in neuropsychological outcome was interesting as there was 
a significantly higher number of microemboli in the valve replacement group. On the other hand, 
Zimpfer et al (2002)24 compared 30 patients having CABG with 30 age and sex matched 
patients having isolated tissue aortic valve surgery. A reduction in auditory evoked P300 
potentials possibly indicating greater impairment was seen at 7 days and 4 months post surgery 
in the valve group compared to the CABG group. However the significance of these auditory 
evoked potentials in such a population is unknown and this limits the significance of this result. 
Zimpfer did not measure microemboli. Therefore although it is a consistent finding that there is 
a greater number of detectable cerebral microemboli during valve surgery compared to CABG 
surgery, there is no clear consensus as to whether this leads to worse neuropsychological 
outcome in the valve patients. The potential role of microemboli in causing NP deterioration 
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after CABG surgery is discussed later in Chapters 2 and 3. 
Atrial fibrillation (AF) is another patient factor which has received recent attention. AF is very 
common after cardiac surgery, occurring in up to 20 to 40% of cases25 and leads to ineffective 
beating of the atria. There is a well- recognised association between post- operative AF and 
strokes or transient ischaemic attacks26. In addition there is one study which has suggested that 
AF may be associated with a worse early post- operative neuropsychological decline. Stanley et 
al (2002)27 prospectively observed 411 patients having elective CABG of whom 69 developed 
AF. Multivariate analysis controlling for age and other potential determinants of 
neuropsychological outcome showed that those patients with AF had a greater cognitive decline 
than those without AF. 
There is a theory that suggests that patients with a higher intelligence should be less susceptible 
to the insult of cardiac surgery (the cognitive reserve theory) but there is no evidence of an 
association of intelligence with NP outcome. There is, however evidence that higher levels of 
education may protect against NP decline15. A recent study5 examined NP function five years 
after surgery and found that the main predictors of cognitive decline at five years were increased 
age, decreased level of education and the cognitive function at discharge. Genetic factors may 
also have a role in determining NP outcome. One study by Tardiff et aí28 has shown an 
association between apolipoprotein E e -4 and NP decline. Tardiff et al found that in a relatively 
small group of 65 patients there was a higher level of cognitive deterioration post surgery in 
those patients who possessed the e4 allele. They also found that higher levels of education 
protected against cognitive decline in all patients and that this effect was more marked in those 
with the e4 allele. It is postulated that patients with this genotype may have impaired neuronal 
repair and maintenance because patients with the e4 allele also recover more slowly after closed 
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head injury or stroke. However, a more recent study by Steed at aí29 replicated Tardiff's study 
with a greater number of patients (n =111) and found that there was no association between 
cognitive decline and the presence or absence of apolipoprotein e4. The influence of this 
particular genetic factor therefore remains unresolved. Another genetic factor recently studied is 
polymorphism of the gene for the platelet glycoprotein 3a (GPIIIa) receptor. Polymorphism of 
this gene may affect thrombogenicity and risk for cerebrovascular thrombosis but this is, at 
present, controversial. Mathew et a130 have shown that presence of the PA2 allele is associated 
with significantly greater early neurocognitive decline. However their study group consisted of 
only 70 patients and they only used a single NP test (the Mini Mental State Exam which, as 
mentioned, is relatively insensitive to change) at 4 days post surgery. The extent of the patients' 
cardiac and atherosclerotic disease may have a direct effect upon their neuropsychological 
outcome. For example, Hammon et aí31 found that the presence of a palpable aortic plaque was 
significantly associated with the incidence of new neuropsychological deficits. M. Newman et 
aí15 also found that severity of atherosclerotic disease of the aorta was associated with cognitive 
decline. Patients' pre- operative medications may also be important although, as far as the author 
is aware, there has been no study of the effect of medication on post- operative 
neuropsychological outcome. 
Another patient factor which has been shown to affect NP outcome is endotoxin immunity. 
During cardiac surgery most patients are exposed to endotoxin32 which is the lipopolysaccharide 
component of the cell wall of Gram negative bacteria. The origin of endotoxin is unclear but 
thought to arise from the translocation of bacteria across ischaemic gut mucosa33. Mathew at aí34 
have recently found that patients with low anti -endotoxin core antibody were more likely to 
suffer from post- operative cognitive dysfunction. 
Patients with severe cardiac disease have been shown to have a NP impairment before surgery 
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compared to age matched controls without cardiac disease35. Also, CABG patients have been 
shown to have MRl abnormalities suggestive of cerebrovascular disease pre -operatively. This 
then raises the issue of whether patients with cardiac disease are more at risk of cognitive 
decline after surgery because of their inherent disease rather than due to the surgery itself. 
(Conversely, a low pre - surgery NP performance could actually mask a further decline due to the 
statistical phenomenon of regression towards the mean; this issue is discussed later.) Finding 
suitable non -surgical controls to compare neuropsychological outcome is problematic. Seines et 
aí36 compared 140 patients having CABG with 92 matched patients with coronary artery disease 
not having CABG. Both groups had baseline then 3 and 12 month NP testing. There were no 
differences between the groups at 12 months. However this was not a randomised study (it 
would be difficult to withhold CABG from half a study group) and it is not clear why the control 
group, if they were so well matched were not suitable for CABG surgery. 
1.5 Study Design 
Moving on from patient factors to issues of study design, there is the possibility that selective 
recruitment of patients may lead to the study population being unrepresentative of the general 
cardiac surgery population. Even if one aims to be as inclusive as is practical, a proportion of 
patients will inevitably decline consent to be studied leading to a possible sampling error. 
Borowicz et al3 report a refusal rate of 61% and in the refusal group they found the stroke and 
mortality rate was 7.1% and 6.1% respectively compared to 2.8% and 1.1% in the consenting 
group. Although strokes and mortality are a different entity to neuropsychological decline this 
study by Borowicz illustrates the potential difference in the studied and non -studied populations. 
Apart from this consent example, researchers may deliberately select more healthy patients for 
their trial. The study for this thesis has deliberately not recruited patients over the age of 80 or 
patients with insulin -dependent diabetes. Both these factors increase the risk of NP deficit and 
have the potential to confound results. Another practical reason for not including such patients is 
the increased risk of complications which would make post- operative follow up and assessment 
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more difficult and reduce the number of patients able to be studied in a given time. 
Selective attrition at follow up may also alter the reported incidence of NP deterioration after 
cardiac surgery. Patients who suffer a severe deterioration may become unable or may be 
unwilling to attend follow up and so lead to an underestimate of the incidence of deterioration. 
Borowicz found that patients who performed badly on the pre- operative baseline test were less 
likely to attend follow up assessment3. He also found that those who deteriorated more at l 
month were less likely to attend at 1 year. However, follow up data at the institution of this 
study does not support this37. 
The timing of NP assessment both pre- and post -operatively may have a considerable affect on 
performance. Patients who are tested pre- operatively, especially if it is on the day prior to 
surgery are frequently anxious. Although there is little evidence that anxiety depresses 
performance, it has become conventional to assess anxiety and depression contemporaneously to 
the NP assessment14. A study at UCLH38 has found that patients are less anxious the day before 
surgery than they are a week before surgery but that this difference in anxiety did not alter the 
NP performance. 
After surgery, the timing of testing undoubtedly influences the incidence of NP deterioration 
found. Higher NP deficit rates are reported in the first few days after surgery. However the 
lower incidence at longer term follow up shows that some of the deterioration found immediately 
post- operatively is of a temporary nature. In the first few days the patients' pain, tiredness or 
anaesthetic or analgesic drugs are likely to cloud the NP tests. A recent consensus decided that 
the ideal timing of the post op assessment would be at 3 months when any detected deficit would 
be a true, permanent deficit14. However many workers see their patients at 6 to 8 weeks post - 
surgery in order to coincide with the return of the patient for outpatient surgical review. There is 
some evidence that the early cognitive decline found at discharge seems to predict the late 
cognitive decline found at five years37. Any causal link, however, remains unproven and it could 
simply be that those patients who decline most in the early days of the post- operative period are 
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more susceptible to cerebral injury and so are the ones who will decline more with age, anyway. 
Whatever the validity of tests in the first few days after surgery, the fact remains that doing NP 
assessment so early after surgery is also practically difficult and may be distressing for the 
patient. 
1.6 Methods of Analysis 
In addition to patient factors and study design, the statistical analysis of NP data may have a 
significant influence on the incidence of neuropsychological deficit found. Methods of analysis 
have evolved in an effort to be more sensitive but there is no universally accepted method. Some 
investigators have been criticised for using as many methods as possible to analyse their results 
and then presenting the method which yields the most significant result. It is therefore important 
to define the type of analysis to be used when designing a trial and deciding on sample numbers. 
One has to choose a method of analysis to use before starting a trial and then keep to this plan. 
The earlier, descriptive studies, which involved a single group of patients undergoing cardiac 
surgery, examined NP change from before to after surgery. The change in performance was 
analysed as group comparison or individual comparison. Group comparison consists of pooling 
data and determining whether the group as a whole has altered its performance. In order to 
detect a deficit the mean of the group has to drop significantly. This makes the assumption that 
most patients will experience a deficit, but in fact only a minority of patients are likely to. Also 
it takes no account of the potential learning effect of the tests. The patients who improve through 
learning may mask the patients who deteriorate. This type of analysis therefore has flaws. 
Probably superior for single group studies are individual comparisons which examine individual 
changes with each patient acting as his own control. The main problem that then arises is how to 
define what extent of neuropsychological deterioration constitutes a deficit. There is still no 
consensus as to what constitutes a deficit. However most researchers accept that deterioration on 
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at least two tests is required as a poor performance on only one test may simply reflect a lapse in 
performance. (Although it may also mean that only one cognitive domain has been affected). A 
deficit has usually been defined in standard deviation (SD) terms with most investigators 
classifying a deficit as a drop in one or more SDs from the pre- operative to post- operative 
levels. The SD may be a population SD when standardised tests are used or it may be calculated 
from the pre- operative performance in an attempt to establish a notional standard score for the 
group being examined. However this method may become insensitive because it applies a fixed 
amount of deterioration to all individuals regardless of their absolute levels. Another similar 
approach is to take a drop in 20% in a test performance to reflect a significant deterioration. This 
therefore overcomes the problem by taking a proportional drop in performance to define a 
deficit. 
When interventional studies are analysed, there are again a number of approaches. In these 
studies, there are two or more groups having cardiac surgery with or without a particular 
intervention. There are now several ways in which group comparisons can be performed in 
interventional studies. As with the descriptive studies, the use of group means is best avoided. 
One alternative method, the individual incidence approach, used by Pugsley8, and described by 
Newman39 enables a comparison to be made between the groups in terms of the number of 
individuals showing a deficit. A standard deviation (SD) unit is first calculated from all the 
patients' pre- operative scores. One then calculates the change in score for each patient for each 
test. In an identical manner to the methods of descriptive studies, a deficit in a test is said to 
occur when the patient's individual score in a test decreases by more than one SD from their 
preoperative score. A patient has a significant deficit if this occurs in 2 or more tests. One then 
compares the incidence of deficits between two or more groups. This conventional definition was 
widely applied in research until a few years ago when some drawbacks became apparent. In 
addition to the problem of arbitrarily defining a deficit, as explained above, it has also become 
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less sensitive. This method classifies a patient in a binary fashion as either having a deficit or 
not having a deficit with no intervening scale. Sensitivity is therefore reduced when analysing by 
incidence of deficits. As the incidence of NP deficits has declined with improvements in surgical 
and perfusion and anaesthesia practice, the lack of sensitivity has become more apparent. 
Another criticism of the incidence of deficits method is the phenomenon of "regression towards 
the mean ". Regression towards the mean is the statistical observation of a biological 
phenomenon whereby extreme baseline scores tend to become less extreme on repeated testing. 
In the case of NP testing before and after cardiac surgery it has been argued that those with 
higher preoperative scores are more likely to regress towards the mean and show an apparent, 
although not real, deterioration40. Conversely, those with low scores pre -operatively would 
improve in a similarly spurious way if they regressed towards the mean. However this 
theoretical argument can be refuted by the facts observed after cardiac surgery which are the 
exact opposite: those patients with better pre -operative NP scores tend to deteriorate less41 
More recently Arrowsmith et al29,42 -44 have introduced "Z ", or "change" scores and these are now 
becoming an additional accepted way of analysing NP data with greater sensitivity. To calculate 
a Z score each patients' test score on each occasion is converted into a standardised score by 
dividing by the SD of the pre- operative group performance of all patients in a study. A change 
score is then calculated for each patient by subtracting the post- operative standardised score from 
the pre- operative standardised score. One can then calculate a mean of the change scores for 
each group. This method is more sensitive because it is a continuous change score without 
absolute cut -offs. It also allows group comparisons which take into account potential learning 
effects. Since Z scores have only recently been introduced, it is a more sensible approach to 
analyse NP results using deficit scores as well as Z scores. This has the advantage of making it 
possible to compare incidence of deficits to previous studies. 
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In summary, this chapter has shown how NP testing has been adapted from a single clinical 
assessment to repeated testing to measure change in NP performance from before to after cardiac 
surgery. Analysis has evolved from comparing pre- operative and post- operative means, via 
measuring incidence of individual deficits, to the use of Z change scores. The wide range of 
incidence of NP deficits reported in the literature can be accounted for by the variation in the 
way the tests are conducted, patient variables such as age, atrial fibrillation, endotoxin immunity 
and aortic atherosclerosis. Study design may also impact on the incidence of NP deficits found. 
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Chapter 2 
Interventions which affect neuropuc iolog call 
outcome after cardiac sur 
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2.1 Types of Intervention 
Having already reviewed the inherent patient risk factors such as age and genetic 
susceptibility, this section will review studies which have investigated various interventions 
to reduce NP deterioration after cardiac surgery. These interventions include filters, drugs 
(anti- inflammatory or neuroprotective), pH control and temperature control during bypass, 
surgery with and without CPB and other surgical techniques. Filtration will be discussed in 
most detail in Chapter 3. Only studies that have directly measured NP outcome will be 
discussed in this section. Other studies have used various interventions and then measured 
microemboli or surrogate markers of NP outcome such as S100b. Since the relationship of 
S100b or microemboli to NP outcome is complicated, these studies are discussed separately 
in later sections on S100b (Chapter 6) and microemboli (Chapter 3.3). 
One can separate interventions into pharmacological and physical but there is an important 
theoretical consideration which distinguishes the two main types of intervention used to 
reduce cerebral injury. Agents such as arterial line filters or anti -inflammatory drugs act on 
specific postulated mechanisms of damage (i.e. microemboli and the inflammatory 
response). The other group includes agents such as hypothermia and neuroprotective drugs. 
They do not attempt to prevent or attenuate the agents and mechanisms of damage but they 
are designed to protect the brain against any type of injury. 
There are good data from randomised controlled trials (RCTs) suggesting that conventional 
401,tm arterial line filtration and the use of alpha stat rather than pH stat acid base control 
reduces the incidence of cognitive decline, and the more widespread use of these 
interventions may have already contributed to the general reduction in decline seen in recent 
years. The data regarding other interventions such as temperature control, anti -inflammatory 
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agents, reducing aortic manipulations or avoiding CPB altogether are less clear and there are 
as yet no results from randomised trials to guide practice regarding these issues. However, 
this lack of data has not prevented strong recommendations regarding certain surgical 
practices. For example recent reviews have advocated avoiding repeated aortic cross 
clamping45 or using aprotinin46 when the evidence supporting such practices is not 
conclusive. Apart from remacemide42 (an NMDA [N- methyl -D- aspartate] receptor 
antagonist), no drugs have been shown to have significant beneficial effects although some 
such as aprotinin have shown promise. This part of the review examines the current evidence 
for three main types of intervention to reduce the neuropsychological deficits seen after 
cardiac surgery. These are equipment (surgical and perfusion), drugs, and techniques 
(surgical and perfusion). 
2.2 Filters 
Arterial line filters have gained in popularity, especially in the USA, due to their ability to 
remove microemboli and also large air emboli in the event of a perfusion accident4'. Their 
use has not been as great in the UK. Filters however have an important role in 
neuroprotection and are discussed more fully in Chapter 3. 
2.3 Oxygenators and Type of Bypass Pump 
Because membrane oxygenators produce less microemboli detected by transcranial Doppler 
(TCD) than bubble oxygenators48, their almost universal use in current practice is likely to 
have a beneficial effect on neuropsychological outcome. There is one study which suggests 
that there is less neurocognitive decline when membrane oxygenators are compared to 
bubble oxygenators49. A randomised controlled trial of 103 patients has also found no 
difference in early (5 day) NP outcome when roller or centrifugal bypass pumps are used5o 
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2.4 Pharmacological 
There is an ongoing search for an effective neuroprotective drug for use in cardiac surgery. 
Surgery may be the ideal time to test such a drug because the injury is anticipated and 
treatment can be prophylactic. Two commonly used anaesthetic drugs, propofol and 
thiopentone have been studied the most, and some anti -inflammatory drugs may have a 
neuroprotective effect. 
Nussmeir et al51 first reported neuroprotective effects of thiopentone. They studied 182 
patients having true open -heart surgery and randomised patients to receive either a 
thiopentone infusion during bypass or fentanyl. The dose of thiopentone was sufficient to 
maintain electroencephalographic silence throughout bypass. It was found that the 
thiopentone group had less "neuropsychiatric" (actual tests were neurological, psychiatric 
and the trailmaking tests) abnormalities at day 1 and day 10 post surgery. Unfortunately, 
longer -term effects were not studied. A later randomised trial52 of 300 coronary artery 
bypass surgery patients found no neuroprotective effect but delayed awakening and greater 
inotrope dependence in the thiopentone group. A recent retrospective review by Pascoe et al 
also found no benefit of thiopentone in open- chamber cardiac surgery53. The evidence is 
therefore on the whole not supportive of thiopentone having a useful neuroprotective effect. 
The evidence that propofol has a neuroprotective effect is equally unconvincing. Although 
propofol has physiological effects on the brain similar to thiopentone, reducing cerebral 
metabolic rate for oxygen (CMRO2) and cerebral blood flow and inducing 
electroencephalographic (EEG) burst suppression54, this does not seem to lead to clinically 
improved neurological or neuropsychological outcomes55. In a trial of 225 patients having 
valve surgery randomised to receive propofol or no propofol, NP outcome was the same at 5 
to 7 days and 3 months post operation in both test and control groups56. Interestingly, it has 
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been suggested that propofol may reduce microembolic delivery to the brain by reducing 
cerebral blood flow and that any cerebroprotective effect may be due to this mechanism 
rather than reduction in CMRO2. 
Calcium channel antagonists such as nimodipine have been shown to reduce ischaemic 
cerebral injury in animals by limiting the amount of ischaemia- induced calcium entry which 
precedes cell death. A small randomised study from 1990 of 35 patients having CABG or 
valve surgery suggested an improvement in certain neuropsychological tests at 6 months post 
surgery in the group given peri- operative nimodipine57. A later, larger, randomised study 
was halted prematurely when increased mortality and bleeding rates were found in the 
nimodipine group58. In the 150 patients randomised, no difference in neuropsychological 
outcome was found. 
Remacemide is an NMDA (N- methyl -D- aspartate) receptor antagonist which has been 
shown to reduce cerebral injury in animal models of focal ischaemia. Arrowsmith et al42 
tested its clinical effects in a RCT of 171 patients receiving CABG surgery using a battery of 
9 neuropsychological tests before and then 8 weeks after surgery. The group of patients who 
received remacemide had a significantly better global change (Z) score of 
neuropsychological function compared to the control group. This probably reflects an 
increased capacity for learning in the remacemide group who have received less cerebral 
injury and therefore provides evidence that remacemide is protective during cardiac surgery. 
Although, in contrast to previous studies of nimodipine or thiopentone, there were no serious 
adverse effects associated with remacemide, it should be noted that its use was associated 
with an increased frequency of dizziness, nausea and ataxia in the short term. 
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It has been known for about 20 years that cardiac surgery with CPB is associated with an 
abnormal systemic inflammatory response (see later). It is also likely that local 
inflammatory processes contribute to brain injury but it is extremely difficult to study this, at 
least in humans. Aprotinin is a non -specific serine protease inhibitor, used mainly to reduce 
peri- operative bleeding due to its anti -fibrinolytic effects. However, aprotinin's lack of 
specificity at inhibiting enzymes has also resulted in a number of other anti- inflammatory 
properties being discovered. As yet, there are no randomised trials assessing the effect of 
aprotinin on neuropsychological outcome. Retrospective analysis of data from trials 
investigating aprotinin's effects on other outcomes suggests that aprotinin may reduce stroke 
rate46 . Therefore while there is potential for aprotinin to be neuroprotective, this concept 
remains untested. 
Clomethiazole (also known as Heminevrin ) is the most recently tested potentially 
neuroprotective drug. It is more commonly used as a sedative to treat alcohol abusers. In a 
randomised controlled trial of 245 patients using a thorough pre- operative and post- operative 
battery of neuropsychological tests Kong et al43 found no improvement in 
neuropsychological outcome using clomethiazole. 
2.5 Acid base management 
The solubility of a gas in blood increases as the temperature falls. Therefore during 
hypothermic bypass, when blood gas samples are corrected for temperature the patient 
appears to have a respiratory alkalosis - a low PaCO2 and a high pH. It is possible to correct 
the pH to the normal range by increasing the PaCO2 and this method is known as pH stat 
control. Alternatively it can be left uncorrected and this is known as alpha stat control. 
There is evidence that alpha stat management leads to a better neurological and 
neuropsychological outcome. Bashein59 in 1990 found no difference in neuropsychological 
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outcome when either pH stat or alpha stat was used, but Stephan et a160 found in 65 patients 
that hypothermia with pH stat management was associated with marked cerebral hyperaemia 
and an increase in neurological events by day seven post surgery. This finding was 
supported by a later study of 316 patients by Murkin et aíó1 in 1995 which found that there 
was improved neuropsychological outcome at two months post surgery in a group 
randomised to receive alpha stat rather than pH stat. 
Patel et aí62 (1996) randomised 70 patients to receive pH stat or alpha stat control with both 
groups cooled to 28 °C. A significantly greater proportion of the pH stat patients showed 
deterioration in NP function at six weeks post surgery. Interestingly, Patel also measured 
cerebral blood flow and found that it was greater in the pH stat group as was cerebral artery 
blood flow velocity. Although there was hyperaemia, as measured by cerebral extraction 
ratio for oxygen, in both groups it was more pronounced in the pH stat group. This study 
therefore suggested that the pH stat control disrupted the normal cerebral autoregulation and 
that the increased blood flow was harmful. It is not known why the increased cerebral blood 
flow associated with pH stat control increases the risk of diffuse cerebral injury. It has been 
suggested that an increase in flow leads to an increase in the number of microemboli 
delivered to the brain. Patel et al did not measure microemboli in their study, but there is 
evidence from experimental animal studies that an increase in PaCO2 leads to both increased 
cerebral blood flow and microembolic delivery63. Studies in humans having valve 
replacement surgery do not however show this relationship64. An alternative explanation for 
increased cerebral blood flow being harmful is if the blood brain barrier becomes more leaky 
during CPB. An increased cerebral blood flow could then lead to more oedema. 
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2.6 Temperature 
The two main issues regarding temperature management and subsequent cognitive outcome 
are the degree of hypothermia at which bypass is conducted and then the rate and extent to 
which subsequent rewarming occurs. 
Hypothermia has been used as both a cardioprotective and a neuroprotective strategy 
throughout the history of cardiac surgery. More recently, normothermia and normothermic 
cardioplegia have been investigated as a means of myocardial protection, leading to concern 
regarding possible compromise of cerebral protection using this technique. The following 
studies that have investigated the effect of normothermic compared to hypothermic bypass 
on neurological and neuropsychological outcome reveal conflicting results. 
Singh et aí65 and also Mclean et aí66 found no difference in neurological outcome when 
normothermic or hypothermic bypass was used. In contrast Martin et aí67 found a marked 
increase in neurological events when normothermia was used. A criticism of all three of 
these studies is that the actual brain temperature was not measured. Depending on the bypass 
strategies used the actual brain temperature may be little different whether or not 
hypothermia is used. Also, it is possible that diffuse and focal cerebral injury (producing NP 
and neurological deficits respectively) may be differently affected by hypothermia. This is 
supported by a study of Mora et aí68 in which 138 patients were randomised to hypothermic 
or normothermic bypass and both neurological and neuropsychological outcomes were 
measured. Normothermic bypass increased the risk of stroke but not NP deficit. Regragui69 
randomised 96 adults to receive bypass at 37, 32 and 28 °C. There was a lower incidence of 
cognitive deficit in the 32 °C group compared to the 37 °C group but cooling to 28 °C 
conferred no additional benefit. More recently a study by Grimm et a170 suggested that 
normothermia may be less harmful than hypothermia. However this study is seriously 
limited by a number of flaws. Grimm et al measured P300 auditory evoked potentials, the 
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Mini Mental State exam and Trailmaking A tests to assess neuropsychological outcome in 
patients randomised to normothermia (37 °C) and hypothermia (32 °C). There was no 
difference in Mini Mental State exam and Trailmaking A tests but a prolongation of P300 
potentials in the hypothermia group four months after surgery. They failed to use a battery 
of tests as is recommended, and the relationship of P300 potentials to cognitive function in 
the setting of cardiac surgery is unknown. Also, the paper does not explain the important 
issue of exactly how temperature was managed and it is possible that the hypothermia group 
received damagingly rapid or excessive rewarming. 
Nathan et al" studied the effects of two different rewarming strategies at the end of CPB. In 
a randomised controlled clinical trial all patients were cooled to 32 °C on CPB and then 
rewarmed to either 37 °C or 34 °C with no further rewarming. Although it was found that the 
34 °C group had less cognitive deficit at 1 week and 3 months post -operatively, the method of 
analysing cognitive change was unusual. A battery of 11 tests was used but these were then 
grouped into three domains and patients were classified as having a deficit if there was a 
deterioration in 0.5 of a standard deviation or greater in a domain. At 3 months a difference 
in only one of the 11 tests was seen. This suggests that the difference between groups at one 
week was a temporary effect which had worn off by 3 months. 
Grigore et al72 randomised patients to slow or more rapid rewarming from hypothermia and 
found that those with slower rewarming had a better neuropsychological outcome sex weeks 
after surgery. 
In summary, although hypothermia itself may be neuroprotective, the process of rewarming 
to normothermia and beyond may itself be harmful. Rewarming to 38 °C either deliberately 
or inadvertently may directly injure neurones. It has also been suggested that rapid 
rewarming may force anaesthetic and other gases out of solution and so produce 
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microemboli. It should also be remembered that nasopharyngeal temperature is usually 
measured as a close approximation of "core temperature ". However this may lag behind the 
actual temperature of the brain. 
2.7 Blood Flow Management 
Cardiopulmonary bypass may be performed with either pulsatile or non -pulsatile flow of 
blood. Neither have a clear advantage but pulsatile flow has been recommended for being, at 
least theoretically, more physiological. A single studyb' which compared the effect of 
pulsatile and non -pulsatile flow on neuropsychological outcome found no advantage of either 
method, however. 
2.8 Surgical Techniques and "Off- pump" Surgery 
It is possible that surgical techniques may have a profound effect on both neurological and 
NP outcome following surgery. Although strong opinions tend to be expressed with regard 
to surgical technique there has actually been very little scientific study of this issue. The 
common and logical view is that manipulating a calcific or atheromatous aorta is harmful. 
Such manipulation may dislodge macro- and micro- emboli with the subsequent adverse 
effects. There are three main manipulations to the aorta during CABG surgery which need to 
be considered. The first is the cannulation of the aorta necessary to initiate CPB. The 
second is the cross clamping of the aorta which precedes either cross clamp fibrillation or 
cardioplegic arrest. The third manipulation is the application of a side -biting clamp to 
proximal aorto- coronary anastamoses. Off -pump CABG avoids cannulation and cross 
clamping, but unless an exclusive Y -graft technique is used to avoid aorto- coronary 
anastamoses, side biting clamps remain necessary. 
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Performing coronary artery bypass surgery without the use of cardiopulmonary bypass has a 
number of theoretical advantages and elimination of cerebral injury is potentially one of the 
most significant of these. There is some evidence for a reduction in both microemboli 
production and the inflammatory response, thought to have a major role in causing cerebral 
injury on bypass, in patients who have CABG without CPB. However most of the studies 
carried out so far do not show any difference in neuropsychological outcome in on bypass 
and off bypass patients. 
Malheiros et aí73 (1995) studied 81 patients who had CABG either with or without CPB 
according to surgical technical selection criteria. The CPB group had a mean of 2.9 grafts 
and a mean operative time of 325 minutes whereas the non -CPB group had a mean of 1.7 
grafts and a mean operative time of 251 minutes. The groups were not therefore matched in 
terms of surgical trauma. No differences were found in early (5 to 7 days post surgery) tests 
of neurological or neuropsychological outcome. Although the neuropsychological tests were 
not conventional they were reasonably comprehensive. However at such an early post- 
operative stage many factors cloud neuropsychological performance and tests at this stage 
without later testing cannot be relied upon. 
Bhasker -Rao et aí74 (1998) used ASEM (anti- saccadic eye movement) as a test of pre- and 
post- operative neurocognitive function in 322 CABG patients, 17 of whom had no CPB. 
Unfortunately, although ASEM is a good test of frontal lobe dysfunction in patients with 
dementia it has not been validated in cardiac surgery patients. Therefore the fact that the off - 
pump cases had fewer ASEM deficits post -operatively is of extremely doubtful significance. 
Interestingly they also used a conventional means of measuring intra- operative microemboli 
(transcranial Doppler) and were able to show that the off -pump cases had significantly less 
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microemboli produced during surgery. This is particularly significant because the off -pump 
cases in this study were selected on the basis of a history of stroke or TIA or the presence of 
a calcified aorta. All of these are factors which one would expect to lead to a greater number 
of intra- operative microemboli. If the elimination of CPB is able to reduce the number of 
microemboli then this could have an effect on neuropsychological outcome. It is logical to 
expect the elimination of CPB to reduce microemboli since there will be no cannulation, 
cross clamping or other surgical manipulations which can produce microemboli75. A short 
report by Malheiros et al in 199976 reports no microembolic signals detected in a "series" of 
6 patients. They did however note fairly marked disturbances in middle cerebral artery blood 
velocity during manipulation of the heart. Off -pump surgery thus has the potential for a 
deleterious effect on cognitive function by compromising cerebral blood flow despite the 
relative lack of microemboli. Watters et aí77 showed a definite reduction in microemboli 
counts in off pump compared to CPB treated patients in a group of 20. However Watters et 
al's study was an unrandomised prospective comparative study and the results should be 
interpreted cautiously. 
More recently, a number of studies have continued to give conflicting results regarding 
cognitive outcome after off -pump surgery. Diegler et aí78 in 2000 randomised 40 patients 
to off -pump or conventional CABG with CPB surgery. Unfortunately the tests they used to 
assess cognitive outcome (a "standardised psychiatric assessment" and the Syndrom Kurz 
Test) are un- validated in cardiac surgery and were performed only early after surgery (at 
seven days). Diegler et al's finding that there was a marked increase in cognitive impairment 
in the conventional group and no impairment at all in the off -pump group must therefore also 
be interpreted cautiously. However their positive correlation of conventionally measured 
microemboli with cognitive decline is supportive of microemboli causing deficits on bypass. 
In contrast Taggart et al7 in a study using a conventional neuropsychological test battery pre- 
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surgery, at discharge and at 3 months post surgery were unable to find any difference in 
medium term cognitive outcome between either on -pump or off -pump cases. Taggart's 
study however was not randomised but studied 25 off pump patients compared to 50 matched 
on -pump controls. The fact that Taggart used a validated battery of neuropsychological tests 
lends that study more overall weight. 
The most significant recent study is a large randomised trial comparing on -pump and off - 
pump surgery. Van Dijk et aí44 randomised 281 patients and measured cognitive outcome 
using a recognised battery of ten tests at 3 and 12 months after surgery. They found no 
difference in the two groups at 3 months post surgery using incidence analysis (21% in the 
off -pump group and 29% in the on -pump group) but there was a significant difference in the 
overall standardised change score at 3 months (0.19 vs. 0.13, p = 0.03). There was no 
difference at 12 months using either method of analysis. Van Dijk et al's follow up rate was 
good overall but the follow up rate was 90% in the on -pump group and 98% in the off -pump 
group at 3 months. It is therefore possible that a greater difference between the groups was 
missed because those patients with the greater cognitive impairment are more likely to drop 
out79. The latest study to be published does suggest that surgery without cardiopulmonary 
bypass causes less cognitive impairment than with bypass. Zamvar et a180 (2002) randomised 
60 patients to on- or off -pump CABG and performed pre -operative and I and 10 week post- 
operative NP testing with a battery of nine standard tests. Although the number of patients 
studied was relatively low, an impressive 100% follow up rate at 10 weeks was achieved. In 
a relatively low risk group (patients with previous TIAs and CVAs were excluded) incidence 
of decline (defined as deterioration by more than 1 SD in two or more tests) was 40% in the 
on -pump group and 10 % in the off- pump group (a highly significant difference). Such a 
high incidence is difficult to explain and unfortunately Zamvar et al give very little detail of 
operative procedures in either of their groups, thus limiting the applicability of their study. 
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In summary, there is convincing evidence that the use of both arterial line filters and alpha 
stat acid base control can reduce the incidence of cognitive decline after cardiac surgery. 
There is no evidence that hypothermia is of benefit and the only pharmacological agent to 
have a neuroprotective effect, remacemide, has not been used beyond the experimental stage. 
The evidence regarding on -pump and off -pump surgery is conflicting. The present study, in 
keeping with current best practice, uses alpha stat acid base control and has a strict 
temperature management protocol. 
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Chapter 3 
Mechanisms of cerebral injury during cardiac 
surgery which impact on neuropsychological 
outcome 
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3.1 Inter -relation of Aetiological Factors 
As the preceding review of interventions and their effect on NP outcome implies, the 
pathophysiology of cerebral damage secondary to CPB is complex and incompletely 
understood. The likely differing aetiologies for diffuse cerebral injury and stroke are again 
emphasised. The three main aetiological factors to be discussed in this chapter are cerebral 
blood flow, micro -embolism, and inflammatory mediators. It is likely that these factors are 
inter -related. One speculated inter -relation suggested is increased inflammation or cerebral 
blood flow leading to an increased microembolic load. When there is a greater inflammatory 
response there will be greater activation of neutrophils and platelets which when they 
aggregate may produce more particulate microemboli. Also an increased cerebral blood flow 
will potentially increase the microembolic load for a set microembolic concentration in the 
blood and so high cerebral blood flow rates may not always be beneficial. Microemboli and 
inflammation are potentially affected most by leucocyte depleting filtration and therefore 
will be discussed in greater detail. Most studies to date have concentrated on microemboli 
and their preponderance is reflected in this chapter. Little study has been made of the 
aetiological role of the inflammatory response and so this area is far more theoretical and a 
separate chapter (four) is devoted to the inflammatory response. 
3.2 Cerebral Blood Flow 
As cerebral blood flow (CBF) may be a factor, attempts are made to keep it constant in the 
present study. Cerebral blood flow is auto regulated across a range of blood pressure 
although this needs to be higher in hypertensive patients. Cerebral blood flow is normally 
40- 60m1s /g /min and during bypass is 20- 60mis /g /min. Astrup et aí81 have shown that CBF 
must fall to below 20m1s /g /min before ischaemic cell death occurs at normothermia. Recent 
studies have shown that even with pump flow rates reduced to 1.751 /min /m2 the lowest CBF 
was 24m1s /g /min62. It can therefore be seen that although a global reduction in CBF may 
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cause ischaemia it is unlikely in itself to be the main cause of the cerebral injury occurring in 
20% of cases. There is, however, some evidence that hypoperfusion can be a significant 
contributory factor to cardiac surgery related ischaemic cerebral injury. Tufo et a182 found 
that in 100 patients having CABG (in 1970) that the incidence of post operative neurological 
signs was higher (78 vs. 27 %) in those with a mean perfusion pressure of 40mmHg 
compared to 60mmHg. In a much more recent randomised study Gold et aí83 found that the 
incidence of strokes was higher (7.2 vs. 2.4 %) at 6 months post surgery in patients 
maintained on CPB at a perfusion pressure of 50 to 60mmHg compared to 80 to 100mmHg. 
Gold et al however found no difference in cognitive outcomes between the two groups. 
However, studies by Caplan et aí84 suggest that cerebral blood flow may have a significant 
effect upon neuropsychological and neurological outcome via effects on microemboli. 
Caplan et al hypothesise that the effect of emboli is worse when the perfusion pressure to the 
brain is less because there is less "washout" of emboli. However there is no direct evidence 
to support this. Conversely a higher cerebral blood flow (not necessarily resulting in a higher 
perfusion pressure) could theoretically result in more microemboli being delivered to the 
brain. These are the reasons why it was decided to measure cerebral blood flow velocity as 
well as microemboli in the present study. 
Hypoxia is a common complication of coronary artery bypass surgery and a post hoc 
multiple regression analysis by Browne et aí85 in 115 patients having CABG surgery showed 
that hypoxia at 5 days was a weak but significant (r = 0.24, p <0.03) predictor of the Z score 
at 5 days. Although pain, hypoxia, effects of analgesia and anaesthesia are a reason for not 
performing tests five days after surgery early post- operative cognitive impairment has been 
shown to predict later deteriorations. It is therefore possible that early post -operative hypoxia 
is a contributing cause of long -term impairment. 
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3.3 Microembolism 
Microemboli have received most attention as possible mediators of cerebral injury. This 
section will define microemboli, discuss their consistency, explain the various ways of 
measuring them with emphasis on transcranial Doppler (TCD), examine the evidence 
supporting their aetiological role in the production of neuropsychological deficits and, 
finally, outline theories as to how they could produce cerebral injury. 
A microembolus has been arbitrarily defined as an embolus which measures no more than 
2001.1m in diameter86. A larger embolus is then said to be a macroembolus. Microemboli 
may be gaseous, particulate or lipid with further subdivisions into organic or inorganic. 
Gaseous microemboli have a number of sources, which may be related either to the 
cardiopulmonary bypass circuit or to surgical techniques. Air inevitably enters the left side 
of the heart when it is opened for valve operations and there is evidence that even vigorous 
de- airing techniques do not completely remove the air87. Cannulation of the aorta and right 
atrium can theoretically entrain air. Although studies have shown that there is an increase in 
the number of microemboli at the time of aortic cannulation these could well be 
atheromatous or calcific particles rather than air. Air may continue to be entrained into the 
right atrium via the venous cannula if the purse string holding it is inadequate and the 
pressure in the right atrium is sub atmospheric. Air has also been demonstrated inside the 
heart during "closed heart" coronary graft operations. Using M -mode echocardiography, 
Oka et aí88 were able to detect air in 2 of 18 (11 %) of patients having CABG compared to 12 
of 15 (79 %) having valve surgery. "Trace" or "moderate" grades of air were seen in the left 
atrium or aorta for 1 to 5 minutes after termination of bypass. Air or oxygen may also enter 
via the bypass equipment. Bubble oxygenators used to be a major source of microemboli but 
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membrane oxygenators, which are now used almost exclusively, produce far less 
microemboli48. Anaesthetic gases have also been implicated in the production of gaseous 
microemboli86. Bubbles are more likely to form or grow during the rewarming phase of 
cardiopulmonary bypass when the partial pressure of the gas will increase and tend to force it 
out of solution. Rapid rewarming could thus have a detrimental effect on neuropsychological 
function via this mechanism but there have been no studies examining the rate of rewarming 
and microemboli production. 
There is a long list of potential particulate microemboli. Thrombin, fibrin, platelets, 
leucocytes, fat globules, atheroma, calcium and even denatured proteins may form organic 
particles. It is these types of microemboli that arterial line filters were designed to trap. 
There is further discussion of particulate microemboli in the section on filters. Liu et al 
attempted to quantify particulate microemboli during cardiopulmonary bypass in in- vitro, 
animal and clinical studies89. They used a Coulter counter (an electronic particle -size 
analyser) to detect microemboli between 15 and 801km in diameter and also electron 
microscopy to directly view the particles. Liu et al found that the three main sources of 
microemboli were transfused blood, cardiotomy reservoirs and bubble oxygenators. These 
in -vitro experiments showed that the degree of destruction of blood elements in the perfusion 
circuit was most significant during the first hour on bypass and that there was a linear 
correlation between time of perfusion and blood destruction. The number of microemboli 
detected steadily increased during the first hour on the perfusion circuit and then ceased to 
change thereafter. Particulate microemboli may therefore be produced by damage to the 
blood elements and their subsequent aggregation. Activated blood is allowed to collect in 
cardiotomy reservoirs and Liu found that the number of microemboli increased 5 fold after 
passing through the reservoir. It is interesting that they also found that the number of 
particles produced by the bubble oxygenator was 2 to 3 times that of the membrane 
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oxygenator. 
As well as the cellular blood element studied by Liu et al, lipid microemboli also seem to be 
produced by cardiotomy suction. Stump and Moody's group have devoted much attention to 
cardiotomy- derived lipids and their subsequent microembolisation to the brain. In 1998 
Brooker at a190 found a significantly greater number of small capillary and arteriolar 
dilatations (SCADs) on cross sections of dog's brains after 60 minutes of CPB in which 
cardiotomy suction was used. These SCADs are presumed to be lipid microemboli which 
are dissolved by the alkaline phosphatase staining technique used in preparing the sections of 
brain. Later work by the same group91 shows that processing the cardiotomy suction blood 
with a cell saver was able to reduce the number of SCADs found. Interestingly, this study 
also showed that arterial line filtration including leucocyte filters did not reduce SCAD 
density. Kaza et a192 have found that patients randomised to have cardiotomy suction rather 
than a cell saving device have greater lipid microemboli at the end of CPB. A standard 21 
micron filter removed all these lipid microemboli. 
Particulate microemboli are more susceptible to capture by arterial line filters and also, in a 
study by Harringer et al93, an intra aortic filter has been used to capture particles within the 
aorta distal to the arterial cannula. The filter was a 1201im diameter pore size polyester mesh 
and it was inserted prior to removing the cross clamp used to construct the distal aorto- 
coronary anastamoses. The filter was then removed just before de- cannulation and was fixed 
and examined with light microscopy. Sixty two % of filters contained fibrous atheroma, 
52% contained fibrin /platelet strands and 22% contained thrombus or red blood cells. 
A number of investigators maintain that the atheroma of patients is the most significant of 
the microemboli sources and that the atheromatous microemboli are detrimental to 
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neuropsychological outcome46;94'95 However when all the studies are considered it seems 
that microemboli are heterogeneous with many sources. The fact that microemboli are 
detectable in children46.94'96 having surgery to correct congenital cardiac defects suggests 
that non -atheromatous sources are important in the production of microemboli. 
Researchers have used a variety of methods to measure the microemboli produced during 
cardiac surgery and have also focussed on a number of different sites. It is possible to 
measure the microemboli in the aorta, carotid artery, middle cerebral artery or even the 
retinal arteries. The methods themselves can be direct or indirect. An early, indirect method 
was the "screen filtration pressure" technique of Swank97. This was initially developed to 
measure micro aggregates in stored blood and then adapted for cardiac surgical patients' 
blood. The technique relied on the fact that the pressure required to push blood through a 
screen filter of a given pore size was directly proportional to the number of micro aggregates 
in the blood. This has not been used recently. Another indirect method, the Coulter counter 
has, however, continued to be used89. It measures micro particles of 0.4 to 800µ,m in 
diameter, again in vitro. Although reported to be sensitive and accurate89 it can be criticised 
for not measuring gaseous microemboli and because any manipulation required to measure 
the microemboli is liable to alter the emboli86. It also cannot continuously measure 
microemboli, but measures at a single time point. Other workers have used histological 
methods to examine the brains of animals and humans after cardiac surgery, looking for 
evidence of microemboli. Moody98 was the first to report small capillary and arterial 
dilatations (SCADS) in autopsy brains of patients post cardiac surgery. It is thought that 
these SCADS are the "footprint" left behind by mainly lipid microemboli when the solvent 
used to prepare the specimens has removed the actual embolic material. However, although 
SCADS are exclusive to cardiac surgical patients, their actual cause remains unknown90. 
Workers such as Blauth et al have used the retinal circulation as a visible extension of the 
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cerebral microvasculature86'99 Blauth et al used the photographic technique of retinal 
fluorescein angiography to demonstrate retinal micro -vascular occlusions consistent with 
retinal microemboli. They found that retinal micro -vascular occlusions were more common 
in those patients with neuropsychological deficit. Compared to Doppler ultrasound, this 
technique is invasive, complicated and also does not allow continuous monitoring for 
microemboli. With retinal fluorescein angiography, one merely sees the effect of 
microemboli at discrete time points. Blauth et al developed a method to quantify the 
microemboli producing the occlusions but the technique has not gained popularity. In 
contrast, TCD is the most commonly used method for micro embolus detection. As well as 
allowing the continuous "live" detection of microemboli it also measures blood velocity and 
so gives an indication of flow. 
To obtain a TCD trace, an ultrasonic beam from a probe placed against the skull is directed at 
blood flowing in the middle cerebral artery. There is a variable temporal window of thinner 
bone above the zygomatic arch in about 90% of people. In the remainder it is not possible to 
obtain a TCD trace. The acoustic properties of embolic material, gaseous or particulate, 
differ from blood so that the emboli reflect the ultrasound much more strongly than blood. 
An increase in reflection produces a characteristic "high intensity transient signal" (HITS). 
These can be recorded on videotape for off line analysis. Software has been developed for 
automatically counting emboli but is not as good as an experienced human analyser10 °. HITS 
detected by TCD have been shown to correspond to microemboli made of air, platelets, 
fibrinogen or atheroma in laboratory in vivo experiments101 ,102. HITS may therefore be 
equated with microembolic events (MEE). TCD is able to detect both solid and gaseous 
microemboli, which is advantageous but cannot unfortunately distinguish between the two. 
Russell and Brucher has recently claimed to have developed technology that can 
automatically distinguish solid and gaseous emboli103. This has not yet been used clinically. 
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Blauth criticises TCD because the number of HITS may not exactly reflect the number of 
emboli, especially if automated counting is carried out. However, the same criticism applies 
to all the other methods previously mentioned which do not have TCD's advantage of 
continually detecting both types of emboli. In order to standardise their detection and make 
studies comparable a number of recommendations for their detection and recording have 
been made by an international consensus group104. In order to qualify as a HIT or MEE the 
Doppler signal must fulfil the following criteria: 
1) Be transient - less than 300 millisecond 
2) The amplitude should be at least 3 decibels higher than that of the background 
Doppler signal. 
3) The signal should be unidirectional within the Doppler velocity spectrum (as the 
embolus is travelling in one direction in the bloodstream). 
Padayachee et al48 (1987) were the first to use TCD during cardiac surgery. They found that 
there were embolic signals in 22 out of 27 patients at the time of aortic cannulation. During 
CPB, they found that emboli were detected in all patients with a bubble oxygenator but in 
none with a membrane oxygenator. A few years later Pugsley8, in a randomised controlled 
trial, found emboli in all patients with bubble oxygenators and that a 40µm filter reduced the 
number of emboli. The modern trend in perfusion technique of using membrane oxygenators 
and arterial line filters105 has not led to the complete disappearance of microemboli and they 
continue to be detected by TCD. 
An often discussed issue in the TCD technique of detecting cerebral emboli is whether 
bilateral or unilateral middle cerebral artery detection should be used. The majority of 
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studies have not shown a difference in right and left hemisphere counts although some have 
found more on the left. Some investigators argue that a combined bilateral count is more 
accurate as it gives the total number of microemboli. However even this is likely to only be 
a proportionate estimate unless all arteries supplying the brain are monitored. Moser et al106 
examined unilateral and bilateral monitoring in 29 patients and found only a 4% difference 
between sides. Therefore, which side is used in unilateral monitoring is probably not 
important. Wijman et al107 have shown that cerebral microembolism occurs more frequently 
in the middle as compared to the anterior cerebral artery when TCD is used to detect 
microemboli. The number of microemboli detectable is probably related to the proportion of 
cerebral blood flow in each artery. 
Mullges et al108 have shown that microemboli counts during cardiopulmonary bypass also 
depend on the position of the aortic cannula. Mullges at aí108 randomised 60 patients to have 
the aortic cannula short so that it sat in the ascending aorta or long so that it sat in the 
descending aorta. The number of HITS detectable in the long cannula group was 
significantly lower (mean of 223 vs. 994). 
The evidence relating microemboli to post- operative neuropsychological deficits is now 
fairly strong but not consistent. The earliest study to implicate microemboli was that of 
Aberg in 1974109 in which 144 patients were given a battery of NP tests pre -op, eight days 
and then eight weeks post -op. Only six patients were given an arterial line filter but these 
patients had a better NP outcome. At that time no measure of microemboli was possible. 
Although there were a number of subsequent studies relating a variety of filters to NP 
outcome it was not until Pugsley's work, published in 1994, that the effect of arterial line 
filtration on microemboli was studied. Pugsley8 studied the incidence of microemboli in the 
middle cerebral artery using TCD and NP outcome in a randomised controlled trial of 100 
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patients who received either a 401.tm arterial line filter or no filter. It was found that patients 
with the 40µm filter had less microemboli during bypass than the non -filtered group and that 
the number of microemboli was related to the likelihood of a patient having a 
neuropsychological deficit at eight weeks post op. Significantly more patients in the non - 
filtered group had NP deficits at both 8 days and eight weeks post op. 
Although Pugsley's was a well designed and appropriately controlled randomised trial, it 
may have limited applicability to modern practice because it was carried out at the time when 
bubble oxygenators and pH stat acid base balance were used during bypass. Bubble 
oxygenators are now known to produce more microemboli than membrane oxygenators and 
so membrane oxygenators are almost exclusively used. It is also known that cerebral blood 
flow auto regulation is better preserved with alpha stat pH balance during CPB and leads to a 
better NP outcome so most centres use this at present. An interesting study by Plochl64 
albeit in pigs, has shown that a reduction in PaCO2 results in less embolisation of 
microspheres to the brain. It is therefore possible that as well as membrane oxygenators 
producing less microemboli, alpha stat may reduce their delivery to the brain. 
Despite these caveats, the evidence linking microemboli and NP outcome from Pugsley et 
al's study8 remains strong and is supported by later studies. Clark et alp 10 showed that even 
when using alpha stat and membrane oxygenators the number of microemboli detected was 
related to the NP outcome. In a prospective study of 127 patients who had TCD monitoring 
during bypass, 41 of these patients had pre- operative and post- operative NP evaluation. It 
was shown that by dividing the patients into categories of microemboli count ( <30, 30 -60 
and >60) that those with more microemboli had worse NP outcome. The major fault of this 
study is the timing of the postoperative tests at 5 -10 days post op. As already discussed this 
is too early for results to be meaningful as so many factors influence NP deterioration at this 
53 
stage. Also, the exact battery of tests is not detailed and the number of patients studied 
(n =41) relatively low. Barbut et al"' in 1997 used TCD to count middle cerebral artery 
emboli in 82 patients having coronary artery bypass grafting of whom 4 (4.9 %) had peri- 
operative strokes. Patients with strokes had a mean microemboli count of 449 compared to a 
mean of 169 in those patients without strokes - this was a statistically significant difference. 
NP outcome was not assessed, but the finding regarding strokes was highly significant. 
More recently, a number of investigators have studied the relationship between NP outcome 
and microemboli in more detail in an attempt to discover how they could be causally related. 
Sylviris et aim in Australia have investigated microemboli at different stages of CABG and 
both NP outcome and MRI changes. A relatively small population (n =41) was studied and 
of these only 32 had NP testing. Also, the NP tests were again performed too early at 5 or 6 
days post surgery. Despite small numbers they were able to show a significant association 
between increased numbers of microemboli during bypass and increased NP deficits. In 
contrast to Barbut et al's study"', an increase in microemboli during bypass was not 
associated with stroke (defined as cerebral infarction seen on post- operative MR1). 
However a strong association was found between pre- bypass microemboli and cerebral 
infarctions seen on MRI scans at 6 weeks post op. Only 28 patients in this study received 
both TCD and MRI and of the 5 of these who had MRI evidence of stroke 2 were also found 
to have significant carotid artery stenoses. Pre -bypass microemboli are detected before any 
surgical or bypass interventions have been made and are likely to be caused by atheroma and 
so this association is not surprising. 
Jacobs et aí13 in Germany have examined the relationship between microemboli, NP 
outcome and cerebral glucose metabolism. This was also a small study of only 18 patients 
having coronary artery bypass grafting. Two patients also had valve replacements and thus 
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had much higher microemboli counts. They found that in those patients whose regional 
glucose metabolism was reduced post operation the regional reduction was correlated to the 
microemboli count. However there was no overall correlation between the number of HITS, 
the neuropsychological outcome or global cerebral glucose metabolism. The significance of 
all this is doubtful in such a small study. 
Borger et al' 14 have conducted several studies in which they have shown perfusionist 
interventions during which air is entrained into the venous side of the CPB circuit contribute 
to microemboli production. Borger et al's study was designed to test the hypothesis that an 
increase in air entrainment with these interventions would lead to impaired postoperative NP 
performance. They divided a non -randomised cohort of patients into two groups receiving 
either more or less than 10 interventions during CPB. They found that the group with less 
than 10 interventions had less NP impairment post surgery, however this group also had 
significantly shorter cross clamp and CPB times. A further flaw was the failure to perform 
actual microemboli counts such that they were not able to make a direct correlation between 
the microemboli count and NP outcome. More interventions could simply reflect longer 
more complicated surgery. Additionally Borger et al's hypothesis14 that the majority of 
microemboli during CPB are gaseous secondary to perfusionist interventions is likely to be 
flawed. It certainly is not consistent with the majority of the microemboli literature which 
suggest that some microemboli are "bypass related" and some are aortic manipulation 
related. 
Fearn et al115 studied a group of 70 patients having CABG surgery with TCD of the middle 
cerebral artery to measure both microemboli and middle cerebral artery blood velocity and 
NP testing pre- operation then one week, two months and six months post operation. Fearn et 
al found a weak but significant (r=0.3, p <0.02) correlation between emboli and a reduction in 
55 
"overall memory reaction time" (a composite of several memory tests) at one week post 
surgery. Interestingly Fearn also found a correlation between measures of cerebral blood 
flow (perfusion pressure, middle cerebral artery blood velocity and cerebrovascular 
reactivity) and poor attention at one week. This therefore suggested that microemboli are a 
determinant of a specific NP outcome but that cerebral blood flow was also important. 
Neville at aí23, as has previously been discussed in chapter 1, seem to provide evidence to the 
contrary. That is, they suggest that the number of microemboli may not be a significant 
determinant of NP outcome, at least when comparing valve and CABG patients. Neville et 
al23 confirmed previous findings that there were more microemboli detected during valve 
surgery but they were unable to find any difference in NP outcome. Although the two groups 
of valve and CABG patients in Neville's study 23 were well matched for age, other potentially 
significant characteristics such as diabetes prevalence were not well matched. Another 
possible explanation for the apparent disparity between Neville and Fearn's studies is that 
different types of microemboli may have been detected in the two studies. In Fearn's study 
all patients were having CABG surgery and so were likely to have had similar types, if not 
numbers, of microemboli (for example 40% particulate and 60% gaseous) thus allowing a 
correlation between microemboli and memory loss. In Neville's study there may have been 
more gaseous microemboli (possibly less harmful) in the valve group leading to a lack of 
correlation. Additionally, Fearn measured middle cerebral artery microemboli but Neville 
measured common carotid microemboli. It seems logical that middle cerebral artery 
microemboli are more likely to be associated with NP outcome than common carotid 
microemboli as many of the common carotid microemboli may not end up in the cerebral 
circulation. This comparison of Neville and Fearn's studies demonstrate how the differing 
methods and measures used to study microemboli lead to conflicting results regarding the 
relationship between microemboli and neuropsychological outcome. 
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Most recently, Stygall et aí37 investigated the relationship between intra- operative 
microemboli and outcome five years after surgery. In a longitudinal study of 107 patients 
having CABG surgery microemboli as well as post- operative change at 6 days and extent of 
recovery at 6 weeks were all found to predict NP performance at five years. No arterial line 
filters were used in this study and, as the authors point out, the number of microemboli 
detected may simply reflect the extent of the patients' cerebrovascular disease. Therefore as 
an alternative theory to microemboli causing the decline, microemboli could be a feature of 
those who will decline anyway. 
The mechanism of damage arising from microemboli is unclear but unlikely to be merely a 
mechanical plugging effect. The small capillary and arterial dilatations that have been found 
in autopsy specimens post bypass and which seem to result from microemboli16 suggest that 
microemboli may also have a locally destructive effect. Microemboli may induce a local 
inflammatory reaction as well as mechanically plugging capillaries. 
Different types of microemboli are likely to produce different effects and although the 
evidence from valve versus CABG studies in which more microemboli (presumably air) in 
the valve groups does not lead to worse NP outcome suggest that air microemboli are less 
harmful, this is far from proven. 
There is a consistent finding in the literature that when microemboli are compared in patients 
having surgery with and without CPB there are less microemboli in the patients not having 
CPB. This has been shown in both retrospective or non -randomised studies74'77'78'17 and in a 
prospective randomised study18. Interestingly, in Lund's study18 despite a significant 
reduction in the number of microemboli detected in the middle cerebral artery during off 
pump surgery, no difference in neuropsychological outcome was found. Cerebral blood flow 
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was not monitored by Lund and reduced cerebral blood flow in the off -pump group could 
have had an equally harmful effect as the microemboli in the on -pump group. 
In summary at this stage, most work investigating mechanisms of the diffuse cerebral injury 
associated with cardiac surgery has concentrated on microemboli, that is solid, gaseous or 
lipid matter less than 200µm in diameter. Microemboli are most commonly and most 
accurately measured using transcranial Doppler, although even this technique has important 
limitations. A considerable number of investigators (eg Pugsley et al8, Clark et aí110, Fearn et 
aí115 and Stygall et aí37) have found a correlation between the numbers of microemboli 
detected by TCD and NP outcome, with more microemboli being associated with worse 
outcome. However, this has not been a consistent finding and others have found no 
relationship between microemboli and NP outcome (eg Neville et aí23, Arrowsmith et al¢2, 
Mullges et aí108 and Lund et aim). It is likely that the limitations of TCD as well as 
methodological differences between studies have led to this inconsistency. The relative 
contribution of other potential causes of injury such as inflammation and altered cerebral 
blood flow could also interfere with a consistent relationship between microemboli and NP 
outcome. It is for this reason that cerebral blood flow is measured in the present study. The 
present study also uses TCD as the most accurate measure of cerebral microemboli available. 
The next chapter, chapter four, will therefore outline the inflammatory response to bypass 
with emphasis on the physiology of neutrophils, which the present study aims to filter, and 
then chapter five examines what investigation has already been made with various types of 
arterial line filter. 
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Chapter 4 
The role of neutrophils in the inflammatory 
response to cardiopulmip ary bypass and 
potential role in diffuse cerebral injury 
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A vast amount of attention has been devoted to demonstrating that cardiac surgery with 
cardiopulmonary bypass produces a systemic inflammatory response. As with 
neuropsychological injury, it has always been assumed that the CPB circuit was the main 
culprit in producing this frequently harmful response. However more recent studies 
performed on patients having cardiac surgery without CPB, show that there is still a marked 
inflammatory response. This suggests that the cardiac surgery and anaesthesia themselves 
are responsible for a considerable component of the inflammatory response. The purpose of 
this section of the literature review is to outline this systemic inflammatory response 
concentrating on the central role of the leucocytes as these cells are the focus of the present 
study. This section will explain how leucocytes, and in particular neutrophils, become 
activated and how, once activated they interact with other blood components and the vascular 
endothelium to produce tissue injury and possibly microemboli. The evidence in this chapter 
thus provides the rational for attempting to filter leucocytes from the circulation. As has 
already been mentioned, little study has been made of the role of the inflammatory response 
in causing cognitive decline, but the work that currently exists is examined. 
Several factors have been implicated in initiating the inflammatory response. The factors 
include the exposure of blood to foreign surfaces, ischaemia -reperfusion of organs, surgical 
trauma, non -pulsatile flow and endotoxin release. These triggering factors then activate 
complement, coagulation, fibrinolysis and kallikrein -kinin pathways to cause leucocyte 
activation. 
When blood is exposed to the foreign surface of the CPB circuit, the complement protein 
cascade is the first to be activated19 -1' and this leads to formation of anaphylatoxins C3a 
and C5a, mainly via the alternative complement pathway. Activation of complement via the 
classic pathway also occurs when blood meets air and when heparin is reversed with 
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protamine to form heparin -protamine complexes'22'123. Although the surgical procedure can 
itself activate complement, it is seen that levels of C3a only rise markedly at the beginning of 
CPB and then peak at the end of CPB. Levels of C3a also correlate positively with the length 
of CPB121. Endotoxin which is released into the circulation (probably from the bowel) 
during CPB can also activate both the classic and the alternative complement pathways. 
The C5a produced by complement activation then leads to both the margination and 
aggregation of neutrophils124'175 and also the adherence of neutrophils to the vascular 
endothelial cells126. It is thought that both complement activation leading to this 
margination, aggregation and adherence of neutrophils is responsible for the initial fall in 
circulating neutrophils which is seen at the beginning of CPB120. 
The coagulation and fibrinolysis cascades are both activated by the contact of blood with the 
extracorporeal circuit. It is relatively far down this cascade that it is eventually inhibited by 
heparin to prevent coagulation. The negatively charged surfaces on the CPB circuit and also 
exposed collagen from tissue injury cause activation of factor XII. Factor XIIa then 
stimulates neutrophil aggregation and also the release of elastase177. Factor XIIa also 
generates kalekrein which causes neutrophil chemotaxis128, aggregation'29 and 
degranulation130 
At the beginning of CPB there is an immediate fall in the number of circulating leucocytes 
with a particular reduction in mature neutrophils and granulocytes. This is thought to be due 
to haemodilution of blood by the bypass prime, simple adhesion of neutrophils to the 
adsorbed protein layer of the CPB circuit and the complement mediated activation of 
neutrophils leading to their margination. There is a later rise in the leucocyte count towards 
the end of bypass which is presumably due to a release of new leucocytes from the bone 
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marrow or a reversal of their marginated state. Hypothermia reduces this response131 and the 
rise in leucocyte count is often seen during rewarming following systemic hypothermia. 
Neutrophils are activated by C3a, C4a, C5a, PAF (platelet activating factor), leukotriene B4 
and other mediators. Within 20 seconds of being exposed to activated complement, 
Craddock et a1132 were able to photograph the morphological changes in neutrophils as they 
became rigid and grew pseudopods. When neutrophils become activated, they express 
specific adhesion molecules on their surface such as CDI lb /CD18. Gu et äl133(1992) studied 
16 patients having CPB and showed that CD11b /CD18 expression on neutrophils increased 
immediately after starting CPB at the same time as the rise in C3a. There was then a second 
peak in CD1 1 b /CD18 expression after release of the aortic cross clamp and only this second 
peak was followed by a marked rise in serum elastase. Therefore, in order to cause tissue 
damage in vivo, neutrophils do not only themselves need to become activated, but also need 
to adhere to activated endothelial cells. 
Endothelial cells in their resting condition are normally relatively inert. In response to a host 
of inflammatory signals such as cytokines, endotoxin, activated complement and others they 
are converted to an activated state and express their own adhesion molecules such as E- 
selectin (also known as Endothelial Leukocyte Adhesion Molecule 1) and ICAM 
(Intercellular Adhesion Molecule). There are two phases of endothelial cell activation which 
occur during cardiopulmonary bypass. In the first immediate phase circulating complement 
activation products cause an immediate but short -lived neutrophil adhesive response. The 
second phase occurs after several hours as the endothelial cells, in response to circulating 
cytokines and endotoxin, manufacture and express surface activation proteins such as ICAM 
and E- selectin. 
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Foreman et aí'33;'34 has shown in vitro that C5a is a potent agonist of endothelial cell P- 
selectin (also known as Platelet Activation- Dependent Granule) expression. It is therefore 
thought that the immediate expression of P- selectin resulting from endothelial C5a exposure 
could cause the sudden leucosequestration which follows commencement of CPB. P- selectin 
is the most readily available of all the endothelial cell activation molecules and is stored in 
cytoplasmic vacuoles and can be rapidly transported to the cell membrane for expression 
without having to be manufactured. Once neutrophils have adhered to the complement 
activated endothelium they release proteases such as elastase and oxygen derived free 
radicals. These harmful substances then cause endothelial cell dysfunction and subsequent 
leakage of fluid through the capillaries into the extravascular spaces. Although rapid, both in 
vivo135 and in vitro136 studies show that the response is short lived and as it wears of it is 
replaced by a more prolonged response. 
During CPB cytokine and endotoxin levels rise in proportion to the length of the procedure 
and bind to the endothelial cells. In the first 4 to 8 hours after CPB the E- selectin and ICAM 
are expressed. The delay results from these proteins requiring synthesis. E- selectin cause the 
initial rolling phase of neutrophil- endothelial cell interaction through low affinity binding. 
ICAM then forms the form bond with the neutrophils. This phase is more prolonged and last 
up to 24 to 48 hours after CPB. Chello et aí137 have shown that following CPB apoptosis 
(programmed cell death) of leucocytes is delayed. That is the leucocytes live for longer. This 
effect was abolished by depleting the surgical plasma of IL -6 and IL -8. Leucocyte depleting 
arterial line filters can only reduce activated leucocytes during CPB and so if they have any 
effect it would be on the initial short lived neutrophil- endothelial cell interaction. Whether 
leucocyte filtration can inhibit the leucocyte platelet adhesion which occurs in bypass138has 
yet to be studied. 
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There are a considerable number of studies which report an increase in serum elastase during 
CPB. As an alternative to measuring the proportion of neutrophils expressing CDl lb /CD18 
molecules it has been used as a measure of neutrophil activation. Connective tissue in vivo is 
protected against elastase injury by an anti -protease called a -1 -antitrypsin which binds 
irreversibly to elastase in the plasma and inactivates it. When elastase levels are measured 
what are actually being measured are levels of the inactivated elastase -a -1 -antitrypsin 
complex. 
All investigators have found that levels of serum elastase rise progressively during CPB and 
peak at the end of CPB. Levels then return to pre- operative levels by about 24 hours. 
Ascione et aí139 investigated the effect of CPB itself on the inflammatory response. They 
measured elastase, IL6, C3a and C5a peri- operatively in 60 patients randomised to receive 
CABG either with or without CPB. As with other studies, elastase was found to peak just 
after bypass in patients having CPB. In those not having CPB, elastase rose slowly and to a 
much less extent. C3a and C5a levels were similarly attenuated. Therefore this study 
suggested that avoiding CPB reduced but did not abolish the inflammatory response. 
A significant study has recently suggested that neutrophils become primed and sensitised 
before CPB begins. In a relatively small study of 20 patients undergoing CPB for a variety of 
procedures, Gu et aí140 (2002) found that the primeability and release of elastase by 
neutrophils on stimulation in vitro by cytochalasin B increased and actually peaked before 
the beginning of CPB. In contrast the primeability of neutrophils was relatively low in the 
subsequent period during and after CPB. This suggested that neutrophils become 
preactivated by surgical trauma or anaesthetic treatment rather than contact of blood with the 
CPB circuit as most other studies have demonstrated. The exact relative roles of surgical 
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trauma, anaesthesia and CPB in initiating and maintaining the inflammatory response have 
yet to be elucidated. 
This chapter has shown that neutrophils have a pivotal role in the inflammatory process 
which causes tissue injury. However, there has been little study so far of the link between the 
inflammatory response and NP outcome. A potential relationship between the two was first 
proposed by Smith in 1996141. There is only one study to date which has directly investigated 
any link between inflammatory mediators and post- operative NP functioning. Westaby et 
aí142 prospectively measured a variety of inflammatory mediators (beta -thromboglobulin, 
thromboxane, interleukin -6, prothrombin fragment 1 and 2, D- dimer, complement C4 split 
product and terminal complement complex) and NP performance pre- operatively and 5 days 
and 3 months post- operatively in 100 patients undergoing elective CABG surgery. Westaby 
et aí14' found no significant correlation between levels of inflammatory mediators and NP 
outcome. All the markers measured are ones which become raised when there is blood and 
foreign surface interaction. There is therefore, currently no evidence that the inflammatory 
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5.1 Development of Filters 
Arterial line filters are an optional addition to the cardiopulmonary bypass circuit which have 
been clinically available in evolving forms since the early 1970s. These filters are designed 
to remove bubbles, particles and also, in the case of the LG -6 filter, activated leucocytes 
which may pass from the CPB circuit into the patient with potentially damaging results. 
Filters were originally developed in the 1960s by two American pioneers. Swank, in 
Oregon, developed a Dacron wool depth filter to first remove microaggregates from stored 
blood97 and then for use during CPB143. Simultaneously, Patterson in New York City 
designed a screen micropore filter which was able to reduce the number of microemboli in 
animals and improve their neurological outcome following CPB144. This was a 25um 
stainless steel filter and caused haemolysis to a degree unacceptable for clinical CPB. In the 
1970s, the Dacron -wool depth filter made by Pioneer -Swank and the polyester -mesh screen 
filter made by Pall were the earliest commercially available filters suitable for placement in 
the arterial line. Variants of both were subsequently made by other companies but the screen 
filter became dominant, so that by the early 1980s, 99% of arterial line filters used were 
screen filters145 "46 
The depth filter became obsolete and the two types of filter available today are the 
conventional "stand alone" screen filter, of which there are several with different pore sizes 
from a variety of manufacturers, and the screen filter with a leucocyte depleting element (the 
LG -6 filter). Pall introduced leucocyte depleting arterial line filters in the early 1990s as a 
result of a number of animal studies which clearly showed that leucocyte filtration was able 
to reduce the inflammatory mediated damage to a number of organs. 
In 1981, 64% of American perfusionists surveyed used an arterial line filteri46. By 1995, 
this figure had increased to 92 %105. Although filters have been available for 30 years, they 
67 
have not been universally accepted and, of note, there is a marked disparity in the prevalence 
of use between the USA and the UK. Despite Professor Treasure, working in a UK centre, 
stating in 1989 that "we should recommend their use in all cases "147 a survey in the UK nine 
years later in 1998 revealed that they are used routinely by only 57% of surgeons148. This 
contrasts with a 98.5% use in the USA recorded in 200047. 
This section of the review will analyse the clinical evidence relating to their use and 
determine, if possible, what benefit they may have. Although there is a great deal of 
published work showing a benefit from arterial line filters in animal models, this literature 
review is restricted to in -vivo studies on humans. Studies were selected if they used an 
arterial line filter on humans. Investigations into other aspects of filtration such as 
cardiotomy suction filtration, cardioplegia filtration, venous line leucodepletion and filtration 
of blood retransfused post CPB were excluded. A range of different outcomes have been 
studied including the broad (length of hospital stay)149 to the more precise (biological assays 
such as the marker of neurological damage S100b)150. The two main types of filter, the 
conventional (25 -40µm) filter and the leucocyte depleting (LD) filter, will be considered. 
Table 3.21 (following page) summarises the design and sample characteristics of the studies 
reviewed. Most of the studies (23/28 = 82 %) were randomised controlled trials (RCTs), but 
there were also some observational, historical and retrospective studies. Results of the latter 
types of study must be treated with caution. The RCTs fall into two main groups: those 






























70, infection, liver disease, D
M





















































 /valve /aortic cases 
N
one - w
as deliberately designed to include a w









elective valve cases 
em





























































open ht cases 
N
one m






















































































































o valve cases 
abnorm































 patients age <
 70 
H















































































. left heart opened in 30%









open ht "surg patients 














 /valve, ventric. aneurysm
ect. 
patients selected m
ainly by the m








































Coleman et aí163, Conne11175 and Lust'56 have no exclusion criteria whereas Mihaljevic161 and 
Palanzo'64 ;167 appropriately exclude patients with abnormal pre- operative lung function. 
Another problem relates to the definition of "open heart surgery ". Strictly, it should mean 
surgery in which chambers of the heart are opened, however in some studies it is not clear 
whether chambers of the heart have or have not been opened. Henrikson et al's159 "open 
heart surgery" patients do include both CABG and valve surgery whereas one cannot be clear 
from Garvey et al's "' , Page et al's14 or Palanzo et a1's164;167 whether this is the case. 
This is likely to be of crucial importance in studies of microemboli or neuropsychological 
function because these outcome measures may be affected by whether or not the heart 
chambers are opened. 
It is unclear in some papers whether the population used was high or low risk, especially as 
relative risk will have changed greatly over the time period from which these studies are 
drawn. Most studies seem to have used a low or mixed risk population. Di Salvo et al's155 is 
the only randomised controlled trial to have selected a high risk population. There is a 
theoretical argument suggesting that filters may be of more benefit in high risk cases, but 
there is little evidence to support this. In fact, in the only study comparing the filter 
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non -filtered control group (which all investigated microemboli and /or cerebral outcomes) 
and those comparing a leucocyte -depleting filter to a conventional filter all of which 
measured inflammatory and related clinical outcome. 
The sample size in these studies varies considerably from 14 to 400. One might expect 
investigators to perform a power calculation before deciding on a sample size but Hurst154 
was the only one to document such a calculation in the published paper. The power of a 
study is especially important when the outcome is negative but none of the studies with 
negative outcomes discuss power. 
The characteristics of a study sample are important in relation to the generalisation of the 
findings. The details of the characteristics of the samples inevitably vary considerably 
between studies which span 30 years. However, only 15 out of 28 (54 %) studies defined their 
population. In some cases the population was clearly defined, e.g. Taggart et aí15° used only 
elective first time coronary artery bypass graft (CABG) patients and excluded patients with a 
history of strokes, transient ischaemic attacks or renal impairment. This contrasts with 
studies such as Dutton et al's173, which refers to "cardiac cases" with no definite inclusion or 
exclusion criteria. In those studies which examine the mechanical characteristics of filters or 
those relating to reduction in microemboli, the type of surgery or the risk stratification of the 
population may not have relevance. However, those studies whose outcomes are clinical 
should ideally have a more strictly defined selection criteria. For example, Henrikson159 
Sellman168 and Taggart150 investigated cerebral blood flow, magnetic resonance imaging 
(MRI) brain changes and S100b levels respectively. Since they were all measuring outcomes 
related to the brain and brain injury they all excluded from their study population patients 
with a history of cerebrovascular disease. In this respect these studies were well designed. 
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between different risk groups, Gott149 found LD filters to be more effective in the lower risk 
group of patients. 
Table 3.22 (preceding page) shows details of study design 
In RCTs it is conventional to demonstrate the similarity of the test and control populations. 
Most (19 out of 28 = 68 %) of the studies in this review either demonstrated or stated the 
similarity. 
Only 6/28 (21%) studies stated if and how they had controlled and standardised all the 
operative variables of surgery, anaesthesia and perfusion. Since these factors have a 
potential confounding effect upon outcome one would wish these to be standardised as much 
as possible. 
Six separate outcomes have been identified and are discussed in turn. These are summarised 
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Of the three main aetiological factors thought to cause diffuse cerebral injury during cardiac 
surgery, namely microemboli, the inflammatory response and altered cerebral blood 
flow /pressure, microemboli have received most attention4. In fact, filters have been 
instrumental in establishing the causal link between microemboli and neuropsychological 
deterioration after cardiac surgery. 
The first clinical controlled trial to show that filtration can reduce microemboli was that of 
Dutton et al13 in 1974 which compared a 271.1m polyurethane stratified filter (Bentley) with 
either a bubble or membrane oxygenator to bubble oxygenation with a 400µm stainless steel 
filter (effectively no filtration). The 4001km filter removed no microemboli (defined as 
emboli less than 200µm diameter) whereas the Bentley filter removed 90% of microemboli 
>150 tm and 60% of microemboli 50 - 15011m. Dutton13 examined a very narrow aspect of 
filtration as he was able to detect platelet aggregate microemboli only, whereas it is now 
known that microemboli may be gaseous or particulate and that the particulate emboli can 
consist of a wide range of substances - lipid, calcium, platelets, fibrin, spalated tubing to 
name a few. In the same year, Page et aí14 used the Pioneer Dacron wool filter in a small 
randomised controlled trial. They used an indirect measure of microemboli - the "screen 
filtration resistance" (SFR) which only reflects particulate microemboli - to show that 
filtration reduced the SFR and also, presumably, microemboli. Loop et aí172, two years later, 
evaluated four of the then available arterial line filters by recording pre- and post - filter 
ultrasound of the arterial line when bubble oxygenators were used. Their ultrasound 
transducer detected bubbles or particles (without distinction) down to 80µm in diameter, 
although microemboli may be smaller than this. The efficiency of the filter was then 
determined by subtracting from 100% the number of counts occurring downstream of the 
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filter divided by the number of counts occurring upstream. The Dacron wool depth 
absorption filter had the highest efficiency (99 %) followed by the 20µm woven nylon mesh 
filter (92 %), the 40µm polyester mesh filter (79 %) and a 27µm stratified polyurethane filter 
(75 %). Although the Dacron wool filter was the most efficient, Loop12 notes that one of 
these filters became obstructed- a potentially dangerous complication of all filters. Also 
microemboli may be smaller than the 80µm limit of the transducer used and the filters may 
not be as efficient as they appear. The filters may be letting through microemboli less than 
8011m diameter. 
With previous studies showing filtration to remove microemboli from sampled blood, 
Padayachee et all 69 was subsequently able to show that filtration can reduce the number of 
microemboli that actually reach the cerebral circulation. Using bubble oxygenators, 18 
patients were randomised either to no filter, a 404m screen filter or a 251.tm screen filter 
groups. Transcranial Doppler (TCD) was used to measure the number of microemboli 
reaching the middle cerebral artery and there was a significant reduction in microemboli 
counts in both the 40 and 254m groups. The authors report this as a reduction in "gaseous 
microemboli" although their TCD could not distinguish between particles and bubbles. The 
fact that membrane oxygenators produce less microemboli than bubble oxygenators suggests 
that the excess produced by bubble oxygenators may be bubbles, however, as was mentioned 
in the previous chapter, bubble oxygenators also produce more particulate microemboli than 
membrane oxygenators so this is not certain. 
Borowicz166 showed that heparin coating of arterial line filters reduces the adhesion of 
cellular material to such filters. The biochemical or clinical consequences of this were not, 
however, studied. 
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5.3 Cerebral Outcomes 
There are four published studies examining the effect of filtration on neuropsychological 
outcome. Garvey", in 1983, compared 46 unselected open heart surgery patients who 
received either a Pall 40lum or Bentley AF -10 (25µm) filter with a historical group from nine 
years previously which had received no filtration. Neither anaesthesia, surgical or perfusion 
protocols are mentioned and the fact that the controls are historical makes any comparison 
very problematic. Additionally, intellectual brain function was assessed using the CLAT 
(conceptual level analogy test) which is a single global measure of cognitive function. This 
type of assessment is unlikely to have the sensitivity required to detect changes following 
cardiac surgery. The decreased impairment found with the filter group could be due to many 
changes which could have occurred in the nine years between sampling the different groups. 
In his RCT of 100 cases, Aris10 used a more comprehensive battery of neuropsychological 
tests. This was therefore a much more rigorous study than that of Garvey. Aris compared 
patients who had a Shiley 20tum nylon screen filter with a non -filter control group but was 
unable to show any difference in outcome between the two. A negative result in a study of 
this size is unlikely to be the result of a type II error, but could be due to a number of other 
factors. The filter could have no effect or the filter could have a detrimental effect due to its 
small pore size or unusual form (nylon). More relevant is the possibility that the 
neuropsychological tests were performed at too early a stage post- operatively. Aris 
performed these tests at ten days post -operatively when many peri- operative factors such as 
anaesthesia, analgesia, pain or anxiety may continue to cloud the patients' 
neuropsychological function. The 1995 consensus suggests that the ideal time to perform 
post- operative testing is three months post surgery14. Many studies use four to twelve weeks. 
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A better NP assessment technique was used by Sellman165 who tested three groups with a 
battery of NP tests before surgery and at one and six months post surgery. The post- 
operative testing was therefore likely to be far more sensitive than Aris'. Sellman did not find 
a significant difference between the bubble oxygenator group with 101,tm in -depth adsorption 
filter and the bubble oxygenator group without a filter. However, the membrane oxygenator 
group (without filter) was found to perform better than the bubble oxygenator group without 
filter at one month post surgery on certain NP tests. Unfortunately the value of this study is 
limited by the small numbers (17 to 20 in each group). 
It was not until the study of Pugsley et alb a year later which used a greater number of 
subjects and a neuropsychological battery at appropriate times that more convincing 
evidence of a neuroprotective effect of filtration was produced. One hundred patients 
receiving bubble oxygenated CPB were randomised to receive either the Pall 40µm 
(Polyester screen) arterial line filter or no filter. Perfusion, anaesthesia and surgical 
technique were all well controlled. NP function was assessed pre- operatively, at 8 days and 8 
weeks post operatively. TCD was used to assess the number of microemboli occurring in the 
middle cerebral artery intra- operatively. Confirming the results of Padayachee et al's 
study169, Pugsley showed that the 40gm filter significantly reduced the number of 
microemboli. Most importantly, Pugsley demonstrated a correlation between the number of 
microemboli detected and the incidence of a NP deficit post operatively. Those with a 
microemboli count < 200, 5/58 = 8.6% had a deficit whereas those with counts > 1000, 3/7 = 
43% had deficits. Examining the effects of the filter, filtered patients at eight weeks post 
surgery showed less deterioration on eight out of ten NP tests compared to the non -filtered 
group. A deficit in performance (defined in Pugsley's study as a reduction in one SD of test 
score in two or more tests) occurred in 4 of 49 filtered patients and 12 of 45 non -filtered 
patients (p<0.03). Although Pugsley used bubble oxygenators and pH stat pH control, both 
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of which are little used today, the study provides good support for the value of arterial line 
filtration. 
Three studies have investigated the effect of conventional filtration on cerebral outcomes 
other than neuropsychological function. Henrickson159 (1995) investigated the effect of two 
different types of filter on cerebral blood flow, Sellman168 (1992) examined the effect of a 
single filter type on post- operative magnetic resonance imaging (MRI) of the brain and 
Taggart150 (1 996) studied the effect of filtration on serum S 100b. All three studies used 
suitable, although not identical populations. Sellman used elective CABG patients, Taggart 
used elective first time CABG patients but Henrikson used both valve and CABG patients. 
It has been shown that there are increased serum S100b levels after valve surgery compared 
to CABG and so there may be a higher potential for brain injury in valve patients. All three 
were RCTs and those of Taggart and Sellman were the more rigorously constructed as they 
standardised anaesthetic, surgical and perfusion protocols. Henrikson was unable to 
standardise surgical protocol. 
Henrikson found that there was brain hyperperfusion on CPB in the control group and that 
both the 20 and 40 pm filters reduced this hyperperfusion but did not bring it to or below 
physiological levels. It would therefore seem unlikely that these filters are having a 
detrimental effect upon brain perfusion and could even protect the brain from hyperperfusion 
and the increased "embolic load" that this could entail. However, the relationship between 
cerebral blood flow and NP or neurological outcome is complicated and so one should not 
extrapolate too far beyond Henrikson's actual finding. Sellman was unable to find any MRI 
changes whether or not filters were used. This is not surprising as MRI has been found to be 
relatively insensitive at detecting brain injury at the diffuse cellular level (although some 
changes can be found post cardiac surgery16). Taggart found a significantly decreased 
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S100b level at 5 and 24 hours post surgery when 43µm heparin coated filters were used 
indicating that they may be reducing brain injury. Taggart's study was particularly 
interesting because although the previous studies discussed showed that filters could reduce 
microembolisation and improve neuropsychological function, these studies all used bubble 
oxygenators. Nearly everyone uses the superior membrane oxygenators now and Taggart's 
study provided evidence that filtration may reduce brain injury even when membrane 
oxygenators are used if S 100b is a good marker of cerebral injury. 
It therefore appears that the evidence regarding non -NP cerebral outcomes and filtration is 
inconclusive. The evidence regarding emboli and neuropsychological function is far more 
convincing. Neuropsychological outcome remains the gold standard measure of brain injury 
and S 100b levels are a controversial measure in cardiac surgery. 
5.4 Inflammatory Indices 
Cardiac surgery with cardiopulmonary bypass produces a systemic inflammatory response. 
Without detailing the complex process which is well reviewed elsewhere16 "77 it is relevant 
to outline the pivotal role of leucocytes in this inflammatory response. Via the activation of 
complement, coagulation, fibrinolysis and the Kallikrein -kinin system leucocytes are 
themselves activated. When leucocytes become activated they express cell surface activation 
markers such as CDl lb and CD18. They can then aggregate with each other, adhere to 
endothelial surfaces and degranulate to release superoxides, elastase and other proteases. 
These released substances destroy extracellular structures and thus increase tissue 
permeability causing inflammation and oedema. Activated leucocytes are therefore 
important mediators of tissue damage. 
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Leucocyte depletion for example by plasmapharesis was used as an experimental model in 
the 1980s to reduce the inflammatory response162. Depletion of leucocytes in animal models 
of cardiac surgery and bypass led to definite cardiopulmonary protective effects. The 
Leukoguard 6 (LG -6) filter was then developed to remove leucocytes from the arterial line in 
human CPB. The LG -6 filter has a conventional woven polyester 401-tm screen component 
but it also contains a non woven polyester fibre mesh element which specifically traps 
leucocytes. Initial in vitro studies with this filter were encouraging. Using bovine blood the 
filter was able to remove 70% of neutrophils during 90 minutes of perfusion. Further studies 
with human blood showed the selective removal of activated neutrophils18. To date there 
have been five published clinical studies investigating the effects of the LG -6 filter on 
inflammatory markers. 
Thurlow157 randomised seven patients to LG -6 and seven to a conventional filter (AV -6) and 
measured peri- operative white cell count and differential, platelets, haemoglobin and in three 
patients only (two from the AV6 group and one from the LG -6 group) leucocyte cell surface 
activation markers and superoxide production. There was no difference in peri- bypass WCC, 
platelets or superoxide production. However, in the one patient studied there was a gradient 
in CD45RO and CDI la expression on leucocytes across the LG -6 filter that was not present 
in the two AV -6 patients similarly studied. This suggests that the LG -6 filter could 
selectively remove activated leucocytes. However as this was only demonstrated in one 
patient it might have been more appropriate to write it up as a case report. 
Hurst154 used a slightly larger sample size (n =24) to also investigate haematological 
measures including the cytokines IL -6 and IL -8 as well as CD1 lb and CD18 markers. 
Although they had used elective valve surgery patients in order to have cases with longer 
bypass times than CABG cases, the only significant difference found was a decrease in 
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CD18 on neutrophils in the LG -6 group. This difference persisted for up to 24 hours post 
surgery. The study therefore added some weight to the theory that the filter could selectively 
reduce the number of activated leucocytes. Hurst was unable to find any clinical (cardiac 
and lung function as measured by cardiac index, ejection fraction, blood pressure, inotrope 
use, FVC /FEV 1, Pa 02 and length of hospital stay) in this relatively small group of patients. 
This result differed from a previous study by the same group16° which had used CABG 
patients with shorter bypass times and showed a significant reduction in WCC at four hours 
post surgery. They suggest that the capacity of the LG -6 filter to filter leucocytes may have 
been exceeded by the longer bypass times in the valve study. 
Baksaas153 measured a raft of inflammatory markers in 40 patients who were randomised to 
receive LG -6 or a conventional filter. Leucocyte count, myeloperoxidase, cytokines, 
complement or platelets were not affected by the filter and, of note, bypass times were not 
particularly long in this study (about 80 minutes). This lack of a result led Baksaas et al to 
employ an alternative strategy of LG -6 filter use. In a study published a year later151 the LG- 
6 filter was only used during the reperfusion phase of bypass. That is, only after cross clamp 
release until the end of bypass. The only significant finding was a reduced WCC at 2 hours 
post surgery. All other measures were unchanged. This strategy was therefore barely more 
successful than the usual method of using the filter throughout the whole period of bypass. 
Although there is a specific part of the inflammatory response which occurs during 
reperfusion, white cell activation occurs throughout bypass. Therefore if filtration is to be 
useful it seems logical to use it throughout bypass. 
A recent study by Mair152 was also unable to find any benefit from leucocyte depleting 
filtration in a prospective randomised clinical controlled trial. Forty patients were 
randomised to receive either a LG -6 or AV -6 filter. Surprisingly for a study investigating 
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inflammatory markers, Mair used low dose aprotinin in the pump prime. Aprotinin is a serine 
protease inhibitor with known anti -inflammatory effects which could thus potentially 
interfere with any filtration effect. They did not find a significant difference in WCC, 
differential, malondialdehyde and C- reactive protein. However, they found an increase in 
plasma elastase in the LG -6 filtered group during and immediately after bypass. Elastase is a 
proteolytic enzyme released by activated neutrophils. It is thought to have a locally 
destructive effect and becomes bound and inactivated in the bloodstream. Although it can 
logically be used as a marker of neutrophil activation, in the case of leucocyte filtration it 
crucially gives no indication as to where the leucocytes have become activated. A raised 
elastase could therefore reflect an increased release by those neutrophils trapped together in 
the filter rather than an increased activation of neutrophils in the tissues. One has to question 
whether trapping activated leucocytes in a filter can actually prevent them from doing harm 
as they are not totally removed from the circulation. They are clearly prevented from having 
a local destructive effect which is of potential benefit, but they could continue to release 
biologically active cytokines into the circulation which might then have a distant adverse 
effect. 
In a more recent randomised study of 24 patients, Chen et aí179 in 2002 support the finding of 
leucocyte depletion being able to reduce expression of adhesion molecules. Chen et al 
showed that use of the LG -6 filter not only significantly reduced the total number of 
circulating neutrophils, but also reduced both CDI lb and L- selectin expression during CPB, 
thus adding evidence that the LG -6 filter can selectively filter out activated leucocytes with 
these surface adhesion molecules. 
In conclusion, it appears that the LG -6 filter has not been found to consistently reduce the 
actual number of circulating leucocytes during bypass. The bone marrow seems able to 
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supply more during bypass. Although three studies suggest that the filter may be able to 
selectively remove activated leucocytes this is not convincing and is not accompanied by a 
decrease in inflammatory mediators. One must conclude that even if filters can remove 
activated leucocytes these leucocytes are not totally removed from the circulation and are 
thus not prevented from releasing enzymes and possibly cytokines. 
5.5 Cardiac Outcomes 
The three studies that have investigated the effect of filters on measures of cardiac function 
all show a positive beneficial result despite being on different populations of cardiac surgery 
patients. Hachida et aí158 used 28 valve patients, Johnson et al'60 used elective CABG 
patients and Di Salvo et al155 used 20 high risk CABG patients. All were RCTs and used LD 
filters tested against Pall Autovent 40µm filters. Di Salvo et al and Hachida et al were able 
to standardise surgery but not anaesthesia or perfusion techniques. 
Di Salvo et aí155 found that the use of the LG -6 filter resulted in a decrease in serum 
troponin -T and an increased glutathione providing indirect evidence for a decrease in 
myocardial damage. Johnson et al's only positive clinical finding was increased blood 
pressure at 4 hours post surgery 160 Hachida et aí158 showed that filtered patients had lower 
serum CK -MB levels and required less inotropic support. These studies therefore show either 
indirect evidence of decreased myocardial damage (by three different methods) or an only 
temporary clinical benefit. There is nothing to suggest a lasting clinical benefit from these 
outcomes and the long term effects on patients are unlikely to be as great as reducing 
neuropsychological deficits which may persist. 
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5.6 Pulmonary Outcomes 
The greatest number of studies (eight) have addressed the effect of both conventional and 
leucocyte depleting filters on various pulmonary outcomes. A study by Connell "' in 1973 
showed that in a RCT of 37 unselected patients a Dacron wool filter was able to reduce the 
post bypass histopathological lung changes. Interestingly in relation to later studies using 
LD filters they found that the leucocyte aggregates found in the lungs of the unfiltered group 
were reduced by the Dacron filters. This was, however a descriptive decrease not supported 
by numerical data. The other seven studies are all recent and use the LG -6 filter. Palanzo's 
two studies from 1993 and 1994 using both valve and CABG patients indicated that 
leucocyte depleted patients spend less time ventilated and stay a shorter time in 
hospital164'167. However, both studies have flaws. The first, an RCT of 350 patients did not 
determine the characteristics of the patient population with regard to pre- operative lung 
function. The second study, which did exclude patients with abnormal pre- operative lung 
function is a retrospective study of only 36 patients. Coleman163 conducted an observational 
study on 189 CABG patients. He found a decreased oxygen requirement in the filter group 
which, although statistically significant in those aged > 70, is a fairly soft outcome measure 
and must be treated with caution, especially in an observational study. Johnson160 and 
Hachida158 reported RCTs from 1995 in which they found a decrease pulmonary shunt and 
increased pulmonary index respectively. Lust156 and Mihaljevic'61 found no difference in 
post -op lung function when LD filtration was compared to conventional filtration. The 
overall picture is therefore mixed but it does appear that LD filtration can have a beneficial 
effect on lung function and there is histological evidence to support and explain this. 
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5.7 Length of Stay and Cost Implications 
Gott et al's large four arm study of 400 patients149 was deliberately designed to incorporate a 
large range of risk and therefore selected all patients having CABG surgery. They used four 
anti -inflammatory measures - steroids, aprotinin, leucocyte depletion and heparin bonded 
circuitry. It was found that the LG -6 filter significantly reduced the length of hospital stay by 
one day in "low risk" (less than 5% predicted mortality) patients. It is unclear from this 
study exactly what specific clinical benefits were allowing this earlier discharge home. 
Sahlman et a1180 randomised 60 patients to either receive an LG -6 filter or no filter and 
measured clinical patient recovery. In this relatively small study no differences in length of 
ICU or hospital stay, use of inotropy or oxygenation index were found between the two 
groups. 
5.8 Conclusions 
Despite the wide ranging nature of the studies reviewed, a few conclusions are possible. The 
work of Pugsley8 and the Middlesex Hospital group convincingly shows that conventional 
filters reduce middle cerebral artery microemboli and also the incidence of 
neuropsychological deficit. However, these studies were performed using bubble 
oxygenators and pH stat acid base management on bypass. Most centres now use membrane 
oxygenators and alpha stat acid base management and the neuroprotective effect of filters has 
not been assessed in this situation. Indeed it is possible that this is why some surgeons and 
perfusionists believe that arterial line filters are not necessary in this modern environment 
and this could account for their lower usage in the UK. Logically, conventional filters 
should filter out emboli produced by either type of oxygenator and there is no doubt that 
microemboli occur even with membrane oxygenators, if not in such great quantities as 
bubble oxygenators. Taggart et al's studyi5° suggests that filters may reduce brain injury 
when membrane oxygenators and alpha stat are employed. Clark et al's study of 1995 has 
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shown that even when using alpha stat and membrane oxygenators the number of 
microemboli detected was related to the NP outcome110 
The non -NP cerebral outcome studies are interesting, but even the potentially most 
significant, that of Taggart et al, awaits further validation of S100b as a marker of clinically 
relevant brain injury in cardiac surgery. Indeed all work involving S100b in which 
cardiotomy suction was used may now, in fact have little relevance because cardiotomy 
suction itself may make a major contribution to serum S100b levels18'. Further work is 
required to relate these findings to those involving microemboli and neuropsychological 
change. 
LD filtration has been the focus of recent studies showing a cardiopulmonary benefit. In 
high risk patients155 there is certainly biochemical evidence for a cardioprotective benefit 
from LD filtration. Clinical benefit appears to be transient. As discussed, the effect of LD 
filtration on clinical lung function seems greater but there are some flawed studies as well as 
negative results and overall the studies are not conclusive. 
Interestingly, there is a clear split between the outcome groups. All the cerebral studies 
compared a filtered to a non -filtered group. The more recently studied cardiac, pulmonary 
and inflammatory groups have compared the LG -6 filter to a conventional filter. This is 
obviously based on the reasoning that the LG -6 filter, by reducing the inflammatory response 
could attenuate inflammatory mediated damage to the heart and lungs. Since the studies of 
Pugsley, several potentially neuroprotective drugs have been tested in cardiac surgery with 
little or no benefit as far as the author is aware. To date there is no published data 
investigating the effect of the LG -6 filter on cerebral outcomes. The basis of this thesis is 
87 
therefore the investigation of the effect of leucocyte filtration on inflammatory response, 
microemboli production and neuropsychological outcome. 
In conclusion there is enough evidence to justify the routine use of at least conventional 
filtration, if only for its neuroprotective effect. Leucocyte depleting filters are approximately 
twice the price of conventional filters and it is more difficult to justify their routine use as 
yet. They may benefit cardiac patients with co- morbid pulmonary disease, or they may 
benefit lower risk cases as demonstrated by Gott et al149. An increase in the use of both types 
of filter should be accompanied by further investigation into their clinical benefit using larger 
RCTs of sufficient power. 
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Chapter 6 
The role of S1006 as a marker of cerebral injury 
in cardiac surgery 
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Chapter one detailed the relatively laborious process of neuropsychological testing and also 
discussed the limitations of such testing. A simple biochemical marker of brain injury in the 
peri- operative period would therefore be an attractively convenient alternative to NP testing. 
It is for this reason that the role of the neuroprotein S100b as a marker for cerebral injury in 
cardiac surgery has been investigated quite intensively over the last ten years. This chapter 
will discuss what is already known about S100b and its relationship to cardiac surgery, 
cardiopulmonary bypass, microemboli and neuropsychological outcomes. 
S100b is only one of a number of potential markers of brain injury. Other substances shown 
to be released from neurons, neuroglia, endothelium, platelets and leucocytes following 
cerebral hypoxia, ischaemia or other injury include Myelin Basic Protein (MBP) and Glial 
Fibrillary Acidic Protein (GFAP) from glia and Neuron Specific Enolase (NSE) and 
Adenylate Kinase (AK) from neurones. Such markers may be useful in indicating the 
severity or size of a cerebral lesion but they will all have certain inherent limitations. At the 
most they are likely to be useful as a guide rather than a substitute for clinical tests. A 
biochemical marker cannot give any anatomical localisation of a lesion nor may the degree 
of release reflect the clinical effect of a lesion. For example, a large infarct in the frontal 
lobe could produce a large release of marker with minimal clinical effect whereas a small 
infarct in the internal capsule might result in minimal marker release and yet a dense 
hemiplegia. However, these drawbacks of correlating marker release with neurological 
outcome may not apply to the global cerebral injury thought to produce neuropsychological 
deficits. As will be discussed in this chapter, there is some evidence that the degree of 
marker release does correlate with the degree of global brain injury as reflected by NP 
impairment. However, there still remains a lack of consensus in the literature on the 
relationship between S100b and neuropsychological outcome. It is not clear whether an 
increased S100b in the context of cardiac surgery reflects increased cerebral injury or is 
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actually an artefact. At present the evidence is mainly against S100b having a useful role. 
Nevertheless, at the time of planning this study there was intense interest in S 100b and other 
assays as potential markers of brain injury after cardiac surgery. S100b was chosen as a 
marker for this study because an assay for S100b was available at a reasonable cost in our 
institution. S100b has no obvious superiority over other potential markers but as this study 
has utilised S100b as a marker of cerebral injury, discussion here is limited to this marker. 
S100b is one of a family of 16 calcium binding proteins found in a variety of tissues. S l 00b 
is present in high concentrations in astroglial, microglial and Schwann cells and is highly 
specific to the brain. Its exact function is not known, but it has a role in the control of cell 
growth, cell structure and in signal transduction'82. It was first identified in 1965 by BW 
Moore and called S100b due to its solubility in 100% ammonium sulphate. It is eliminated 
by the kidney and has a biological half -life of 113 minutes' $3. 
The nomenclature in the literature has changed as more members have been discovered182 
and the relevant nomenclature is as follows. There are three main dimeric isoforms SIOOaO, 
S100b and S 100a made up from two monomeric subunits, Al and B. S 100a0 consists of Al- 
Al , S100b consists of B -B and S100a consists of Al -B. This is a crucial point because the 
initial studies which used S100b in the diagnosis of CNS pathology were describing the 
S100b dimer which is specific to the CNS. Later studies have, however, shown that the 
SIOOB subunit is present in extra CNS tissues such as the heart and aorta1". The terms 
S100b and S100B should not be used interchangeably, however the nomenclature in the 
literature is often confused and some researchers still refer to Sloop' 
85. 
To date and as far as the author is aware, studies evaluating cardiac surgical patients have 
exclusively used various versions of the Sangtec S100b assay which is commercially 
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available as a kit. The validity of the Sangtec S100b assay has never been published184 and 
there are concerns that it may not be specific enough for cerebral S100b to make its use in 
cardiac surgery useful. As S 100B is contained in the heart, aorta and other mediastinal 
tissues182 which are disrupted by cardiac surgery there is therefore the potential for 
contamination from these tissues. The Sangtec assay detects S 100B subunit and so may 
detect S100a. The fact that differing profiles of S100b release have been found after cardiac 
surgery depending on whether or not cardiotomy suction is used suggests that the Sangtec 
assay may be detecting mediastinally released S10013181. When cardiotomy suction is 
avoided the amount of S100b detected is far lower. Also a much higher S 100b concentration 
has been detected in the cardiotomy suction blood compared to the systemic blood samples. 
This would suggest that the majority of the SI 00b being detected is mediastinal rather than 
cerebral in origin. 
S100b was first used as a diagnostic and prognostic marker for central nervous system 
tumours. Increases in serum levels of S100b were then found after strokes, subarachnoid 
haemorrhage and cerebral trauma186°187. Since then, it has been found that S100b serum 
levels are raised after adult cardiac surgery. Johnsson et aí188 (1995) measured S100b levels 
in 38 patients undergoing various types of cardiac surgery with CPB. Eight patients had 
neurological complications - either stroke or delayed awakening after surgery. Seven of the 
patients with neurological complications had raised S100b. A raised S100b was found in 
only 4 of the remaining 30 who had no neurological complication. Westaby189 in 1996 
measured serial serum S100b levels in 34 patients undergoing CABG with CPB and 
compared them to 9 patients undergoing CABG without CPB. He found that in the non -CPB 
group none had a raised S100b apart from one patient who suffered a stroke. In the CPB 
group S100b was significantly raised after CPB, decreasing to normal levels within 24 hours. 
Of significance, none of the CPB group patients had a neurological event, despite raised 
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S100b levels. Also, SI00b levels were strongly correlated (r= 0.89, p <0.001) with duration 
of CPB. These two facts raised the question of whether a raised S100b in the context of 
cardiac surgery with CPB reflected a sub clinical cerebral injury or was merely a bypass 
related epiphenomenon perhaps due to increased permeability of the blood brain barrier. 
Although it has been suggested that the inflammatory response to CPB may cause the blood 
brain barrier to become more leaky, a study in piglets has shown no increase in blood brain 
barrier permeability after 2 hours of bypass190. Also, the concentrations of S1 00b found in 
the serum after cardiac surgery are far greater than the normal CSF S100b concentration. It 
would thus seem unlikely that permeability changes alone could account for raised S1 00b 
after cardiac surgery. 
Aberg190 used a mock CPB circuit and compared S100b release in patients undergoing 
cardiac and non -cardiac operations. Peak S1 00b levels were found at the end of CPB and 
were not due to surgery, anaesthesia or blood trauma implying that they were due to cerebral 
injury. Westaby191 was also able to show that S 100b was not elevated in patients who receive 
CABG without CPB (supported by a more recent study from Bristol192). In the same study, 
Westaby also showed that there was a strong and significant correlation between S1 00b 
levels and the length of bypass but this was not repeatable in subsequent studies150;193 
Taggart 193 has shown in a prospective study that patients in whom the heart is opened for 
valve replacement or atrial septal defect closure have a significantly greater elevation in 
S1 00b than CABG patients. S 100b was more frequently elevated, elevated to a significantly 
greater magnitude, and also remained significantly elevated for longer. The interpretation of 
these results as showing that the brain suffers greater global injury when the heart is opened 
is consistent with those studies showing greater neuropsychological deficit following valve 
surgery compared to CABG surgery24. 
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As has been discussed, there is strong evidence that microemboli are involved in the 
pathogenesis of global cerebral injury. Grocott showed a weak but highly significant 
correlation between the number of microemboli detected during aortic cannulation and the 
S100b elevation in a population of patients undergoing elective CABG'9a 
Also, as has already been discussed at length, a reduction of microemboli by arterial line 
filtration may reduce NP deficit8. Taggart et al's prospective randomised controlled trial 
which demonstrates a reduced S100b in patients who receive arterial line filtration's° 
therefore provides further indirect evidence that an elevated S100b does reflect a global 
cerebral injury. However neither of these two studies shows cause and effect, that is that 
microemboli cause cerebral injury which then leads to S100b release. A reduction in S100b, 
as in Taggart's filter study would not then imply a reduction in NP deficits. Also, the fact 
that more S 1 00b is released after valve replacements may be directly due to the cut heart 
releasing more S100b rather than a consequence of increased cerebral injury even if there is 
an actual increased NP deficit. 
There are now several studies in which S100b levels and neuropsychological changes have 
been directly compared. Overall findings remain inconclusive. Kilminster et al195 (1999) 
studied 130 unselected cardiac surgical patients and evaluated S100b release and 
neuropsychological change. They used well- described and validated tests pre -operatively and 
at six to eight weeks post- operatively. Kilminster et al found that lower S100b was 
correlated with better neuropsychological outcome. Area under the curve of S 100b release 
correlated with age and bypass time and the peak S100b level also correlated with bypass 
time. Kilminster et al used multiple regression models to show that neuropsychological 
performance accounted for 23% of the variance associated with S100b release after partialing 
out the effects of age and bypass time. This suggests that S100b release is not just an epi- 
phenomenon related to cardiotomy suction or bypass associated leakage of S100b via the 
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blood brain barrier but does have a true association with neuropsychological outcome. 
Hermann et aI196 also looked at S100b release in a smaller group of patients (n =36) 
undergoing CABG (N =18) or valve replacement (n =18). They found a weak correlation 
between S100b release and degree of post- operative decline in neuropsychological function 
in the valve replacement group only. Although Hermann et al found an increase in NP 
decline in the valve replacement group compared to the CABG group, there was no 
difference in S100b release between the groups. In addition to conflicting with Kilminster et 
al's results195 this also contrasts with Taggarts study193 which found a greater release of 
S100b in valve replacement and other open heart procedures compared to CABG patients. 
A more recent study by Westaby et al (2000) found no significant correlation between S100b 
release and neuropsychological outcome at 5 days or 6 months post operation189. In this 
study a comprehensive battery of neuropsychological tests were used as well as a new and 
supposedly more sensitive immunoluminometric S100b assay. However they were very 
careful to minimize surgical bleeding and there was no use of cardiotomy suction or the re- 
transfusion of mediastinal shed blood. This was done to avoid the detection of non -cerebral 
sources of S100b, as identified by Andersen181, and may have led to the lower peaks of 
S100b found in this study. Westaby's study suggests that when non -cerebral sources of 
S100b are eliminated, there is no correlation of early S100b release with neurological 
outcome. 
Although there is evidence that cardiotomy suction blood is a significant source of mainly 
lipid microemboli90, Anderson has shown in two studies that the S100b detected by the 
Sangtec assay in cardiac surgical patients may well derive from the high concentrations of 
S100b in cardiotomy suction blood returned to patients. In his first study Andersen18' 
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randomly allocated 20 patients having CABG surgery to either cardiotomy suction or a cell 
saving device and measured serial serum S100b (he labels it as S10013 in this study) as well 
as S100b levels in the blood from the wound and the cell saving device. A significantly 
lower S I O0b level was found at the end of CPB in the cell saver group (0.441Ag /L) compared 
to the cardiotomy suction group (2.47µg /L). The level in the cell saver group was 
comparable levels in patients having off -pump surgery197. Andersen also found that levels of 
S100b were 421.tg /L in the cell saver reservoir and 33µg/L in the blood from the mediastinal 
wound. This study therefore showed that, at least when the Sangtec assay is used, it is the 
cardiotomy suction rather than CPB itself causing the rise in S100b levels. Jonsson198 has 
found almost identical results to Anderson. Jonsson found that a group of patients treated 
with a cell saver had S100b levels of 0.53µg /L at the end of bypass compared to S100b 
levels of 2.40µg /L at the end of bypass in patients who had cardiotomy suction. In a further 
study199Anderson specifically measured S100 Al-B and S100 BB dimers (i.e. S 100a and 
S100b) using specific antibodies. (In this paper he states " S 100B is not a unique protein, but 
rather denotes collectively all SI 00 dimers that contain one (3 subunit." This statement is 
potentially confusing because by SIOOB he means not he monomer, which using the correct 
nomenclature it is, but what is detected by the Sangtec assay which detects any dimer with 
the S l 00B monomer. He calls the S100 monomer the "(3 subunit" but (3 is also not a correct 
term in the nomenclature. This confusion in the literature may well have arisen because the 
Sangtec assay detects the S 100B monomer and is detecting S 100a and S l 00b.) Anderson 
found that both S100b and S l 00a were released in approximately equal quantities during 
CPB with cardiotomy suction and in lower but equal quantities during CPB with a cell saver. 
Interestingly, the sum of the S 100a and S100b did not quite account for the detected 
"SIOOB" suggesting that the Sangtec assay may even be detecting S100a0. This suggests 
that S 1 00b may not be as specific to cerebral neurones as thought and that the detected 
release from the mediastinum may not be purely artefactual due to cross reactivity of the 
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Sangtec assay but that S100b may actually be released from mediastinal tissues. 
Cardiotomy suction blood- containing mediastinally released S100b could therefore be a 
direct cause of both microemboli and increased S100b levels. This would then explain the 
relationship between S100b and neuropsychological outcome. 
cardiotomy suction S 1 00b release 
microembolil cerebral injury NP deficit 
rather than 
microemboli cerebral injury NP deficit 
S100b release 
In conclusion one has to be very circumspect about interpreting papers which have found a 
positive correlation between S100b levels and neuropsychological outcome. These studies 
must be interpreted in the light of the later studies which have shown that most of the rise in 
S100b levels can be accounted for by the release of S100 from the mediastinum. Studies 
which have eliminated this mediastinal source by not using cardiotomy suction have not been 
able to find any correlation between S100b and neuropsychological outcome. 
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Chapter 7 
Methods and Materials 
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7.1 Design 
This study was a prospective, randomised, double blind, controlled clinical trial. 
This single centre study was a collaboration between the University College of London Unit 
of Health Psychology and University College London Hospitals Department of 
Cardiothoracic Surgery. 
7.2 Ethical Approval 
Approval was obtained from the University College London Hospitals ethics committee (see 
appendix 1). The trial protocol was also approved by the hospital Research and 
Development committee. 
7.3 Statistical Planning 
Sample size calculation was based on the Z change scores in the previous study conducted at 
the institution of the present study by Arrowsmith et al42. The sample size was formulated on 
a two -sided hypothesis with alpha significance set at 0.05 and power set at 0.80. Mean 
difference and standard deviation data from the Arrowsmith et al data were 1.25 and 2.7 
respectively. It was assumed that there would be equal size and equal variance for the control 
and treatment groups. Using the formula below: 
Sample per group = 2 *[Z(,_co + Z(í_0)]2/ 
A2 
Where A2 represents the standardised difference (i.e. the treatment difference divided by its 
standard deviation). 
The sample size required was 74 per group, i.e. a total sample of 148. It was estimated that a 
25% loss to follow up was possible and so 1.25 x148 = 197 patients in total were calculated 
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to be required. 
7.4 Study Population 
Patients scheduled for non emergency coronary artery bypass surgery in the department of 
cardiothoracic surgery at The Middlesex Hospital (University College Hospitals NHS Trust) 
were invited by the author to participate. A letter of invitation and a patient information sheet 
was sent to all patients together with the letter informing them of their date of surgery about 
4 to 6 weeks prior to surgery. Both inpatients and patients from the "at home" waiting lists 
were recruited. Inpatients were patients who were kept in for surgery following coronary 
angiography. The decision to keep patients in was based on their coronary anatomy. 
Demographic and other differences between inpatients and "at home" patients were not 
analysed. 
7.5 Recruitment and Consent of Patients 
The following patients were excluded from recruitment: - 
Patients taking oral or intravenous corticosteroid medication. Patients taking non -steroidal 
anti -inflammatory medication were allowed to participate. 
Patients aged over 80 years. Although these patients are at most risk of NP injury, they also 
have the highest co- morbidity and mortality, which may make them less likely to attend for 
follow up. 
Patients considered or found unable to perform the pre- operative NP testing for whatever 
reason. Examples were inability to speak or read English, blindness or physical disability. 
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Patients who had previously had cardiac surgery. Patients having such "re -do" surgery may 
have suffered a previous NP insult. They are also likely to be given aprotinin, an anti - 
inflammatory agent which is used to reduce bleeding but which might also confound the 
leucocyte depleting effects of the filters. 
Patients with a history of transient ischaemic attacks or strokes or a recent history of cardiac 
arrest (within I month). A history of previous cerebral injury could also confound results. 
Patients with carotid artery stenosis. (Patients were screened with auscultation of the neck. If 
a bruit was audible the patient then had carotid duplex scanning.) It is accepted that this is an 
imperfect method for screening for carotid stenoses. However this was the departmental 
policy and facilities were not available for screening all study patients with carotid Doppler. 
Patients with insulin dependent diabetes mellitus. It is not known whether these patients are 
more at risk of NP deficits but there is evidence that the way in which serum glucose is 
managed on bypass can affect NP outcome13. 
Patients with renal failure (defined as creatinine greater than I 50mmo1/1 pre - operatively). 
S100b is secreted predominantly by the kidney and so assays of this marker would be 
invalidated in patients with renal failure. 
Patients with a pre- operative white cell count outside the normal range of 
3-11 x 106/mm3. 
Patients fitting the criteria were then invited to participate. In accordance with ethics 
committee guidance, fully informed consent was obtained from all patients. The trial was 
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explained verbally to patients who were then given a written information sheet to read (see 
appendix 2). Patients were requested to sign a consent form if they agreed to participate (the 
consent form was part of the case report file, see appendix 3). 
7.6 Randomisation 
Full randomisation to test or control groups was used. 200 sealed envelopes containing 100 
test and 100 control group slips were given to the perfusion department. A perfusionist drew 
an envelope at random when informed the day before surgery that a patient was in the trial. 
The perfusionist then set up the bypass circuit using the appropriate filter. Only the perfusion 
department kept a record of the filter used for each patient, so that all other investigators 
were blinded to the patient groups. If a patient was cancelled on the day of surgery then their 
allocation was kept for the date when they did have surgery. If a patient had to be removed 
from the trial due to breaking of the protocol (e.g. surgery done off -pump or propofol used) 
then their allocated envelope was not re -used. 
7.7 Type of Filter 
The original plan for the study was to compare two filters only. The test filter was the Pall 
Leukoguard -6 (LG -6) and the control was to have been the routine arterial line filter used in 
our unit, the Avecor affinity. Both filters have a 40[tm screen polyester element but the LG -6 
has an additional non -woven polyester mesh downstream of the screen, which gives it its 
leucocyte depleting properties. However the LG -6 is also an auto -venting filter. Auto 
venting allows the LG -6 to vent air filtered by the screen directly to the atmosphere. In 
102 
contrast, the Avecor filter vents any air back to the oxygenator through a closed vent line. 
This potential effect on microemboli production or elimination of this difference in venting 
properties was not appreciated until mid way through the trial. The effect of venting on 
microemboli has not been previously studied and its potential effect on microemboli is 
unknown. The AV -6 is auto -venting in an identical manner to the test filter but has no 
leucocyte -depleting element. It is arguably a more suitable control filter. It was therefore 
decided at this midway stage, to use a second control filter, the Pall Autovent -6 (AV -6). 
There was, however, a time delay between this decision and being able to implement the 
decision. This was because the second control filter had to be ordered and made up in pre - 
made bypass circuits. A second batch of envelopes was given to the perfusion department 
when the AV -6 filter began to be used. This led to an uneven number of patients eventually 
randomised to the three filter groups and a greater overall number of patients in the control 
group compared to the test group (see Table 8.3). The use of these two control filters also 
enabled a comparison to be made between an auto -venting and non -auto -venting filter, 
although the study was not originally designed or powered to do this. 
7.8 Theatre Protocol 
Anaesthesia, surgical technique, cardio pulmonary bypass, control of blood pressure and 
perfusion pressure, control of pH and NCO'? all followed a set protocol developed in previous 
trials assessing neuropsychological outcome after cardiac surgery. 
7.9 Anaesthesia 
Premedication consisted of morphine (5 -10mg) and hyoscine (0.3- 0.4mg). Diazepam (5- 
10mg) or temazepam (10 -20mg) was given according to the anaesthetist's preference. 
Supplemental oxygen was administered via a face mask at a rate of 41 /min from the time of 
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medication until induction of anaesthesia. Intravenous midazolam was used during insertion 
of peripheral and central cannulae, as necessary. Induction was carried out with midazolam 
(2- 10mg), fentanyl (0.5- 2.0mg), pancuronium and or suxamethonium. The trachea was 
intubated with a cuffed endotracheal tube and mechanical ventilation was used to achieve an 
end tidal CO2 of 5.3 kPa. Maintenance was with nitrous oxide and oxygen and then 
isoflurane. 
Propofol, etomidate and thiopentane were specifically avoided as these have potential but 
unproven neuroprotective effects but are used by only some anaesthetists. Post -operatively 
patients were kept sedated with intravenous midazolam. 
7.10 Surgical Technique 
Patients of all six consultants in the unit were used. These were Mr Pugsley, Mr Walesby, Mr 
Pattison, Mr Kallis, Mr Kolvekar and Mr Hayward. All consultants used the same technique 
of intermittent cross clamp fibrillation as myocardial protection. The left internal mammary 
artery and /or appropriate lengths of long saphenous vein were first harvested. After the 
commencement of CPB distal aorto- coronary anastamoses were fashioned on the surface of 
the heart with the proximal aorta cross -clamped and the heart in electrically induced 
ventricular fibrillation. Proximal aorto- coronary anastamoses were made after each distal 
anastamoses with the aortic cross clamp removed and the heart beating normally. 
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7.11 Cardiopulmonary Bypass Technique 
Cardiopulmonary bypass was established between a cannula placed in the right atrium and a 
cannula in the ascending aorta. The bypass circuit was primed with 1.6 litres of Hartmanns 
solution heparinised with 5000iu of sodium heparin. Full anticoagulation was achieved prior 
to aortic cannulation with 300iu/kg heparin. Further doses of heparin were given throughout 
CPB to maintain the activated whole blood clotting time (ACT) greater than 400 seconds. 
Heparin concentration was not measured, as this assay was not available, although this may 
be a superior method of controlling anticoagulation200. A flat bed membrane oxygenator 
(5400, Bard, UK) and a roller pump (Stockard, USA) and tubing (Bard, UK) was used to 
give non -pulsatile flow. Flow was initially 2.4L/m2 /min at 37° C reducing to 1.8L/m2/min at 
32 °C. Patients were actively cooled to 32 °C (nasopharyngeal) and then re- warmed to 37 °C 
(nasopharyngeal) during late CPB. During both cooling and re- warming the gradient between 
the arterial line blood and the nasopharyngeal temperature was always less than 10 °C. 
Perfusion pressure was maintained between 50 and 60 mmHg using the pressor 
phenylephrine and vasodilator phentolamine, which have no direct effect on the cerebral 
circulation. PaCO2 control was alpha stat; that is maintained at 5.3 kPa temperature 
uncorrected. Cardiotomy suction was via a Harvey cardiotomy reservoir connected to two or 
three low- pressure cardiotomy suckers. At the end of CPB the anticoagulant effect of heparin 
was reversed with protamine sulphate to correct the ACT to pre -CPB levels. 
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7.12 Monitoring 
Apart from the transcranial Doppler and extra blood samples, theatre monitoring was routine. 
Patients were monitored with a right radial arterial line, central venous pressure via the right 
internal jugular vein, pulse oximetry, catheterisation of the bladder and end tidal CO2. 
Temperature was monitored with a nasopharyngeal probe. This was left in for 24 hours to 
measure temperature for this period. 
In addition to the recording of standard intra- operative variables such as bypass and cross 
clamp times, five specific intra- operative variables which have a potential influence on 
microemboli production and neuropsychological outcome were also recorded. These were: - 
1) Clinical presence of aortic atheroma or calcification - either visible on CXR or palpable 
intra- operatively by the surgeon. 
2) Whether or not a side -biting clamp was used for aortic cannulation. 
3) Minimum temperature on CPB. 
4) Maximum temperature reached during rewarming. 
5) Time taken to rewarm from start of rewarming to reach 37 °C. 
Some surgeons preferred to use a side -biting clamp for cannulation whereas others did not 
and it was not possible to standardise this. Although there was a set protocol for cooling and 
rewarming as stated earlier there was some inevitable variation in the temperatures actually 




The following battery of nine neuropsychological tests was chosen to cover a range of 
domains as detailed below. The battery had been developed at UCLH and includes the core 
battery as recommended by the consensus meeting14. A trained psychologist who was 
blinded to the patients group administered these tests. A single psychologist saw all the 
patients pre- operatively. Patients were only recruited when this psychologist was available. 
There were six occasions (6/162 = 3.7 %) post -operatively when this psychologist was not 
available and, because patients were returning on this one occasion only, the tests were 
performed by one of two other psychologists. All patients were brought from their ward to 
the same room where tests were carried out under relaxed conditions. The following battery 
of nine widely used tests was conducted: 
7.13.1.1 The Rey Auditory Verbal Learning Test201 
This is a test of immediate memory span, serial learning and also retention following 
distraction. A list of 15 words is read to the patient who then attempts to recall them 
immediately under free recall conditions. After the first recall, all 15 words are presented 
again and the patient is again asked to recall as many as possible. This is repeated on three 
occasions. A second list of 15 different words is then presented to the patient and they are 
again asked to recall as many as possible from this new list. Finally the patient is asked to 
recall as many as possible from the first list without the first list being re -read to the patient. 
This final test measures recall following distraction. The score is the total number of correct 
answers from list 1 -5 and 7. 
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7.13.1.2 Trailmaking Tests A and B 
This test has been taken from the Army Individual Test Battery and it assesses both attention 
and motor speed. It has been found to be very sensitive to brain injury. For trailmaking A the 
patient has to draw lines through consecutively numbered circles. For trailmaking B, which 
is more difficult, the patient has to join a sequence of alternating letters and numbers. The 
result of each test is a time to completion score. 
7.13.1.3 Grooved Pegboard Test 
This test requires the patient to put pegs into a board containing grooved slots. Each slot has 
a groove at various angles and each peg has a corresponding ridge along each side. The 
patient therefore has to rotate each peg to the correct orientation before it can be inserted. 
The grooved pegboard test therefore measures manual dexterity and fine motor co- 
ordination. The test is performed using the dominant and then the non -dominant hand so that 
both right and left cerebral hemisphere function is assessed. Again the result of each test is a 
time to completion score. 
7.13.1.4 Symbol Digit Replacement Test202 
This is a pen and paper test adapted for use on a computer. A key appears on the screen with 
nine different symbols each with its own corresponding digit from 1 to 9 shown underneath 
the symbol. Below the key on the screen there is a row of symbols with the digits missing. 
The patient is required to put the digit beneath each symbol. The number of correct 
responses and the time taken is recorded. The result of the test is a time to completion score. 
7.13.1.5 Non -verbal Memory Testé 
The patient is required to look at a chequered board design on the computer screen which is 
presented for 10 seconds and then disappears. Three smaller designs then appear on the 
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screen and the patient is required to identify which of these three is the one identical to the 
original design shown. This is repeated 20 times and the number correct and the response 
times are recorded. The result of the test is a time to completion score. 
7.13.1.6 Letter Cancellation Test2o3 
The patient is asked to scan an A4 sheet of paper containing rows of a list of randomly 
interspersed letters and cross out a designated target letter. Performance is scored on number 
correct and time to completion. 
7.13.1.7 Choice Reaction Time Test 8 
In this test the patients are asked to discriminate between and respond, as quickly as possible, 
to two letters displayed on a computer screen. Response time and accuracy are recorded. 
In addition to the above neuropsychological tests, measures of anxiety and depression were 
taken pre -operatively and post -operatively. Subjective Cognition, that is, the patients own 
perception of any change in cognitive function was assessed post- operatively with a simple 
nine question questionnaire. The CESD (Centre for Epidemiologic Studies Depression scale) 
was used to assess depression. It is a 20 item self -report scale which measures the presence 
and severity of depressive symptoms. The STAI (Spielberger state and trait anxiety 
inventory) was used to measure trait anxiety pre -operatively and state anxiety pre- operatively 
and post -operatively. Trait anxiety measures how anxious a personality a patient possesses, 
whereas state provides an immediate measure of anxiety in the patients current situation. 
All tests were performed during the week pre- operatively (usually on the day preceding 
surgery) and then 6 -8 weeks post surgery. The pre- operative test was usually done the 
afternoon prior to surgery and the post- operative test on the day that the patient returned to 
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the routine surgical follow -up clinic. 
There is no ideal time for performing pre- operative neuropsychological tests. It has been 
conventional at the institution of the present study to perform the tests the day before 
surgery. In fact, as has previously been discussed in chapter 1, patients have been found to be 
less anxious a day before surgery compared to a week before surgery38. This difference in 
anxiety had no effect on NP performance38. 
7.13.2 Transcranial Doppler 
Intra- operative transcranial Doppler was used to measure both a) cerebral artery blood 
velocity and b) embolic load. It therefore functioned both as a control measurement (as 
blood velocity should be the same in both groups), and also a measure of a potential end 
point variable (i.e. embolic load). 
Cerebral artery blood velocity was assessed at the following discrete points: 
1) 10 minutes pre bypass 
2) 1 minute pre bypass 
3) 15 minutes into CPB 
4) 30 minutes into CPB 
5) 60 minutes into CPB 
6) 90 minutes into CPB 
7) 10 minutes after discontinuing CPB 
Monitoring for microemboli took place for two continuous periods: 
1) During CPB 
2) For the 10 minutes following bypass. 
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The Doppler machine used was a Nicolet EME Pioneer 4040 Transcranial Doppler system. 
The right middle cerebral artery was isonated using a 2 MHz pulsed wave transducer and the 
probe was secured to the skull using an elasticated headset, which allowed for prolonged 
monitoring. Microembolic events and cerebral blood flow velocity were recorded onto 
videotapes for subsequent analysis. A plot of mean velocity against time and spectra of 
detected microemboli were separately taped for each patient so values of blood velocity for 
the times detailed were then obtained. The micro emboli were counted manually "off- line" 
(i.e. after the operation) using their unique auditory and visual characteristics. International 
consensus criteria were used for defining microemboli104. The same investigator blind to the 
patient group performed microemboli counting. A second investigator (Jan Stygall) 
reviewing 10% of the tapes assessed inter -observer reliability. These data were unfortunately 
lost. 
7.13.3 Biochemical 
Haemoglobin, white cell count with differential, platelets, creatinine, S100b, and neutrophil 
elastase were measured. Neutrophil count was used to check the efficacy of the LD filter, 
although the removal of activated neutrophils by this filter tends to lead to their replacement 
from the bone marrow, and platelet count was used to assess the effect of the filter on this. 
Neutrophil elastase measured neutrophil activation and degranulation. Creatinine checked 
renal function, which may affect S100b clearance. We planned to be able to correlate the 
effect of leucocyte depleting filtration on neutrophil activation with the overall inflammatory 
status and neuropsychological changes. S100b was measured as a potential marker of 
cerebral injury. The following table summarises when each of these samples were taken: 
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6hrs 24hrs 48hrs 
Full Blood Count + + + + + + 
Urea+ Electrolytes + + 
S100b + + + + + 
Elastase + + + + + 
S100b and elastase samples were taken from the first 80 patients in the trial. This was 
because funds were not available to test all patients. Full blood count and differential white 
cell count were taken from all 192 patients. 
S100b 
S100b was measured using a previously described sandwich enzyme linked 
immunoabsorbant assay (ELISA)204'205 For this assay, monoclonal anti-S100b antibody was 
bound to the wall of a microtitre plate. This is called the "capture" antibody. The capture 
antibody was then incubated with the patient's plasma sample. 
The microtitre plates were first coated overnight with monoclonal anti -S100b at a 
concentration of 9.4tg /ml in 0.05 carbonate buffer (pH 9.5). The plates were then washed 
with 0.1% bovine serum albumin in phosphate buffer solution. 50µ1 of the patient's plasma 
sample was added in duplicate to the plate and 501i1 of 0.06M barbitone buffer (pH 8.6) 
containing 1mM calcium lactate were then added to each well (this was the incubation 
buffer). Plates were then incubated at 37 °C for three hours. After washing, rabbit anti -S100b 
antibody conjugated with horseradish peroxidase diluted 1 /1000 with incubation buffer was 
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added. The microtitre plate was then incubated at room temperature for one hour. The plates 
were again washed and then 100µ1 of enzyme substrate (1 mg /ml of phenylenediamine in 
0.05 M acetate buffer containing 0.01% hydrogen peroxide) was added. After incubation in 
the dark for a further 30 minutes the reaction was stopped by adding l M HC1. Absorbance 
was then read at 492nm with 405 nm as the reference wavelength using an Anthos 2001 Plate 
Reader (Denley Instruments, Sussex, UK). An ELISA standard curve had been constructed 
using S 100b standard samples and the S 100b concentration was then read from this curve. 
Elastase 
Neutrophil elastase was assayed as a complex with alpha -I- antitrypsin, in citrated plasma 
(0.105M citrate). The complex was measured using an enzyme linked immunoabsorbant 
assay (ELISA), as previously described206. Sheep antihuman neutrophil elastase was used as 
a coating antibody, and a peroxidase conjugated sheep anti -human alpha -l- antitrypsin 
antibody was used as a detector (Serotec, Kidlington, UK). A range of dilutions of test and 
standard plasmas were applied. The assay was standardised using neutrophil elastase: alpha- 
1-antitrypsin complexes generated according to Brower & Harpe1207 using human neutrophil 
elastase isolated according to Baugh & Travis208. 
All results were written by the author in each patient's individual case report file as the data 
was collected. Data were then transferred to a database (SPSS version 6.1) on a personal 
computer for subsequent statistical analysis. 
As well as the specific tests detailed above other descriptive data were prospectively 
collected for each patient as follows:- 
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7.14 Demographic and other pre- operative data 
Age, sex, race, body mass index, grades of angina and dyspnoea, history of myocardial 
infarction, hypertension, peripheral vascular disease and smoking, ejection fraction, 
Parsonnet score, and pre- operative medication. 
7.15 Intra- operative data 
Operation time, intra- operative systolic diastolic and mean arterial pressures, time on CPB, 
cross clamp time, number of grafts and whether or not a left internal mammary artery was 
used, presence of aortic atheroma or calcification (this was a subjective decision made by the 
operating surgeon - yes or no), whether a side clamp was used at cannulation of the aorta, 
minimum temperature, maximum temperature, and time taken to rewarm from minimum 
temperature to 37 °C. 
7.16 Post -operative data 
Pulse, SBP, DBP, respiratory rate, oxygen saturation, arterial oxygen tension, inspired 
oxygen concentration and temperature at 1,2,3,4,8,12,16,20,24 hrs post op, use of inotropes, 
time to extubation, cumulative blood loss at 6,12,18,24 hrs, record of complications, and 
time in days to discharge. 
7.17 Neuropsychological and other Test Statistical Analysis 
The x2 test was used for all categorical data. The Kolmagorov- Smirnoff test was used to test 
whether all continuous data was normally or non -normally distributed. Normally distributed 
data was analysed using the t test to test for significant differences in means between groups 
at a single time point. Normally distributed data was analysed using repeated measures 
analysis of variance (ANOVA) to test for significant differences in means between groups at 
several time points. Non -normally distributed data was analysed using the Mann Whitney U 
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test. Correlation between normally and non -normally distributed data was analysed using 
Spearman's correlation coefficient. Significance was set at the 95% level. That is: P <0.05 
was taken as significant. A summary of all statistical tests used for all tables is given at the 
end of the results chapter. 
The primary outcome measure of the study was the standardised change (Z) score. Z scores 
were calculated for individual tests and to give a total Z score for each group using the 
standard deviation of the pre- operative group performance. Z score was calculated as Z = 
(X2 -X1)/ µSD,), where X1 is the pre- operative score, X2 is the post- operative score and µSDI 
is the standard deviation of the pre- operative group scores. A higher postoperative score 
gives a positive Z score and a lower post- operative score gives a negative Z score. However, 
some of the tests are timed tests and a better performance is reflected in a lower time score. 
Therefore X2 and Xi are swapped for timed tests to ensure that positive Z scores consistently 
indicate improved performance. The t test was used to test for significant differences in Z 
score between groups. The previous conventional definition of a neuropsychological deficit 
is that a patient's postoperative score has dropped by one standard deviation or greater from 
their preoperative score in two or more tests. As a secondary neuropsychological outcome 
the incidence of deficits in each group using this definition measure were calculated. 
Comparison of the proportion of patients with deficit in the test and control groups was 
performed using the x2 test. 
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7.18 Time plan of methods 
Time Action 
6 -8 weeks before surgery Write to patient with information sheet 




Day of surgery Blood tests 
Transcranial Doppler 
1 day post surgery Blood tests 
2 days post surgery Blood tests 







One hundred and ninety eight patients were recruited over 30 months between April 1999 
and September 2001. All 198 patients received pre- operative neuropsychological testing and 
were randomised to test or control filter groups. A summary of the number of patients 
receiving the main tests is given at the end of this chapter (Fig 8.26). 
8.2 Removal from study before or during surgery 
One patient was found to have carotid artery stenosis and was removed from the study before 
surgery. A further five patients were removed from the study during surgery either because 
their surgery was performed without cardiopulmonary bypass or because the anaesthetic 
protocol was broken by using Propofol. 
Table 8.1 Summary of reasons for removal from study after recruitment 
Reason for Removal No. of Patients 
CPB not used 4 
Propofol used I 
Carotid artery stenosis discovered I 
Therefore 192 patients were randomised, completed pre- operative neuropsychological 
assessment and successfully completed theatre protocol. 
8.3 Outcome after surgery 
162 out of 192 patients (84 %) returned for repeat neuropsychological assessment. Thirty 
patients failed to return for follow up for reasons summarised in Table 8.2 
Table 8.2 Summary of reasons for not returning for follow up neuropsychological 
assessment. 
Reason for Not Returning for Follow -Up No. of Patients 
Death 9 
CVA 2 
Medically unfit to return for testing (No CVA) 11 
Unwilling to return for testing 8 
There were no significant differences in final outcomes between the filter groups (Table 8.3) 
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Table 8.3 Outcomes for all patients and the three filter croups. 
Final Outcome All % LD % Av % AV -6 % 
n =192 n =82 n =73 n =37 
Dead 9 4.6 4 4.9 4 5.5 1 2.7 
CVA 2 1.1 0 0 2 2.7 0 0 
Medically unable to FU 11 5.7 5 6.1 4 5.5 2 5.4 
Unwilling to attend FU 8 4.2 2 2.4 4 5.5 2 5.4 
Completed 162 84.4 71 86.6 59 80.8 32 86.5 
Total 192 100 82 100 73 100 37 100 
LD = LG -6 leucocyte depleting filter group, Av = Avecor conventional filter group and AV- 
6 = AV -6 conventional filter group. There were no statistical differences found between 
groups using the x2 test. 
As has been explained in the methods section, and will be discussed in the final chapter, the 
uneven distribution between the three filter groups arose because the control filters were 
changed about three quarters of the way through the trial. 
Of the 4 deaths in the LD group 3 died of multi -organ failure on ITU and one had a fatal MI 
on post- operative day 6. The 4 deaths in the Av group consisted of I patient with intra- 
operative myocardial infarction who could not be weaned from bypass, 1 patient with sepsis 
and 2 patients with multi -organ failure. The one death in the AV -6 group was caused by 
post- operative cardiac failure on post- operative day 17. 
8.4 Patient Characteristics 
As table 8.4 shows, there were no differences in the demographic and clinical 
characteristics between the three filter groups. 
Table 8.4 Pre -operative and demographic data for all patients and separate croups. 
ALL (192) LD (82) Avecor (73) AV -6 (37) 
Age (years) 64.1 (8.7) 63.6 (8.7) 65.5* (8.3) 62.3* (9.1) 
Sex (n m:f) 165:27 69:13 65:8 31:6 
Sex (% m:f) 86:14 84:16 89:11 84:16 
Body mass index (Kg /m2) 27.8 (4.5) 27.9 (4.9) 27.6 (4.1) 28.1 (4.2) 
Grade of angina (CCS) 2.16 (0.8) 2.20 (0.8) 2.14 (0.8) 2.14 (0.9) 
Grade of dyspnoea (NYHA) 1.68 (0.8) 1.67 (0.8) 1.68 (0.9) 1.74 (0.8) 
History of MI (n yes) 74 28 31 15 
History of MI ( %yes) 38 34 42 40 
Hypertension (n yes) 102 44 42 16 
Hypertension ( %yes) 53 54 57 43 







3 Peripheral vascular disease ( %yes) 
Ejection fraction 
(n good /mod /poor) 
27/115/50 13/43/26 6/48/19 8/24/5 
Ejection fraction 
(% good /mod /poor) 
14/60/26 16/52/32 9/66/25 21/66/13 
Parsonnet score 6.13 (5.6) 6.21 (5.9) 6.46 (5.5) 5.26 (4.9) 
Smoker (n ex /yes /never) 142/42/8 57/22/3 55/16/2 30/4/3 
Smoker (% ex /yes /never) 74/22/4 69/27/4 75/22/3 80/14/6 
Recruitment (n at- home /in- patient) 170/22 71/11 66/7 33/4 
Recruitment (% at- home /in- patient) 89/1 1 87/13 91/9 89/11 
Numeric data are expressed as means with standard deviation in brackets. There were no 
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statistical differences found between groups using the x2 test for categorical data and the t 
test for continuous data. Despite an apparent difference in age between the Avecor and AV- 
6 groups, this was not statistically significant ( *p = 0.07) using the 2 tailed t test. 
The average age of the patients and the predominance of male patients are both typical of the 
UK population of patients having CABG surgery (UK National Adult Cardiac Surgical 
Database Report 2000 -2001). 
This study has used the original Parsonnet risk stratification system209. This was the first to 
become popular of various models used to predict mortality from pre- operative patient 
variables. Although it is still used it has more recently been superseded by the Euroscore 
model. This issue is discussed further in chapter 9. 
An average Parsonnet risk stratification score of 5 -6 places patients into the "elevated risk" 
group with a predicted operative mortality of 5% (Table 8.3 shows that overall actual 
operative mortality was 4.6 %). 
8.5 Pre -operative Medication 
The pre- operative medication regime was dependent partly on the discretion of the patients' 
attending physicians. However as it may also reflect the severity of disease and may 
potentially affect outcome variables such as microemboli production or the inflammatory 
response, details of the percentage of patients in each group taking the major groups of 
medication used to control ischaemic heart disease is shown in Table 8.5. 
Although aspirin was stopped seven days prior to surgery in most patients Table 8.5 includes 
the numbers who were on aspirin prior to this time. A small percentage of patients were 
taking warfarin for AF. A record of each patient's rhythm was not taken. 
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Table 8.5 Pre -operative medication rates in each croup. 
ALL (192) LD (82) Avecor (73) AV -6 (37) 
Statins (% yes) 76 79 66 89 
B Blockers (% yes) 77 76 77 83 
Aspirin (% yes)* 92 94 92 89 
Nitrates (% yes) 56 44 63 71 
Calcium channel blockers (% yes) 43 46 45 34 
ACE inhibitors (% yes) 30 33 26 28 
K channel antagonists (% yes) 25 20 30 23 
Warfarin (% yes) 1.6 2.5 1.4 0 
* This included patients who stopped asprin 7 days prior to surgery. 
All figures are expressed as percentages. There were no statistical differences found using 
the x2 test in the pre -operative medication use between groups. 
8.6 Intra -operative data 
No statistically significant differences were found between the groups. It can be seen in 
Table 8.6 that for all groups, mean operation time is under 3 hours, mean bypass time is 66 - 
68 minutes and mean cross clamp time is 30 - 32 minutes. The mean number of coronary 
bypass grafts performed per patient was approximately 3. This relative speed of surgery 
compared to other, published studies is most likely due to the use of cross clamp fibrillation 
for myocardial protection. Most studies in the literature have used cardioplegic myocardial 
protection which is associated with longer cross clamp and bypass times. 
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Table 8.6 Intra -operative data. 
ALL (192) LD (82) Avecor (73) AV -6 (37) 
Operation time (mins) 169 (30.5) 166 (33.9) 172 (29.1) 171 (25.0) 
CPB time (mins) 67.7 (19.1) 66.5 (22.1) 68.7 (17.0) 68.4 (15.5) 
cross clamp time (mins) 30.9 (9.2) 30.6 (10.1) 31.9 (8.9) 29.5 (7.0) 
number of grafts 2.88 (0.7) 2.86 (0.7) 2.95 (0.7) 2.78 (0.6) 
LIMA (n / % yes) 157/82 68/83 58/79 31/84 
Aortic atheroma or 
calcification (n / % yes) 
13/7 3/3 7/10 3/10 
Side clamp (n / % yes) 25/13 9/11 11/15 5/13 
Min temperature ( °C) 31.9 (0.8) 32.1 (0.8) 31.7 (0.8) 31.8 (0.5) 
Max temperature ( °C) 37.7 (0.3) 37.7 (0.3) 37.7 (0.4) 37.6 (0.3) 
Time taken to rewarm (mins) 12.7 (4.4) 12.0 (3.8) 12.7 (4.8) 14.7 (4.1) 
For numeric data, figures are expressed as means with standard deviation in brackets. The 
remainder are expressed as percentages. Numeric data are expressed as means with standard 
deviation in brackets. There were no statistical differences found between groups using the 
x2 test for categorical data and the t test for continuous data. 
Factors which potentially affect the degree of aortic manipulation and potential subsequent 
microemboli production - i.e. number of grafts, use of the LIMA, side clamp use for 
cannulation and aortic disease - were equal in all groups. Although the aim of rewarming 
was to reach 37 °C, this target temperature was overshot, with the maximum temperature 
reached in all groups being 37.7 °C. 
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8.7 Neuropsychological Tests 
8.7.1 Pre -operative 
All patients received baseline pre- operative neuropsychological testing. Table 8.7 details 
these results. 
Table 8.7 Pre -operative Neuropsvcholoaical Test Scores. 
ALL (192) LD (82) Avecor (73) AV -6 (37) 
Choice Reaction Time Test 
(secs)11 
0.64 (0.18) 0.63 (0.14) 0.67 (0.23) 0.59 (0.13) 
Grooved Pegboard Test D 
(secs)* 
79.16 (14.49) 77,30 (12.81) 80.42 (13.68) 80.86 (18.95) 
Grooved Pegboard Test ND 
(secs)* 
86.52 (18.28) 86.78 (18.05) 87.08 (19.05) 84.83 (17.62) 
Letter Cancellation Test (secs)* 92.56 (25.04) 90.81 (22.49) 95.68 (29.16) 90.46 (21.46) 
Non -verbal Memory Test 
(secs)# 
77.72 (21.18) 76.13 (21.35) 77.53 (21.26) 81.45 (20.79) 
Rey Auditory Verbal Learning 
Test' 
55.32 (11.84) 55.78 (12.26) 53.44 (11.44) 58.09 (11.29) 










Trail Making Test A (secs)* 39.99 (14.09) 39.25 (12.85) 41.04 (15.50) 39.57 (14.09) 
Trail Making Test B (secs)* 92.06 (36.96) 90.63 (31.71) 94.01 (39.33) 91.46 (43.34) 
Speilberger Anxiety State' 36.68 (9.75) 36.38 (10.01) 37.42 (9.98) 35.61 (8.50) 
Speilberger Anxiety Traita 35.01 (9.48) 33.54 (9.09) 37.28 (10.03) 33.32 (8.41) 
CESD Depression Scoren 11.81 (8.65) 11.73 (9.11) 12.89 (8.58) 9.25 (7.08) 
*time to completion #total answer time mean response time 'score on 
questionnaire µtotal number of words recalled in 7 trials (max 105). ND non -dominant, 
D dominant. 
There were no significant differences using the t test in pre- operative neuropsychological 
scores between the three filter groups. The three groups were therefore well matched in 
terms of pre- operative neuropsychological performance. 
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8.7.2 Six Week Post -operative Mean Z Change Scores 
There was no significant differences between mean Z score changes for the Avecor and AV- 
6 filter groups (Table 8.8) and so the data from these two control groups were combined to 
give "standard" filter data. The purpose of this was to increase power of analysis. 
Table 8.8 Mean Z Change Scores for neuropsychological tests at six weeks post 






Choice Reaction Time Test -0.13 -0.04 0.56 
Grooved Pegboard Test D 0.18 -0.01 0.35 
Grooved Pegboard Test ND 0.02 -0.01 0.82 
Letter Cancellation Test 0.04 -0.17 0.18 
Non -verbal Memory Test 0.03 0.33 0.09 
Rey Auditory Verbal Learning 
Test 
0.36 0.35 0.93 
Symbol Digit Replacement Test 0.24 0.15 0.51 
Trail Making Test A 0.13 0.12 0.93 
Trail Making Test B 0.16 -0.14 0.22 
Total Z score 0.98 0.58 0.57 
Differences between groups were analysed with the independent 2 tailed t test 
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Table 8.9 Mean Z Change Scores for all neuropsychological tests at 
six weeks post surgery in leucocyte depleting (LD) and standard filter 
croups. 
LD (n =71) Standard (n =91) p value 
Choice Reaction Time Test 0.03 -0.10 0.13 
Grooved Pegboard Test D 0.22 0.11 0.19 
Grooved Pegboard Test ND 0.15 0.01 0.06 
Letter Cancellation Test -0.03 -0.04 0.48 
Non -verbal Memory Test 0.08 0.14 0.33 
Rey Auditory Verbal Learning 
Test 
0.41 0.35 0.31 
Symbol Digit Replacement Test 0.25 0.21 0.34 
Trail Making Test A 0.26 0.13 0.13 
Trail Making Test B 0.18 0.02 0.16 
Total Z score 1.54 0.84 0.07 
Differences between groups were analysed with the independent 1 tailed t test 
There was no difference in the Speilberger Anxiety Trait between LD (28.88 +1- 8.83) and 
standard (29.28 +1- 8.27), p =0.54, groups at the 6 week follow up visit. Also, there was no 
difference in the CESD Depression Score with scores of 9.19 +1- 7.63 in the LD group and 
10.74 +1- 8.95 in the standard group, p =0.40. 
It can therefore be seen that there was no statistically significant difference between the 
leucocyte depleting and standard filter groups for post- operative Z scores either for 
individual tests or for total Z change score. However, as is better illustrated in Figure 8.1, 
there was an overall trend towards greater improvement (that is: a greater positive change) in 
Z scores for all tests, apart from the non -verbal memory test, in the leucocyte depletion 
group. 
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Figure 8.1 Mean Z Change Scores for all neuropsychological tests at six weeks 
post surgery in leucocyte depleting (LD) and standard filter groups. 
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8.7.3 Six Week Deficit Scores 
Deficit is defined as a decline by more than one standard deviation in two or more tests. In 
the standard filter group the incidence of deficit was 7/91 (7.8 %) and in the LD group 4/71 
(5.6 %). 
Table 8.10 Incidence of deficits in standard and leucocyte depleting (LD) filter 
rouas. 
Filter 
Standard (n =91) LD (n =71) 
Deficit 
No 84 67 
Yes 7 4 
Figures are absolute numbers of patients 
This difference did not reach statistical significance using the Chi squared test. (x2=0.30, 
p >0.50) 
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8.7.4 Comparison of characteristics of patients followed up and withdrawn 
As shown in Table 8.3, there was an overall follow up rate of 84% for the 6 week repeat NP 
testing. In order to see if there was any selective attrition of patients, pre -operative and intra- 
operative characteristics were compared between those who did and did not return for follow 
up. The aim was to examine all patients who failed to return for whatever reason and so the 
patients who had died were included in the 30 patients withdrawn. 
Table 8.11 Peri -operative characteristics of patients followed uo or withdawn. 
Returned (n =162) Withdrawn (n =30) p value 
Age 63.9 (8.3) 63.8 (8.3) 0.9 
Yrs of Education 10.7 (1.7) 10.8 (1.6) 0.6 
Parsonnet Score 5.9 (5.4) 6.3 (4.3) 0.8 
Speilberger State (anxiety) 36.4 (9.3) 38.3 (11.7) 0.3 
CESD (depression) 11.4 (8.3) 14.0 (10.1) 0.1 
Bypass time 67.2 (19.1) 70.7 (19.2) 0.4 
Number of Grafts 2.9 (0.7) 2.8 (0.5) 0.6 
Microemboli on CPB 61.6 (101.7) 125.2 (193.2) 0.04 
Days to Discharge 6.9 (2.3) 7.1 (2.5) 0.2 
Data was analysed using the two- tailed t test for all characteristics which were normally 
distributed. Only microemboli on CPB was not normally distributed and this was analysed 
using the Mann Whitney U test. 
It can be seen that those who did not return to follow up had a significantly greater number of 
microemboli on CPB. 
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p value on two 
tailed t test 
Choice Reaction Time Testi 0.64 (0.18) 0.66 (0.22) 0.80 
Grooved Pegboard Test D 
(secs)* 
78.50 (14.86) 83.00 (11.66) 0.10 
Grooved Pegboard Test ND 
(secs)* 
85.50 (18.72) 92.32 (14.47) 0.03 
Letter Cancellation Test (secs)* 91.45 (22.16) 98.93 (37.09) 0.23 
Non -verbal Memory Test# 76.92 (18.40) 82.11 (32.54) 0.41 
Rey Auditory Verbal Learning 
Test"' 
55.16 (12.04) 56.22 (10.76) 0.67 
Symbol Digit Replacement Test 
(secs)* 
178.46 (44.85) 205.69 (86.20) 0.13 
Trail Making Test A (secs)* 38.98 (13.03) 45.62 (18.20) 0.02 
Trail Making Test B (secs)* 89.99 (33.74) 103.52 (50.44) 0.12 
*time to completion #total answer time mean response time `total number 
of words recalled in 7 trials (max 105). ND = non -dominant, D = dominant. 
Those patients who withdrew from the study had a significantly poorer pre- operative 
performance in the Grooved Pegboard Test (non- dominant) and Trail Making Test A tests. It 
is therefore possible that those patients who returned had deteriorated less than those who 
withdrew and that the degree of post- operative neuropsychological impairment in the study 
population was thus underestimated. 
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8.8 Transcranial Doppler Data 
127/192 patients received successful intra- operative TCD monitoring of the right middle 
cerebral artery and video recording. Data from the first 35 patients were lost due to 
malfunction of the video recorder. The video recorder failed to record pictures onto tape and 
required servicing.14 patients had no suitable transcranial window or the probe was 
irretrievably dislodged and for the remaining 16 the TCD machine was unavailable for 
monitoring because another patient was simultaneously being studied. 
127 video tapes were then reviewed off line. Velocity of middle cerebral artery blood was 
recorded and microembolic events were counted as described in Methods and Materials. 
8.8.1 Middle cerebral artery blood velocity 
In all three filter groups there was a slight reduction in mean cerebral artery blood velocity at 
15 and 30 minutes into cardiopulmonary bypass compared to pre -CPB velocity followed by 
an increase in velocity during rewarming and at 10 minutes post. Using repeated measures 
ANOVA there were no significant differences over time or between groups. 
Table 8.13 Mean middle cerebral artery blood velocity before during and after 
cardiooulmonary bvaass in the three filter croups. 
Mean Velocity (SD) (cm /s) (normalised velocity) 
Time LD (n =56) Avecor (n=42) AV -6 (n =26) 
1 10 minutes pre -CPB 28.8 (10.3) (100) 31.6 (13.7) (100) 30.3 (12.4) (100) 
2 1 minute pre -CPB 28.3 (9.9) (98) 30.1 (13.2) (95) 26.9 (10.8) (98) 
3 15 minutes into CPB 27.0 (9.3) (94) 30.4 (11.5) (96) 27.4 (9.0) (90) 
4 30 minutes into CPB 29.1 (10.0) (101) 29.7 (11.3) (94) 27.3 (11.1) (90) 
5 60 minutes into CPB 31.4 (9.2) (109) 33.8 (14.6) (106) 31.5 (15.3) (104) 
6 10 minutes post -CPB 34.3 (10.5) (119) 35.3 (11.5) (112) 36.7 (12.1) (121) 
The data in Table 8.13 is also shown in the following Figure 8.2 Values were normalised to a 
baseline of 100% for all three groups in order to compare the groups graphically. 
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Figure 8.2 Mean middle cerebral artery blood velocity before during and after 
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8.8.2 Microemboli Counts During CPB 
The following scattergram, Figure 8.3, shows that the number of microemboli detected were 
not normally distributed. Results for microemboli are therefore expressed as medians. 
Figure 8.3 Scattergram showing range of microemboli count for the three filter 

















1.0 1.5 2.0 2.5 3.0 3.5 
There were three distinct outliers. Two in the Avecor group and one in the AV -6 group. 
Although careful analysis of the conduct of these cases and their characteristics did not 
reveal any cause for the increased number of microemboli, these patients were thought 
unlikely to be representative of the patient population. Data from these three patients was 
therefore removed from further microemboli data analysis. The scattergram in Figure 8.4 




Figure 8.4 Scattergram showing range of microemboli count for the three filter 










1.0 1.5 2.0 2.5 3.0 3.5 
There were less microemboli detected on CPB in the LG -6 group with a median of 15 
compared to 66 and 55 in the Avecor and AV -6 groups respectively. There was no 
statistically significant difference between the two control filters on CPB (p = 0.46). 
Very few microemboli were detected in the ten minute period after CPB except in a few 
cases (Table 8.14) 
Table 8.14 Median microemboli counts on CPB and for the ten minutes post 
CPB for the three filter groups (outliers removed). 
Microemboli LD (n =56) Avecor (n =42) AV -6 (n =26) 
On CPB 15 (3 -177) 66 (5 -212) 55 (2 -245) 
10 minutes post bypass 0 (0 -26) 1 (0 -29) 0 (0 -1) 
Table 8.15 Mann Whitney U test comparing median numbers of microemboli on 
CPB both with and without outliers 
With Outliers Without Outliers 
U p U p 
LG -6 vs. Avecor 325 < 0.001 325 < 0.001 
LG -6 vs. AV -6 349 < 0.001 349 < 0.001 
Avecor vs. AV -6 521 0.47 479 0.49 
It can therefore be seen that inclusion or exclusion of the outliers makes no difference to the 
significance of the results. 
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8.8.3 Relationship of Cerebral Microemboli on CPB to Cerebral Blood Velocity 
Although there was no difference in middle cerebral artery blood velocity between the three 
filter groups, we wished to see if there was any effect of blood velocity per se on 
microemboli counts. Controlling for filter group, there was no correlation found between 
cerebral blood velocity at any time point and microemboli count on CPB (see Table 8.16). 
Table 8.16 Partial correlation coefficients for microemboli counts and cerebral 
blood velocity controlling for filter croup. 
Vl V2 V3 V4 V5 V6 
Microemboli R = -0.12 R = -0.16 R = -0.02 R = -0.06 R = -0.12 R = 0.01 
on CPB p = 0.37 p = 0.19 p = 0.86 p = 0.62 p = 0.33 p = 0.93 
V1 =10 mins pre -CPB, V2 =1 min pre -CPB, V3 =15 mins into CPB, V4 =30 mins into 
CPB, V5 =60 mins into CPB and V6 =10 mins post -CPB. 
8.8.4 Relationship between patient and intra- operative variables and microemboli 
count 
There was no correlation between the age of the patient, the bypass and cross clamp times or 
number of grafts performed and microemboli count. 
Table 8.17 Correlation coefficients (Spearmans) for microemboli counts patient 
and intra -operative variables. 
Microemboli count 
R p 
Age -0.15 0.87 
Bypass time 0.09 0.29 
Cross clamp time 0.15 0.10 
Number of grafts 0.09 0.36 
Examining whether the presence of symptomatic peripheral vascular disease, clinically 
detectable atheroma or side -biting clamp usage influenced microemboli count revealed that 
none of these factors led to a statistically significant difference in microemboli count. This 
can be seen in Table 8.18. In order to enable comparison of these findings, only those 
patients who had data on all these variables are included in Table 8.18. In 6 of the patients 
with a TCD record, the surgeon was unable to say whether there was digital palpation 
evidence of atheroma of the aorta. These 6 are excluded. 
Table 8.18 Influence of variables potentially affecting microemboli count on CPB. 
Factor Microemboli on CPB P (Mann 
Whitney U test) 
Mean Standard deviation 
PVD Yes (n = 7) 58.7 52.8 
No(n111) 71.1 126.6 0.81 
Atheroma Yes (n = 10) 72.6 58.4 
No (n = 108) 70.2 128.6 0.95 
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Side -clamp use Yes (n = 11) 135.5 223.3 
No (n = 107) 63.7 108.6 0.07 
Table 8.18 indicates that there was a trend towards an increase in microemboli count 
when the side -biting clamp was used to cannulate. 
8.8.5 Relationship of Microemboli to NP Outcome 
A total of 107 patients received intra- operative TCD and then completed NP follow up at six 
weeks. 
Despite the significant decrease in microemboli with the leucocyte -depleting filter this did 
not lead to a significant difference in NP outcome using deficit and Z score analysis. It was 
therefore decided to look at the relationship between microemboli and NP outcome more 
closely. 
No Spearmans correlation was found between microemboli count on CPB and Z scores for 
each of the tests and the total Z scores. This held true for the whole study population and also 
for each of the filter groups (Table 8.19). 
Table 8.19 SDearmans correlation for microemboli count and total Z scores 
R P 
For all cases -0.06 0.57 
For LD filter group -0.16 0.25 
For Avecor filter group -0.15 0.39 
For AV -6 filter group 0.06 0.77 
8.8.6 Relationship of Microemboli to Other Outcomes (all cases) 




Time to extubation 0.05 0.64 
Days to discharge 0.14 0.23 
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Table 8.21 Spearmans correlation coefficients for microemboli counts and 
neuropsychological Z change scores. 
Microemboli count on CPB 
All cases Avecor (36) LD (50) Av -6 (21) 
Choice Reaction Time Test -0.06 (0.51) -0.12 (0.47) -0.16 (0.26) 0.06 (0.79) 
Grooved Pegboard Test D 0.09 (0.36) 0.18 (0.31) -0.10 (0.17) 0.16 (0.47) 
Grooved Pegboard Test ND 0.06 (0.55) 0.08 (0.65) 0.09 (0.52) 0.11 (0.62) 
Letter Cancellation Test -0.07 (0.47) -0.01 (0.98) -0.11 (0.47) -0.26 (0.22) 
Non -verbal Memory Test -0.05 (0.64) -0.17 (0.33) 0.09 (0.50) -0.05 (0.84) 
Rey Auditory Verbal Learning Test -0.07 (0.47) -0.06 (0.74) -0.05 (0.71) -0.13 (0.57) 
Symbol Digit Replacement Test -0.07 (0.49) -0.18 (0.31) -0.22 (0.12) 0.09 (0.66) 
Trail Making Test A 0.08 (0.44) 0.17 (0.34) 0.07 (0.63) -0.07 (0.74) 
Trail Making Test B 0.01 (0.90) -0.02 (0.90) -0.22 (0.12) 0.16 (0.47) 
Total z score -0.06 (0.57) -0.15 (0.39) -0.16 (0.25) 0.06 (0.77) 
P values given in brackets 
However dividing the whole cohort into two equal groups using a median split with greater 
or less than 34 microemboli on CPB showed that those with fewer microemboli had greater 
Z scores. 
Table 8.22 Mean Z scores according to microemboli count using a median split of 
34 
<34 (n =53) >34 (n =54) p (t test,l tailed) 
Choice Reaction Time Test 0.07 - 0.03 0.20 
Grooved Pegboard Test D 0.23 0.13 0.23 
Grooved Pegboard Test ND 0.13 0.12 0.45 
Letter Cancellation Test 0.01 - 0.06 0.30 
Non -verbal Memory Test 0.24 0.12 0.21 
Rey Auditory Verbal Learning Test 0.40 0.31 0.25 
Symbol Digit Replacement Test 0.22 0.14 0.20 
Trail Making Test A 0.34 0.18 0.11 
Trail Making Test B 0.24 - 0.03 0.08 
Total Z score 1.88 0.88 0.02 
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This difference reached statistical significance for the total Z scores only. However, as with 
the leucocyte depleting filter group, there was an overall trend towards greater improvement 
(i.e. a greater positive Z score) in the <34 microemboli filter group. This is illustrated 
graphically in Figure 8.5 
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8.9 Clinical Data 
8.9.1 Intra -operative clinical data 
8.91.1 Peri -operative blood pressure 
Table 8.23 Mean peri- operative systolic blood pressure for the three filter croups. 
Systolic Blood Pressure (SD) (mmHg) 
Time LD Avecor AV -6 
Pre -induction 132 (21) 136 (19) 135 (17) 
Post -induction 98 (19) 103(16) 100 (23) 
Pre -sternotomy 116 (19) 113 (18) 116 (14) 
Post sternotomy 112 (20) 112 (18) 121 (19) 
Pre -CPB 91 (17) 94 (17) 88 (17) 
Post -CPB 94 (17) 91 (16) 98 (18) 
Post skin closure 99 (16) 100 (17) 103 (13) 
Using repeated measures ANOVA there were no significant differences over time or between 
groups. 
There were no significant differences at any time point. The same data are shown in Figure 
8.6 
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Table 8.24 Mean peri- operative diastolic blood pressure for the three filter croups. 
Diastolic Blood Pressure (SD) (mmHg) 
Time LD Avecor AV -6 
Pre -induction 71 (11) 72 (20) 80 (17) 
Post -induction 54 (10) 52 (16) 53 (13) 
Pre -sternotomy 59 (1 1) 63 (16) 60 (10) 
Post sternotomy 59 (1 1) 62 (17) 64 (12) 
Pre -CPB 49 (10) 51 (13) 48 (10) 
Post -CPB 47 (16) 50 (12) 49(9) 
Post skin closure 51 (8) 51 (11) 60 (15) 
Using repeated measures ANOVA there were no significant differences over time or between 
groups. 
There were no significant differences at any time point. The same data are shown in Figure 
8.7 
Figure 8.7 Mean peri- operative diastolic blood pressure for the three filter groups. 
Although there was a decline in peri- operative systolic and diastolic blood pressures there 
was no significant differences between the three filter groups. 
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8.9.1.2 Peri -operative Oxygenation 
Table 8.25 Peri- operative p02 for all three filter croups 
p02 (kPa) (SD) 
Time LB Avecor AV -6 
Pre -op 12.1 (1.6) 11.4 (1.9) - 
1 hour 21.6 (8.8) 19.2 (7.1) 25.6 (8.7) 
2 hrs 17.4 (7.3) 17.3 (6.2) 20.8 (7.1) 
3 hrs 16.4 (4.9) 16.5 (4.7) 19.3 (7.9) 
4 hrs 16.5 (5) 16.5 (3.9) 16.9 (4.6) 
8 hrs 15.2 (3.3) 14.4 (3.4) 15.8 (3.9) 
12 hrs 14.6 (3.8) 14.3 (3.4) 14.1 (3) 
16 hrs 13.5 (2.9) 13.5 (3.3) 13.7 (4.6) 
20 hrs 14.2 (7.1) 13.2 (2.7) 14.2 (4.1) 
24 hrs 11.7 (3.3) 12.1 (2.5) 10.7 (1.4) 
5 days 9.9 (1.3) 9.5 (1.1) - 
Using repeated measures ANOVA there were significant differences over time but no 
difference between groups. 
Figure 8.8 Peri -operative p02 
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Table 8.26 Peri- operative Ox en saturation for all three filter groups 
Oxygen Saturation (SD) ( %) 
Time LD Avecor AV -6 
Pre -op 96.6 (1.1) 96.5 (1.3) - 
1 hour 98 (1.6) 98 (1.5) 98.1 (1.1) 
2 hrs 97.5 (1.9) 97.6 (1.9) 97.7 (1.1) 
3 hrs 97.3 (1.5) 97.7 (1.4) 97.4 (1.6) 
4 hrs 97.5 (1.5) 97.7 (1.7) 97.2 (1.3) 
8 hrs 97.3 (1.2) 97.2 (1.5) 96.9 (1.3) 
12 hrs 96.9 (1.7) 97 (1.7) 96.7 (1.1) 
16 hrs 96.8 (1.3) 96.9 (1.6) 96.3 (1.4) 
20 hrs 96.5 (1.3) 96.8 (1.7) 96.3 (1.7) 
24 hrs 95.4 (1.8) 96.4 (1.7) 94.8 (1.6) 
5 days 94.8 (2.1) 94.3 (1.7) - 
Using repeated measures ANOVA there were no significant differences over time or between 
groups. 
Figure 8.9 Peri -operative Oxygen Saturation 
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op hour hrs hrs hrs hrs days 
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Table 8.27 Peri -operative Fi02 for all three filter groups 
Fi02 (SD) (kPa) 
Time LD Avecor AV -6 
Pre -op 20 (0) 20 (0) 20 (0) 
1 hour 58.2 (7.8) 56.3 (8.6) 58.7 (58.7) 
2 hrs 51.4 (8.1) 51.3 (8.2) 51.1 (51.1) 
3 hrs 47.5 (9.2) 47.3 (8.8) 44.1 (44.1) 
4 hrs 43 (11.2) 44.9 (9.7) 41.9 (41.9) 
8 hrs 41.5 (9.2) 40.5 (9) 39.8 (39.8) 
12 hrs 42.5 (9.6) 42.1 (10.6) 39.6 (39.6) 
16 hrs 40.7 (11.4) 40.9 (12.9) 40.7 (40.7) 
20 hrs 38.5 (12.1) 37.9 (12.6) 39.7 (39.7) 
24 hrs 36.3 (13.3) 35.7 (15.4) 36.3 (36.3) 
5 days 20 (0) 20 (0) 20 (0) 
Using repeated measures ANOVA there were no significant differences over time or between 
groups. 
Figure 8.10 Peri -operative Inspired Oxygen Percentage (Fi02) 
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8.9.1.3 Peri -operative Temperature 
Table 8.28 Mean peri -operative nasopharyngeal temperature for the three filter 
rouas. 
Nasopharyngeal Temperature (SD) ( °C) 
Time LD Avecor AV -6 
Pre -induction 36.4 (0.3) 36.5 (0.2) 36.5 (0.2) 
Post -induction 35.6 (0.4) 35.8 (0.5) 35.3 (0.3) 
Pre -sternotomy 35.4 (0.5) 35.6 (0.4) 35.4 (0.5) 
Post sternotomy 35.3 (0.5) 35.4 (0.4) 35.2 (0.6) 
Pre -CPB 34.8 (0.6) 34.9 (0.5) 34.7 (0.8) 
Post -CPB 36.7 (0.9) 36.9 (0.7) 36.5 (0.5) 
Post skin closure 35.9 (0.6) 35.8 (0.6) 36.0 (0.5) 
Using repeated measures ANOVA there were significant differences over time but no 
differences between groups at any time point. 
There were no significant differences at any time point. The same data are shown in Figure 
8.11 












In all groups there was a decline in temperature after induction to the time of beginning 
cardiopulmonary bypass. After rewarming to 37°C at the end of CPB there was then a 
second decrease in temperature to the time of skin closure. Figure 8.1 1 omits to show the 
cooling to 32 ° C which occurred during CPB. 
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8.9.2 Post -operative blood pressure 
Table 8.29 Mean systolic blood pressure in the first 24 hours post surgery for 
the three filter croups. 
Systolic Blood Pressure (SD) (mmHg) 
Time (hrs post op) LD Avecor AV -6 
1 115 (21) 117 (1 9) 116 (20) 
2 124 (18) 122 (17) 125 (20) 
3 118 (15) 120 (19) 118 (15) 
4 117 (14) 117 (19) 114 (17) 
8 113 (15) 114 (16) 110 (17) 
12 116 (14) 116 (15) 117 (13) 
16 118 (16) 116 (19) 112 (12) 
20 118 (18) 118 (18) 116 (14) 
24 118 (16) 118 (16) 116 (18) 
Using repeated measures ANOVA there were no significant differences over time or between 
groups. 
The same data are shown in Figure 8.12 
Figure 8.12 Mean post -operative systolic blood pressure for the three filter groups. 
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Table 8.30 Mean diastolic blood pressure in the first 24 hours post surgery for 
the three filter groups. 
Diastolic Blood Pressure (SD) (mmHg) 
Time (hrs post op) LD Avecor AV -6 
1 56 (11) 57 (9) 58 (10) 
2 60 (11) 57 (8) 61 (11) 
3 57 (9) 57 (10) 59 (8) 
4 56 (10) 56 (9) 57 (12) 
8 57 (9) 55 (6) 56 (9) 
12 58 (9) 55 (7) 54 (9) 
16 58 (7) 57 (10) 55 (9) 
20 58 (9) 58 (6) 55 (10) 
24 59 (9) 58 (9) 56 (10) 
Using repeated measures ANOVA there were no significant differences over time or 
between groups. 
The same data are shown in Figure 8.13 
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8.9.3 Post -operative Temperature 
Table 8.31 Mean nasopharyngeal temperature in the first 24 hours post surgery for 
the three filter groups. 
Nasopharyngeal Temperature (SD) ( °C) 
Time (hrs post op) LD Avecor AV -6 
1 35.2 (0.8) 35.2 (0.9) 35.2 (0.7) 
2 35.5 (0.8) 35.5 (0.9) 35.5 (0.8) 
3 35.8 (0.8) 35.8 (0.9) 36.0 (0.8) 
4 36.4 (0.7) 36.4 (0.8) 36.6 (0.7) 
8 37.3 (0.5) 37.3 (0.6) 37.2 (0.6) 
12 37.4 (0.5) 37.3 (0.5) 37.2 (0.6) 
16 37.2 (0.5) 37.1 (0.5) 37.2 (0.5) 
20 37.1 (0.5) 36.9 (0.4) 37.0 (0.4) 
24 36.9 (0.4) 36.9 (0.4 37.0 (0.5) 
Using repeated measures ANOVA there were no significant differences over time or 
between groups. 
The same data are shown in Figure 8.14 
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8.9.4 Time to extubation 
Figure 8.15 Scattergram of time to extubation for all three filter groups. 1.0 
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Table 8.32 Median time to extubation for all three filter groups. The range is given 
in brackets. 
Avecor (n =69) LD (n =78) AV -6 (n =36) 
Extubation Time 
(Hrs) 
10.8 (5 - 124) 9.8 (3 -58) 7.8 (4 -23) 
Table 8.33 Mann Whitney U test to test for significant differences between 
extubation times. 
LG-6 vs. Avecor p = 0.08 
LG-6 vs. AV-6 p = 0.03 
Avecor vs. AV-6 p = 0.02 
There were significant differences between extubation times between the groups. As this 
difference may still be due to the outliers the analyses were repeated with the removal of 
extreme values (3 standard deviations) and outliers (2 standard deviations). The same 
pattern of significant differences was found in both these analyses as in Table 8.33. 
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8.9.5 Days to Discharge 
Figure 8.16 Scattergram of days to discharge for all three filter 
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Table 8.34 Median number of days to discharge for all three filter groups. 
Avecor (n =69) LG -6 (n =78) AV -6 (n =36) 
Days to discharge 6 (4 -15) 6 (4 -19) 7 (4 -18) 
The range is given in brackets. 
Table 8.35 Mann Whitney U test to test for significant differences in days to 
discharge between all three filter groups. 
LG-6 vs. Avecor p = 0.78 
LG-6 vs. AV-6 p = 0.09 
Avecor vs. AV-6 p = 0.15 
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8.10 Haematological Results 
8.10.1 Total White Cell Count 
One hundred and seventy patients had serial FBC testing. There was a characteristic fall in 
total white cell count in all groups during cardiopulmonary bypass. This was then followed 
by a rise in total white cell count post- operatively. 
Table 8.36 Mean eri- operative total white cell count for all three groups. 
Mean WCC (SD) (x 103 /mm3) 
Time LD (n =78) Avecor (n =63) AV -6 (n =29) 
1 pre op 7.89 (1.85) 7.31 (1.89) 8.05 (1.79) 
2 pre CPB (at cannulation) 6.95 (2.15) 6.59 (2.08) 6.80 (1.84) 
3 on CPB (after 30 mins) 4.76 (2.26) 5.35 (2.30) 5.88 (2.02) 
4 post CPB (10 mins) 8.53 (5.74) 8.57 (3.94) 8.56 (2.99) 
5 post op day 1 9.69 (2.79) 9.50 (2.74) 9.62 (2.74) 
6 post op day 2 11.62 (3.71) 11.22 (3.02) 10.31 (2.34) 
Using repeated measures ANOVA there were significant differences over time but not 
between groups at any time points. 
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8.10.1.1 Correlation of WCC with Microemboli 
Of the one hundred and seventy patients who had serial FBC testing, 120 also had intra- 
operative TCD monitoring of microemboli. The following Table 8.37 shows that there was 
no correlation between white cell count at any time point measured and the intra- operative 
microemboli count. 
Table 8.37 Spearman correlation coefficients between WCC and microemboli. 













8.10.1.2 Correlation of WCC with Z scores 
Of the one hundred and seventy patients who had serial FBC testing, 120 also returned for 
post -operative NP testing and thus had Z scores. The following Table 8.38 shows that there 
were weak but significant inverse correlations between both pre- operative and post- operative 
measures of white cell count and total Z scores as well as various individual test Z scores. 













CRTT R = -0.13 
P = 0.12 
R = -0.08 
P = 0.36 
R = -0.06 
P = 0.49 
R = -0.06 
P = 0.49 
R = -0.11 
P = 0.20 
R = -0.09 
P = 0.29 
GPD R = -0.08 R = -0.02 R = -0.07 R = -0.07 R = -0.06 R = -0.03 
P=0.31 P=0.79 P=0.41 P=0.39 P=0.15 P=0.77 
GPND R=-0.19 R=-0.12 R=-0.11 R=-0.23 R=-0.10 R=-0.06 
P=0.02 P=0.16 P=0.21 P<0.01 P=0.22 P=0.49 
LCT R=-0.19 R=-0.02 R=0.08 R=0.03 R=-0.06 R=-0.02 
P=0.02 P=0.87 P=0.34 P=0.69 P=0.46 P=0.82 
NVMT R=-0.12 R=-0.11 R=-0.03 R=-0.17 R=-0.04 R=-0.13 
P=0.14 P=0.20 P=0.77 P=0.04 P=0.64 P=0.12 
REY R = 0.08 R = 0.00 R = 0.08 R = -0.03 R = -0.17 R = -0.07 
P=0.33 P=0.98 P=0.37 P=0.77 P=0.04 P=0.42 
SDRT R=-0.13 R=-0.13 R=-0.05 R=-0.15 R=-0.13 R=0.04 
P=0.11 P=0.12 P=0.58 P=0.17 P=0.12 P=0.68 
TMTA R = -0.09 R = -0.02 R = -0.10 R = -0.20 R = -0.05 R = 0.00 
P=0.28 P=0.81 P=0.23 P=0.02 P=0.56 P=0.96 
TMTB R=-0.03 R=-0.12 R=0.05 R=-0.08 R=-0.05 R=0.04 
P=0.76 P=0.16 P=0.59 P=0.38 P=0.59 P=0.64 
TOTAL R=-0.19 R=-0.12 R=-0.05 R=-0.21 R=-0.15 R=-0.06 
P=0.02 P=0.15 P=0.15 P<0.01 P=0.28 P=0.18 
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8.10.2 Neutrophil Count 
The pattern of a fall and then rise in total white cell count is mainly attributable to the similar 
fall and rise in neutrophil count (Table 8.39) 
Table 8.39 Mean peri- operative neutroohil count for all three croups. 
Mean Neutrophil count (SD) (x 103 /mm3) 
Time LD (n =78) Avecor (n =63) AV -6 (n =29) 
1 pre op 4.89 (1.44) 4.43 (1.49) 4.75 (1.19) 
2 pre CPB (at cannulation) 4.02 (1.38) 3.85 (1.60) 3.60 (1.07) 
3 on CPB (after 30 mins) 2.54 (1.46) 2.99 (1.62) 3.26 (1.39) 
4 post CPB (10 mins) 5.82 (2.62) 6.42 (3.48) 6.32 (2.51) 
5 post op day 1 7.95 (2.47) 7.81 (2.49) 7.56 (1.82) 
6 post op day 2 9.35 (3.27) 9.01 (2.78) 8.08 (2.14) 
Using repeated measures ANOVA there were significant differences over time but not 
between groups at any time points. 
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8.10.2.1 Correlation of Neutrophil Count with Microemboli 
Of the one hundred and seventy patients who had serial FBC testing, 120 also had intra- 
operative TCD monitoring of microemboli. The following Table 8.40 shows that there was a 
weak but significant correlation between the neutrophil count 10 minutes after CPB and the 
intra- operative microemboli count. 














Microemboli R = -0.08 
P=0.31 
R = -0.10 
P=0.29 
R = 0.13 
P=0.16 
R = 0.23 
P=0.01 
R = 0.01 
P=0.89 
R = 0.05 
P=0.61 
8.10.2.2 Correlation of Neutrophil Count with Neuropsychological Z scores 
Of the one hundred and seventy patients who had serial FBC testing, 120 also returned for 
post- operative NP testing and thus had Z scores. The following Table 8.41 shows that there 
were weak but significant inverse correlations between the neutrophil count 10 minutes after 
CPB and the total and grooved pegboard (non dominant), non verbal memory test, and the 
trailmaking test A Z scores. 














CRTT R = -0.07 R = -0.09 R = -0.04 R = -0.02 R = -0.09 R = -0.07 
P = 0.42 P = 0.33 P = 0.68 P = 0.84 P = 0.29 P = 0.37 
GPD R = -0.07 R = 0.06 R = -0.03 R = -0.07 R = -0.04 R = -0.01 
P = 0.38 P = 0.48 P = 0.76 P = 0.42 P = 0.62 P = 0.91 
GPND R = -0.23 R = -0.11 R = -0.11 R = -0.20 R = -0.11 R = -0.08 
P=<0.01 P=0.23 P=0.23 P=0.02 P=0.18 P=0.36 
LCT R=-0.09 R=0.03 R=0.12 R=0.04 R=-0.06 R=-0.02 
P=0.26 P=0.78 P=0.15 P=0.64 P=0.46 P=0.65 
NVMT R=-0.09 R=-0.09 R=-0.02 R=-0.18 R=-0.04 R=-0.13 
P=0.26 P=0.28 P=0.79 P=0.04 P=0.63 P=0.14 
REY R=0.11 R=0.03 R=0.05 R=-0.01 R=-0.12 R=0.05 
P=0.19 P=0.72 P=0.54 P=0.17 P=0.19 P=0.14 
SDRT R = -0.09 R = -0.04 R = -0.02 R = -0.16 R = -0.13 R = 0.05 
P=0.31 P = 0.34 P = 0.32 P = 0.55 P = 0.13 P = 0.54 
TMTA R = -0.09 R = -0.01 R = -0.13 R = -0.17 R = -0.05 R = 0.00 
P = 0.27 P = 0.87 P = 0.13 P = 0.04 P = 0.52 P = 0.99 
TMTB R=0.09 R=-0.01 R=0.11 R=-0.05 R=-0.01 R=0.07 
P=0.23 P=0.91 P=0.19 P=0.54 P=0.88 P=0.39 
TOTAL R = -0.12 R = -0.03 R = -0.03 R = -0.18 R = -0.12 R = -0.03 
P=0.15 P=0.73 P=0.75 P=0.04 P=0.15 P=0.70 
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8.10.3 Lymphocyte Count 
Lymphocytes in all three groups began to fall during CPB and reached a low on post 
operative day one. There were no significant differences between the groups at any time 
point. 
Table 8.42 Mean peri -operative Ivmo hoc vte count for all three groups. 
Mean Lymphocyte count (SD) (x 103 /mm3) 
Time LD (n =78) Avecor (n =63) AV -6 (n =29) 
1 pre op 2.09 (0.78) 2.02 (0.71) 2.24 (0.98) 
2 pre CPB (at cannulation) 2.16 (1.00) 2.07 (0.77) 2.45 (1.04) 
3 on CPB (after 30 mins) 1.87(1.01) 1.93 (0.81) 2.17 (0.88) 
4 post CPB (10 mins) 1.79 (0.86) 1.74 (0.77) 1.90 (1.02) 
5 post op day 1 0.84 (0.39) 0.87 (0.54) 1.07 (0.57) 
6 post op day 2 1.17 (0.49) 1.12 (0.43) 1.18 (0.49) 
Using repeated measures ANOVA there were significant differences over time but not 
between groups at any time points. 
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8.10.4 Monocyte Count 
Monocyte count fell sharply in all groups while on cardiopulmonary bypass and then rose to 
higher than pre- operative levels by post- operative day one. 
Table 8.43 Mean eri- operative monocyte count for all three croups. 
Mean Monocyte count (SD) (x 103 /mm3) 
Time LD (n =78) Avecor (n =63) AV -6 (n =29) 
1 pre op 0.63 (0.19) 0.62 (0.18) 0.71 (0.53) 
2 pre CPB (at cannulation) 0.53 (0.19) 0.49 (0.19) 0.53 (0.17) 
3 on CPB (after 30 mins) 0.19 (0.21) 0.31 (0.18) 0.29 (0.16) 
4 post CPB (10 mins) 0.24 (0.21) 0.28 (0.16) 0.29 (0.16) 
5 post op day 1 0.85 (0.36) 0.94 (0.86) 0.95 (0.34) 
6 post op day 2 0.99 (0.45) 1.01 (0.41) 0.94 (0.29) 
Using repeated measures ANOVA there were no significant differences over time or between 
groups. 
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8.10.5 Eosinophil Count 
Table 8.44 Mean peri -operative eosinophil count for all three croups. 
Mean Eosinophil count (SD) (x 103 /mm3) 
Time LD (n =78) Avecor (n =63) AV -6 (n =29) 
1 pre op 0.23 (0.16) 0.22 (0.16) 0.34 (0.43) 
2 pre CPB (at cannulation) 0.19 (0.17) 0.19 (0.26) 0.21 (0.16) 
3 on CPB (after 30 mins) 0.09 (0.12) 0.13 (0.15) 0.12 (0.07) 
4 post CPB (10 mins) 0.08 (0.05) 0.18 (0.14) 0.11 (0.09) 
5 post op day 1 0.09 (0.02) 0.02 (0.03) 0.02 (0.05) 
6 post op day 2 0.07 (0.08) 0.09 (0.06) 0.08 (0.09) 
Using repeated measures ANOVA there were no significant differences over time or between 
groups. 
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8.10.6 Platelet Count 
The platelet count decreased steadily from pre- operative levels to a trough after CPB in all 
three filter groups. There was then a slight increase post -operatively but this did not reach 
pre- operative levels. 
Table 8.45 Mean peri- operative platelet count for all three groups. 
Mean Platelet count (SD) (x 103 /mm3) 
Time LD (n =78) Avecor (n =63) AV -6 (n =29) 
1 pre op 225 (59) 229 (50) 234(65) 
2 pre CPB (at cannulation) 172 (44) 177 (44) 190 (55) 
3 on CPB (after 30 mins) 129 (39) 142 (40) 139 (37) 
4 post CPB (10 mins) 110 (34) 121 (44) 117 (34) 
5 post op day 1 145 (44) 150 (46) 162 (45) 
6 post op day 2 140 (44) 149 (42) 151 (48) 
Using repeated measures ANOVA there were significant differences over time but not 
between groups at any time points. 
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Haemoglobin decreased steadily from pre- operative levels to a trough after CPB in all three 
filter groups. There was then a slight increase post -operatively but this did not reach pre- 
operative levels. There was no statistical differences between groups at any time point. 
Table 8.46 Mean Deri- operative haemoglobin levels for all three croups. 
Mean Haemoglobin (SD) (g /dl) 
Time LD (n =78) Avecor (n=63) AV -6 (n =29) 
1 pre op 14.3 (1.5) 14.3 (1.3) 14.2 (1.5) 
2 pre CPB (at cannulation) 10.6 (2.0) 10.9 (1.8) 10.9 (1.6) 
3 on CPB (after 30 mins) 8.2 (1.3) 8.3 (1.2) 8.5 (1.3) 
4 post CPB (l0 mins) 8.4 (1.1) 8.5 (1.1) 8.4 (1.5) 
5 post op day 1 9.7 (1.7) 9.6 (0.9) 9.5 (1.2) 
6 post op day 2 9.8 (1.2) 10.1 (1.0) 9.6 (0.8) 
Using repeated measures ANOVA there were significant differences over time but not 
between groups at any time points. 
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8.10.8 Serum Elastase 
Serum elastase was measured in the first 60 patients of the study and thus for the LD and 
Avecor groups only. Elastase rose in both groups on CPB and 10 minutes post CPB. 
However the rise was significantly greater in the LD group as shown in Table 8.47 and 
Figure 8.24. Elastase levels fell by post -operative day one but remained significantly 
elevated from pre- operative levels. There was no difference between the two groups by post- 
operative day one. 
Table 8.47 Mean peri -operative serum elastase levels. 
Mean Elastase (SD) (mcg /1) 
Time LD (n =26) Avecor (n =34) p (ANOVA) 
1 pre op 40.5 (49.4) 37.4 (62.6) 0.57 
2 pre CPB (at cannulation) 9.1 (23.6) 12.6 (31.1) 0.75 
3 on CPB (after 30 mins) 376.8 (263.3) 108.3 (133.1) 0.002 
4 post CPB (10 mins) 496.7 (283.2) 228.5 (154.8) 0.002 
5 post op day 1 103.6 (95.6) 87.9 (53.8) 0.62 
Using repeated measures ANOVA there were significant differences over time and between 
groups on CPB and 10 minutes after CPB. 
There appears to be a difference between the pre- operative and pre- bypass serum elastase 
levels. This was not statistically significant (p = 0.45 for the LD group and p = 0.62 for the 
Avecor group). 





ÿ 400 - 
ca 
E 300 - 







LD - Avecor 
pre op pre CPB (at 
cannulation) 
on CPB (after 30 
mins) 
Time Points 
post CPB (10 
mins) 
post op day 1 
157 
8.10.10 Serum S100b 
Serum S 100b was measured in the first 60 patients of the study and thus for the LD and 
Avecor groups only. Serum S100b was elevated only at 10 minutes post bypass in both 
groups. There was no difference between LD and Avecor groups in the rise seen. 
Table 8.48 Mean peri- operative serum S100b levels for Avecor and LD groups. 
Mean S100 (SD) (pg /l) 
Time LD (n =29) Avecor (n =31) 
1 pre op 0.04 (0) 0.04 (0) 
2 post CPB (10 mins) 0.31 (0.4) 0.29 (0.26) 
3 6 hours post op 0.04 (0) 0.04 (0) 
4 post op day 1 0.05 (0.01) 0.04 (0) 
5 post op day 2 0.04 (0) 0.04 (0) 
Using repeated measures ANOVA there were significant differences over time but not 
between groups at any time points. 


















8.10.9.1 Correlation between Serum S100b and microemboli on bypass and NP 
outcome 
Of the 60 patients who received S100b sampling, 43 also had intra- operative 
transcranial Doppler monitoring. 
No correlation between serum S100b and microemboli on bypass was seen: 
Table 8.49 Correlation (Spearman's) between Serum S100b and microemboli 
on bypass 
S100b (post CPB) 
Microemboli r = 0.08 
p = 0.69 
Of the 60 patients who received S100b sampling, 51 also returned for post- operative 
NP testing and thus had 6 week Z scores. 
No correlation between Serum S100b and Z scores was seen: 
Table 8.50 Correlation (Spearman's) between Serum S100b and Z scores at 6 
weeks post surge 
S100b (post CPB) 
CRTT r = 0.00 
p = 0.99 
GPD r = 0.23 
p = 0.14 
GPND r = 0.15 
p = 0.34 
LCT r=-0.16 
p = 0.30 
NVMT r = -0.12 
p = 0.32 
REY r = 0.27 
p = 0.08 
SDRT r = -0.22 
p=0.16 
TMTA r = 0.05 
p = 0.75 
TMTB r = -0.05 
p = 0.73 
TOTAL r = 0.12 
p = 0.43 
159 
8.11 Summary of statistical tests used 
The x2 test was used for all categorical data: 
Tables 8.3, 8.4, 8.5, 8.6, 8.10 
The Kolmagorov- Smirnoff test was used to test whether all continuous data was 
normally or not normally distributed. 
Normally distributed data was analysed using the t test to test for significant 
differences in means between groups at a single time point: 
Tables 8.4, 8.6, 8.7, 8.8, 8.9, 8.1 1, 8.12, 8.22 
Normally distributed data was analysed using repeated measures analysis of variance 
(ANOVA) to test for significant differences in means between groups at several time 
points: 
Tables 8.13, 8.23, 8.24, 8.25, 8.26, 8.27, 8.28, 8.29, 8.30, 8.31, 8.36, 8.39, 8.42, 8.43, 
8.44, 8.45, 8.46, 8.47, 8.48 
Non -normally distributed data was analysed using the Mann Whitney U test: 
Tables 8.11, 8.15, 8.18, 8.33, 8.35 
Correlation between normally and non -normally distributed data was analysed using 
Spearman's correlation coefficient: 
Tables 8.16, 8.17, 8.19, 8.20, 8.21, 8.37, 8.38, 8.40, 8.41, 8.49, 8.50 
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Chapter 9 
Discussion of Results 
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This study has shown that leucocyte depleting filters, when compared to standard arterial line 
filters, further reduce the number of microembolic events recorded by transcranial Doppler 
during CABG, and that neuropsychological test results suggest an accompanying degree of 
non statistically significant neuroprotection. The primary outcome measure of this study was 
neuropsychological performance at six weeks after surgery and this will be discussed first. 
The secondary outcomes such as the incidence of microemboli, serum S100b levels and their 
relationship to the neuropsychology results are then discussed individually in turn. Finally all 
the results are summarised and some conclusions are drawn. 
9.1 Neuropsychological Outcome 
It was decided at the outset of this study to analyse the neuropsychological data in two 
distinct ways: firstly to have a Z change score analysis as the primary NP outcome and to 
have conventional analysis of the incidence of deficit as the secondary outcome. Deficit was 
defined as a greater than 1 standard deviation deterioration in 2 or more tests. 
The most important finding of this study is that both methods of analysis show a consistent 
trend towards improved post- operative NP outcome with the use of the LD filter (Fig 8.1). 
The difference however was not statistically significant (p = 0.07). Therefore, although 
standard arterial line filters have previously been shown by Pugsley et alb to reduce the 
incidence of neuropsychological deficit compared to using no filter at all, the use of a 
leucocyte depleting filter does not appear to offer significant additional benefit. 
This study used two methods of NP analysis because deficit analysis, although previously 
widely used, is arbitrary and has a binary cut -off and is therefore less sensitive analysis than 
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Z change score8,42210. Z change score analysis is now an accepted method of 
analysis29,36,37,42,211 used by researchers in both Europe and the United States. Some recent 
studies have continued to use only incidence of deficit analysis34,80,212_2214 By using both 
methods in this study it is possible to demonstrate the difference in sensitivity between the 
two methods as well as using the deficit incidence to compare the results of this study to 
others. 
The incidence method showed minimal difference between the test and control groups in this 
study. However, when the Z change score was used further insight into the potential 
difference between test and control groups becomes apparent. In seven of the nine tests used 
there was a better improvement in the Z change score in the leucocyte depletion group (Fig 
8.1). Also the difference in the total Z change score only just failed to reach statistical 
significance using the 1 tailed t test (Table 8.9). Therefore, although there was no statistically 
significant difference, the Z change score analysis suggests that there is a trend towards an 
improvement in NP outcome with the LD filters compared to controls. The fact that this 
trend extends across almost all the tests in the battery suggests that this is a real effect that 
has not reached significance due to statistical under powering, rather than a chance finding. 
Use of the Z change scores therefore reveals that most patients learn and improve between 
repeat assessments. The difference between groups can be interpreted as better preservation 
of learning in the LD group. Van Dijk et al44 in their randomised controlled trial comparing 
NP outcome in patients having on -pump and off pump CABG also used both deficit and Z 
score analysis. Using a 20% decline in 20% (three of fifteen) of the NP tests used to define a 
deficit, Van Dijk et al found an incidence of deficit of 21% in the off -pump group and 29% 
in the on -pump group three months after surgery. This was not statistically significant using 
Fisher exact test. However the mean total Z change score was 0.19 in the off -pump group 
and 0.12 in the on -pump group, which was statistically significant using the Wilcoxon test. 
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The data of the present study therefore concur with the findings of Van Dijk et al in terms of 
comparing methods of analysis, as both studies show Z change score analysis to be more 
sensitive than deficit analysis. 
The incidence of deficits was low in this study compared to most other studies. As discussed 
in chapter one there are many real (patient) factors and also artefactual (differences in study 
design and analysis) factors which influence measured NP outcome and could explain the 
difference between this and other studies. Also the standard interventions in place in this 
study (such as alpha stat acid base balance) in addition to the test intervention may have 
contributed to the low incidence. This is especially relevant when comparing this study to 
older studies such as that of Pugsley et al8. There are a number of possible explanations for 
the difference in result between this study and Pugsley et al's. Pugsley et al found that four of 
49 filtered patients had deficits and 12 of 45 non -filtered patients had deficits. However the 
overall numbers of microemboli in Pugsley et al's study were much greater, probably as a 
result of the use of bubble oxygenators which produce more microemboli48 and pH stat acid 
base control which may increase cerebral blood flow and so microemboli delivery215 
Additionally, Pugsley et al's study was fundamentally different as it compared the use of 
filters to no filters rather than comparing different filters as the present study has done. 
The incidences of 5.6% in the LD group and 7.8% in the control group six weeks post 
surgery in the present study (Table 8.10) were much lower than most recently reported 
incidences for example by Lund et aí118, Nathan et al71, Zamvar et a180 and Van Dijk et aí44 
but similar to those reported by Kadoi et aí213. It is of note that the study of Kadoi et al is the 
most recently published and so the most contemporaneous to the present study. 
In a randomised controlled trial comparing off -pump and on -pump CABG, Lund et al''' 
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found incidences of cognitive decline of 29% in the off pump group and 35% in the on -pump 
group 3 months after surgery. In terms of the demographics of the sample in Lund et al's 
study the mean ages in their two groups were 62 and 64, similar to the mean age of the 
sample in this study (64.1). The male to female ratio and operation times were also similar 
even though the mean number of grafts per patient was lower (2.3 -2.5 in Lund et al vs. 2.8- 
2.9 in the present study). However, Lund et al included patients with diabetes or who had a 
history of previous stokes whereas such patients were excluded from the present study. Lund 
et al's study sample was therefore at a higher risk of poor neuropsychological outcome216 and 
this could explain the higher incidence of deficits. There were a few minor differences in 
study design and analysis between the present study and Lund et al's. He used a 
comprehensive battery of 12 tests but followed up patients slightly later at 3 months rather 
than six weeks. Also deficit was defined by Lund et al as a reduction of more than 20% in 
two or more tests rather than one standard deviation, although this would not be expected to 
give rise to any major difference. Lund et al do not state in their methods whether they used 
arterial line filters, the type of acid base balance employed or the levels of intra- operative 
blood pressure. All three of these factors can affect NP outcome8'62'83. A lack of arterial line 
filters, pH stat balance and low intra- operative blood pressure could possibly all have 
contributed to the higher incidence of cognitive decline reported by Lund et aí18. 
Nathan et al71 found incidences of deficit of 62% and 48% at one week post surgery in 
patients randomly allocate to normothermia or hypothermia at the time of rewarming on 
CPB. As previously discussed, the consensus14 recommends testing at three months once 
peri- operative issues have resolved. Patients in Nathan et al's study were slightly older, 
diabetics were included, and bypass and aortic cross clamp times were longer which might 
account for the higher incidences found. Also the method of NP analysis in which patients 
were defined as having a deficit if they had a decline from pre- operative testing of more than 
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0.5 standard deviation in one of three domain scores is likely to have classified a higher 
proportion of patients as having a deficit. Incidence of deficit is higher at one week after 
surgery with some recovery by 6 to 12 weeks5'37. Indeed, Nathan et al found some recovery 
by three months although details are not given ". 
Zamvar et a180 found incidences of deficit of 27% in the off -pump group and 63% in the on- 
pump group one week after surgery and 10% in the off -pump group and 40% in the on -pump 
group at 10 weeks after surgery. Zamvar et al's sample had similar demographic features to 
the sample in the present study and patients with previous strokes were excluded. No 
mention is made of diabetes. Also, the definition of deficit in Zamvar et al's study is the 
same as the present study and so it is difficult to explain the high incidence (40 %) of deficit 
at 10 weeks. Zamvar et aí80, like Lund et al18 make no mention of neuroprotective 
techniques such as alpha stat acid base control and arterial line filters leaving their absence as 
a possible explanation. However, one would expect alpha stat and the use of arterial line 
filters to be standard. Interestingly, both Lund et al and Zamvar et al were investigating off - 
pump surgery and therefore were likely to be off -pump enthusiasts, which may explain their 
lack of reporting or actual use of CPB neuroprotective techniques. Conversely, most 
controlled trials in which both groups receive cardiopulmonary bypass are more likely to 
report the use of such techniques43'213;217 A positive point, which could partially explain 
Zamvar et al's relatively high incidence of deficit, is the 100% follow up rate achieved in his 
study. There would have been no selective attrition of those with worse outcome in Zamvar 
et al's study. 
Although Van Dijk et aí44 did use neuroprotective techniques and a method of defining 
incidence of deficit comparable to the present study, they found incidences of NP deficit of 
21% and 29 %. The inclusion of patients with diabetes and a history of strokes may explain 
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the higher incidence in Van Dijk et al's study. 
Comparing the present study to that of Kadoi et aí213 (also only recently completed) in which 
incidences of 6% and 7% were found it is apparent that the design and conduct of the two 
studies was very similar. Kadoi et al were examining the effect of two different anaesthetic 
agents used during CPB and so both study groups had CABG carried out using 
normothermic CPB. Arterial line filters and alpha stat pH regulation were used and perfusion 
pressure was maintained between 50 and 80mmHg. Patients with diabetes or a history of 
stroke were excluded. A battery of six NP tests was used and a deficit was defined as 
deterioration by more than one SD at six months. Therefore taking Kadoi et al's results in 
addition to the results of this study it would seem that a low incidence of deficits using the 
method of the present study could be expected when the study sample is relatively fit and 
healthy and neuroprotective regimes employed. 
The incidence of NP deficits found post -operatively may be influenced by the follow -up rate 
of the study in question. It has previously been found that those patients who perform less 
well on the pre- operative tests are less likely to attend for post- operative follow -up3. 
Therefore unless 100% NP follow -up is achieved there remains the possibility that selective 
attrition leads to an underestimate of the deficit rate in the study sample. Relative to the 
range of follow up rates reported in the literature the follow up rate of 84% found in this 
study is unexceptional. Table 9.1 gives some examples of follow up rates reported from 
prospective randomised interventional studies similar to the present study carried out in the 
last 10 years. Many of the patients who took part in this study (approximately 50 %) were not 
local residents and had to travel distances of 50 to 80 miles from their home to attend the 
follow -up clinic. Although bringing patients back to their tertiary referral centre for follow - 
up was the normal practice of the study institution, the issue of travel may have influenced 
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the decision regarding those patients who were unwilling to return or were deemed too 
unwell to return. 
Table 9.1 Follow up rates. 
Author Year n (total) Age Weeks post -op Follow up rate 
Pugsley et a18 1994 105 55 8 95 
Murkin et a161 1995 316 61 8 85 
Patel et a162 1996 70 57 6 100* 
Mora et aí68 1996 99 63 6 87 
Regragui et aí69 1996 96 59 6 83 
Heyer et aí218 1997 99 64 6 26 
Arrowsmith et al42 1998 171 59 8 93 
Roach et al56 1 999 225 63 8 NR 
Grimm et al70 2000 144 62 12 NR 
Nathan et al71 2001 221 68 12 NR 
Van Dijk et aí44 2002 281 61 12 88 
Kong et aí43 2002 245 64 6 89 
Zamvar et a180 2002 60 63 10 100 
Lund et al18 2003 52 63 12 NR 
Taggart et a1217 2003 150 62 12 93 
Kadoi et a1213 2003 180 65 24 84 
*2 patients died peri- operatively and 2 extra patients were recruited to replace them, NR = 
not reported 
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Although not all studies have reported follow up rates those which do, do not analyse for peri- 
operative differences between those patients who did or did not return for follow up. In order to 
determine whether there might be some selective difference the peri- operative variables of these 
two groups of patients were analysed in this study. It was found that there were no differences in 
demographic data between the patients who did and did not return but that those who did not return 
had a greater number of microemboli on bypass (Table 8.11). However Table 8.12 shows that those 
who did not return had also performed significantly less well on two out of the nine pre -operative 
NP tests. There is evidence to suggest that poor pre- operative NP performance predicts a poor post- 
operative outcome41. The pre- operative differences in this study may mean that those who did not 
return were suffering more neuropsychological impairment than those who did. The incidences of 
5.6% and 7.8% found in this study may therefore reflect less than the true incidence of deficit. 
Initial power calculations for the present study were based on Z change scores from the previous 
study conducted at this institution. Therefore despite conservative statistical planning, it is possible 
that the trial ended up being underpowered. A power calculation based on the present study's 
findings and those of Kadoi et al for detecting a 20% reduction in incidence of 8% with 90% power 
at the 5% level, shows that approximately 3000 subjects would be needed. This would be a 
considerable undertaking. Kadoi et al recruited 180 patients -a similar number to the present study. 
In summary the present study, using the two methods of NP analysis discussed, has found a low 
incidence of NP deficits in comparison with most reported studies. Although the follow up rate at 
six weeks in this study was in accordance with other studies, the loss to NP follow up of 16% of 
patients may through selective attrition have led to an underestimation of the true incidence of 
deficit. The follow up rate was the same in test and control groups (Tble 8.3). The low incidence of 
deficits found may have led to under powering of the present study. The Z change score analysis did 
170 
not show a statistically significant difference between the leucocyte -depleted and control groups but 
suggests a real difference between the groups. 
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9.2 Transcranial Doppler Data - Microemboli and Middle Cerebral Artery Blood 
Velocity 
This study has shown that leucocyte -depleting filters reduce the number of microembolic 
events recorded by transcranial Doppler during CABG compared to standard arterial line 
filters. This remains true whether the control arterial line filter is auto- venting or has a vent 
line (Table 8.14). Although this study was originally designed to compare only two different 
types of arterial line filter (the leucocyte depleting and auto -venting LG -6 and the 
conventional 40µm Avecor), the inclusion of the Pall AV -6, which is conventional and also 
auto -venting as an additional control, allows comparison between the differential effects of 
auto -venting and leucocyte depletion. There is no difference in microemboli count between 
the two conventional filter groups (Table 8.14) indicating that auto -venting itself has no 
direct effect on microemboli count. This indicates that the reduction in microemboli in the 
LD group is due to the leucocyte -depleting element of the LG -6 filter rather than its auto - 
venting properties. Therefore, although no definite neuropsychological benefit has been 
proven in this study, LD filters do seem to be better than standard filters in terms of reducing 
"microembolic load ". 
Henrikson et al have shown that 20 and 40 µm arterial line filters reduce cerebral blood flow 
measured using xenon 133159. In the present study the cerebral artery blood velocity has been 
shown to be the same in all three groups (Figure 8.2) suggesting that a reduction in cerebral 
blood flow is not a mechanism by which these filters influence microemboli delivery. 
This study has not been able to determine how the leucocyte -depleting element achieves a 
reduction in the number of microemboli. Speculation on the mechanism of microemboli 
reduction is hampered because current technology cannot determine whether the LD filters 
172 
are reducing gaseous or particulate microemboli or both. It is unlikely that the LD filter is 
able to remove more gaseous microemboli as it is the screen filter, identical in both types of 
filter, which is designed to remove bubbles (as well as particles). The unwoven mesh of the 
LD filters is designed to adhere to leucocytes but it is possible that bubbles passing through 
the screen are somehow trapped downstream by the leucocyte depleting mesh. 
It would not be possible for any type of arterial line filter to reduce microemboli of 
atheromatous origin (although an intra- aortic filter could). These microemboli would arise 
downstream of the filter from the arterial walls and pass directly to the brain. If the LD filter 
is removing more particulate microemboli it may be simple physical adherence of leucocyte 
and other cellular aggregates to the non -woven mesh of the filter that is occurring. 
Alternatively, by filtering out the activated leucocytes from the circulation the number of 
leucocyte, platelet and fibrin aggregates, which form elsewhere138, may actually be reduced. 
This is speculative and further study would be needed to investigate these potential 
mechanisms. 
lipid microemboli which derive mainly from cardiotomy suction blood90 have been found in 
autopsy specimens of the brain219. However, Kincaid et al91 in a study performed on dogs 
found that although using a cell saver rather than cardiotomy suction reduced lipid 
microemboli, the use of standard arterial line filter (25µm or 401.4,m) or a leucocyte depleting 
filter (40µm) did not reduce lipid microemboli as determined by the number of small 
capillary and arterial dilatations (SCADs) found on cross section of the dogs' brains. More 
recently a study in humans by Kaza et aí92 has found that a 211Am filter was able to remove 
all lipid emboli detectable by red O stain in the blood. The conflicting results may be 
explained by the different methods of detecting microemboli both of which are different 
again from the method used in the present study. It remains possible that the LD filters in this 
study are somehow reducing lipid microemboli. Any role of the LD filters in reducing the 
inflammatory response to surgery will be discussed later. 
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This study has found a low overall number of microemboli detected in all groups (Figures 
8.3 and 8.4, Tables 8.14 and 8.15). Although there are three outliers in the Avecor and AV -6 
groups which had between 600 and 900, microemboli the majority (124/127 = 98 %) of 
patients had less than 250 microemboli and the median microemboli counts ranged from 15 
(LG -6 group) to 67 (AV6 group). To put the microemboli counts in this study in context of 
other recent studies Fearn et a1115 have found 57% of patients had more than 200 
microemboli during CPB, Taylor et a1220 found a median of 132 and Bowles et al "7 reported 
means of 1,766 +/- 2,455. The following Table 9.2 shows some recent studies which have 
measured microemboli. 
Table 9.2 Studies measuring microemboli 













Arrowsmith42 1998 171 59 81 No alpha 2 MHz 146 (med) 
198 (med) 
No 
Taylor220 1999 18 64 85 32µm ? 2MHz 132 ND 
(DWL) 
Fearn221 2001 70 60 73 40µm alpha 2MHz >200 in 57% Yes 
Neville23 2001 193 61 116 ? ? 5MHz 105 (med) No 
73 59 145 ? ? 479 (med) 
Bowles"' 2001 20 65 - - - Nicolet 27 ND 
20 66 40µm ? (? Freq) 1766 
Mullges108 2003 30 59 138 40µm alpha 2MHz 413 (med) No 
30 61 114 4011m alpha 2MHz 175 (med) 
Plochl64 2001 30 61 117 401Am alpha 2MHz 80' (med) ND 
31 63 110 4011m alpha 2MHz 96' (med) 
Lund118 2003 29 62 - - - DWL (? 16.3 (med) No 
23 64 ? ? freq) 90 (med) 
ND = not analysed, ? = not stated, - = not relevant, "these counts were for 15 minutes after 
cross clamp release only, med = median 
It is virtually impossible to compare microemboli counts between different studies in a 
meaningful way because of the various techniques used to measure them. As Table 9.2 
shows, the probe frequency of Doppler used varies and is not always reported. It is rarer still 
for the more precise settings of the Doppler probe to be reported. Although there are 
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consensus criteria for defining a microembolus on the Doppler trace there may be inter- 
observer variability in identifying microemboli between studies. 
The use of filters in all the patients of the present study may have contributed to the low 
microemboli counts. However the studies of Mullges et al108, Taylor et al220, Fearn et aí22' 
and Bowles et all" shown in the above table also all used 32µm to 44µm filters yet found far 
higher microemboli counts. Additional factors other than filters must therefore be 
contributing to the low microemboli counts in this study. The relatively short bypass and 
cross clamp times in the present study (Table 8.6) may have decreased microemboli counts. 
Other studies often report far longer bypass and cross clamp times64'°8 The use of cross 
clamp fibrillation (CCF) is a relatively unusual feature of this study. Although CCF is a 
common practice in the UK, most studies in the literature have used cardioplegic myocardial 
protection techniques which tend to be associated with longer bypass and cross clamp times. 
Although repeated cross clamping can theoretically increase microemboli production there is 
no reliable evidence that intermittent cross clamp fibrillation produces more microemboli 
than cardioplegic techniques. Indeed, it is possible that since intermittent cross clamping 
tends to result in shorter cross clamp and bypass times, total microemboli production could 
be less than with cardioplegia. The two methods have only ever been compared in one 
randomised study in terms of microemboli production or neuropsychological outcome. This 
study reported no difference but was underpowered64 222. An interesting future study would 
be to compare the effects of CCF and cardioplegia on microemboli production and NP 
outcome, and this is planned. 
Whatever the cause of the low overall numbers of microemboli, the effects of individual 
filters on microemboli counts in our study must be seen in the context of a low baseline 
count. In this study no correlation was found between age, cross clamp or bypass times and 
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microemboli counts (Table 8.17). Other investigators have found such correlations19,64,223 and 
it is possible that these correlations only become apparent when bypass and cross clamp 
times are longer. 
Most investigators using TCD report microemboli data but not cerebral blood velocity. One 
exception was Benaroia et aí224 who found no effect of cerebral blood velocity or type of 
arterial cannula used on the number of microemboli detected. This finding was confirmed in 
the present study with no correlation between cerebral blood velocity at any time point and 
microemboli count (Table 8.16). 
Although TCD is the best current method for assessing intra- operative microemboli it also 
has a number of limitations. Only about 90% of people have an adequate window in the 
temporal bone through which to isonate the middle cerebral artery. This anatomical fact and 
technical problems (as explained in the results chapter, the video recorder failed to record a 
picture for the first 35 patients) with trace recording meant that not all (127/192 = 66 %) 
patients in the present study received TCD monitoring. The right middle cerebral artery is 
only one of six arteries supplying the circle of Willis leading to the question of whether 
bilateral or unilateral middle cerebral artery detection should be used. Some investigators 
argue that a combined bilateral count is more accurate as it is closer to the total number of 
microemboli. However even this is likely to only be a proportionate estimate unless all 
arteries supplying the brain are monitored (not a realistic proposition). Moser et al1o6 
examined unilateral and bilateral monitoring in 29 patients and found only a 4% error 
between sides. This suggests that it does not matter whether the right or left middle cerebral 
artery is used for monitoring. Mullges et a1225, on the other hand, found a significant 
difference in microemboli counts between sides with either right or left having more 
microemboli varying for each individual patient. Wijman et al'°7 have shown that cerebral 
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microembolism occurs more frequently in the middle as compared to the anterior cerebral 
artery when TCD is used to detect microemboli. Other investigators use Doppler of the 
common carotid artery23 but this may detect microemboli which are destined for the extra 
cerebral circulation. Another limitation of TCD is its current inability to distinguish between 
gaseous and particulate microemboli, let alone the many potential types of particulate 
microemboli. Additionally the size of each embolus detected by TCD is not known. Size and 
substance of microemboli are likely to have considerable impact on their pathological effect 
and so a simple "microemboli count" as is currently available must be accepted as a fairly 
crude measure. New technology offers the possibility of identifying size and nature of 
microemboli and a future study should have the potential to determine which factors carry 
pathogenic influence. 
As previously discussed, the relationship between microemboli and neuropsychological 
outcome is complex. In this study the highly significant difference in microemboli counts 
between LD and non -LD filter groups did not lead to a significant difference in 
neuropsychological outcome. If a causative link between microemboli and cognitive deficits 
does exist, the low numbers of microemboli in all groups in our study may have masked this 
link (as well as leading to the low incidence of neuropsychological deficits in both groups). It 
is possible that the difference in microemboli explains the trend towards improved cognitive 
function in the LD group but it is equally possible that other factors such as inflammatory 
changes or alterations of brain perfusion are also important. In this study there was no 
correlation between microemboli count on bypass and Z change scores (Table 8.19). 
However when the study population was divided using a median split into those with more or 
less than 34 microemboli on bypass, there was a significantly higher ( "better ") total Z change 
score in the group with less than 34 microemboli (Figure 8.5). Although such a mean split 
was made arbitrarily the finding would suggest that microemboli do have an involvement in 
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cognitive decline. A recent study of 107 patients followed up at UCLH to five years after 
surgery has shown that the number of microemboli recorded during surgery predicts NP 
outcome at five years37. This study therefore may add weight to the theory that microemboli 
cause cerebral injury. However, as the authors of that study point out37, the number of 
microemboli may be a simple reflection of the cardiovascular disease process which itself 
contributes to NP decline over the study period. It is interesting to note that in the present 
study the patients who did not return for follow up testing (including those who had died) 
had a significantly higher number of intra- operative microemboli (Table 8.11). It is therefore 
possible that those who were unable to return had a worse NP outcome due to 
microembolism but because they did not return the relationship between NP outcome and 
microemboli was not revealed. 
Given the limitations of microemboli detection it is unsurprising to find no consensus in the 
literature regarding an association between microemboli and NP outcome. The crude 
microemboli counts used may not be representative of the true embolic load to the brain and 
the potential variation in size and substance and therefore pathological effect of the 
microemboli in each study probably accounts for the inconsistency of the relationship found 
between microemboli and NP outcome. 
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9.3 Haematological Measures 
9.3.1 White Cells 
In the present study leucocyte- depleting filters were not found to reduce the total white 
cell count (WCC) (Table 8.36) and the neutrophil count (Table 8.39) after 30 minutes on 
bypass or at subsequent time points. As far as the author is aware, this study is the largest 
to have measured these cells serially in a comparison of an LD filter to a standard arterial 
line filter. There has previously been conflicting data in the literature as to whether LD 
filters are able to cause a significant reduction in circulating white cells during 
cardiopulmonary bypass. 
Thurlow in 1995 used a simulated in vitro cardiopulmonary bypass circuit and showed a 
45% reduction in total white cells and a 70% reduction in neutrophils using a LG -6 filter 
compared to an AV6178. However a subsequent randomised study in 14 patients having 
CABG surgery again using a LG -6 filter and an AV6 found no intra- operative reduction 
in neutrophils157. Palanzo, in a randomised trial of 36 patients compared the LG -6 to a 
standard filter and found that the LG -6 significantly reduced the WCC immediately after, 
and at four and 24 hours post CPB167. Palanzo did not sample intra- operatively or report 
neutrophil counts. Mihaljevic161, Lust'56 and Hurst154 in clinical studies of 32, 50 and 24 
patients respectively found no difference in infra- operative or post- operative WCC or 
neutrophil count when the LG -6 was compared to a standard filter. These findings were 
confirmed by subsequent studies152;153;18O However two recent studies appear to 
contradict these studies. Ohto et al226 in 2000 randomised 26 patients to an LG -6 filter or 
a standard filter and found a significant reduction in neutrophils five minutes after 
commencing cardiopulmonary bypass. However, there was no difference at subsequent 
time points, which is when the previous studies had made measurements. The timing of 
sampling may therefore account for Ohto's unusual finding. Most recently Chen et aí'79 
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randomised 24 patients to an LG -6 filter or a control and they actually found a significant 
reduction in both WCC and neutrophils at 30 and 60 minutes into CPB. This suggests 
that the LG -6 may be effective for certain patients. Ohto et al's study was conducted in 
Japan and Chenet al's study was from Taiwan and it is possible that the filter is more 
effective in these populations although neither Ohto et al, Chenet et al or the author know 
of a theoretical mechanism to explain such a difference. 
The results of the present study, conducted on a predominantly Caucasian population 
with a larger sample size than any of the studies discussed (170 patients having serial 
WCC sampling), suggest that the LG -6 filter does not significantly reduce the WCC and 
neutrophil count 30 minutes into CPB. Unlike Palanzo167 and Chen179 but in accordance 
with most other studies there were no differences found at subsequent time points. The 
results of the present study therefore confirm previous findings that any effect of the 
filter on white cells in temporary. The common finding that the LG -6 does not actually 
reduce the total white cell count has been explained by the bone marrow rapidly 
replacing the activated neutrophils which had been filtered out157. This study suggests 
that at 30 minutes into CPB the LG -6 continues to be able to filter out the neutrophils 
released by the bone marrow. 
There is evidence179 that the LG -6 can reduce the CD1 lb count on neutrophils suggesting 
that it is the activated neutrophils which are being removed. Funds were not available for 
the present study to use the flow cytometry necessary to measure white cell markers, 
which would have shown whether activated neutrophils were being filtered 
preferentially. 
This study has found a direct correlation between neutrophil count at ten minutes after 
bypass and microemboli count on CPB (Table 8.41). A higher neutrophil count was 
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associated with more microemboli. This suggests that the microemboli may be causing 
an inflammatory reaction and so raising the neutrophils count. However as the LG -6 
filters have been found to simultaneously reduce WCC, neutrophils and microemboli and 
there may not be a direct causal link between the microemboli and neutrophil counts. It is 
possible therefore that the reduction in neutrophils and microemboli are two unrelated 
effects of the LG -6 filter. 
It is interesting that there was also a correlation between WCC and NP outcome (Table 
8.38). A high white cell count both pre- operatively and at ten minutes after bypass 
predict a poorer NP outcome. No studies, as far as the author is aware have previously 
found a relationship between inflammatory markers and NP outcome142. However, a 
significant positive correlation between stroke and raised WCC in cardiac surgery has 
been described227. 
9.3.2 Elastase 
A statistically significant elevation of elastase in the LG -6 group during and immediately 
after CPB compared to the Avecor group has been found in this study (Fig 8.25). 
Elastase was measured as a marker of inflammation. Since elastase is a proteolytic 
enzyme released by activated neutrophils this rise in elastase levels is somewhat 
paradoxical because the LG -6 filters reduced the circulating neutrophils during CPB. 
However, some but not all other studies have found a similar elevation in elastase. 
Palano et al found no difference in elastase levels when LG -6 and standard filters were 
compared' 67. At the end of bypass Mihaljevic et al161 found levels of elastase were 460 
mcg/L in the LG -6 group compared to 230mcg/L in the control group. These figures are 
very similar to those in our study- 497mcg/L in the LG -6 group and 229mcg/L in the 
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control group (Table 8.48). Mair et aí152 also found a greater rise in elastase in the LG -6 
group with similar figures. Although it can be used as a marker of neutrophil activation, 
in the case of leucocyte filtration it crucially gives no indication as to where the 
leucocytes have become activated. A raised elastase may reflect an increased release by 
those neutrophils trapped together in the filter rather than an increased activation of 
neutrophils in the patients' tissues. This hypothesis would require further study to test. It 
should also be pointed out that as elastase was only measured for the LG -6 and Avecor 
filters the auto -venting aspect of the LG -6 was not controlled. It is unlikely that venting 
rather than the LD aspect of the LG -6 is influencing elastase but this cannot be ruled out. 
9.3.3 Platelets and Haemoglobin 
This study confirms previous studies by showing that the LG -6 filter has no effect on 
haemoglobin or platelets peri- operatively. This study therefore provides no evidence that 
the LG -6 causes haemolysis or destruction of platelets. 
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9.4 S100b 
In this study we measured S 100b as a supplementary endpoint to further investigate is 
use as a marker of peri- operative cerebral injury. The evidence discussed in chapter 6 has 
no clear conclusion. There is conflicting evidence as to whether the rise in S 100b seen 
using the Sangtec assay reflects a true cerebral injury or is an epiphenomenon resulting 
from the Sangtec S 100b assay detecting mediastinally released Si 00a and S 100a0. The 
Sangtec validation data has never been published and its potential cross reactivity with 
S 100a and S 100a0 is problematic. 
In our study, using an ELISA assay not previously used in cardiac surgery, but which 
does have published validation data2o4;205, we found a post -operative elevation of S 100b 
at 10 minutes post bypass only (Table 8.49). There was no difference between the LD 
and conventional filter groups and there was no relationship between S100ó and either 
microemboli detected during bypass or neuropsychological outcome. Despite using 
cardiotomy suction in our study, the levels of S 100b detected were relatively low and 
comparable to levels found in studies in which no CPB or cell saving devices have been 
used. It is possible that our assay is more specific than the Sangtec assay and is only 
detecting cerebral S 100b rather than mediastinally released S 100b. 
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9.5 Strengths and weaknesses of the Study 
Choice of neuropsychological tests 
All the neuropsychological tests were delivered according to the clear standardised 
instructions detailed in the methods chapter. However any neuropsychological test battery 
used within the domain of cardiac surgery will always be a compromise given the 
limitations placed over time. The battery used in this study is one that is widely used by 
other centres and reported in a number of articles. However, the battery is limited in that it 
does not include all possible domains although the spread of domains is quite large in that 
it covers verbal and non -verbal memory, attention and concentration, speed of response and 
perceptuo -motor skills. The areas not covered in the battery are issues to do with executive 
function tests (e.g. the Wisconsin Card Sorting test) but these are limited in that they cannot 
be applied repeatedly in any domain as they centrally examine the ability to learn a rule. A 
further limitation of the battery is that two of the tests do not have a large battery of 
normative data from controls. These two tests, the choice reaction time test and the non- 
verbal memory test, have been specifically developed for this domain in order to capture 
certain types of responses that were not easily available on standardised and norm 
referenced tests. 
There are other groups that have selected to use other tests in the limited time available for 
this kind of research but it must be borne in mind that out of the approximately 1,500 tests 
easily available it would not be surprising for certain neuropsychologists to choose 
different tests. The tests chosen in this study are perhaps the most widely used and 
certainly concur with the recommendations made by the consensus statement for assessing 
neuropsychological changes following cardiac surgery14 
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Statistical Analysis of Neuropsychological Data 
There are a number of approaches to assessing cognitive change following 
cardiopulmonary bypass some of which have been discussed in the literature review. In 
particular the binary classification suffers from a number of inherent concerns regarding its 
sensitivity as well as the fact that it is conventionally defined. These two factors limit the 
ability of a binary classificatory system to be sensitive enough to the kinds of interventions 
performed in cardiac surgery in which neuropsychological outcomes are examined. The 
alternative is to use a continuous measure of performance. Here the standardised Z score 
used in this thesis has been widely applied in other studies44. The two measures have both 
been used in this thesis, albeit that it is recognised that the binary classificatory system is 
severely limited42' 44 
There are however alternative approaches that people have used but it was felt that in the 
design of the study that these suffer from a number of limitations. Some researchers5 have 
used a system in which they perform a principle component analysis of the scores that the 
tests produce in the particular sample that they are studying. Whilst this might seem a 
parsimonious approach to reduce the numbers of variables and provide factor scores it has 
its own limitations. It is unclear until the study has been conducted which tests and which 
scores will finally group together. The method of grouping them by means of principle 
component/factor analysis is a volatile technique and often the results and the weightings 
differ by sample. Because these factor groupings are not standardised and well recognised, 
comparisons to normative data are not easily made. Most of the studies that have been 
performed using this technique have used absolute performance preoperatively. It is clear 
that change scores and the sensitivity of change scores over time, could provide a radically 
different grouping to those that are using absolute scores prior to surgery. On balance it 
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was felt that in this study to use both the binary classification as a secondary outcome as 
this is widely used in the literature and the continuous measure which has been highly 
recommended by other researchers and now more commonly practiced. 
Some studies, particularly in non -cardiac surgery have used control groups in order to 
make comparisons. The real difficulties in finding control groups for this sample given that 
these individuals have significant coronary artery disease and MRI analysis has suggested 
that at least 80% of elective coronary artery bypass graft surgery have abnormalities in the 
brain. They may be particularly sensitive to some of the factors that occur in cardiac 
surgery and this might not be well represented in any control group. Furthermore, the 
appropriateness of either a surgical control group or alternatively a normal control group 
outside of surgery would not necessarily be particularly helpful in looking at this subset. 
Most importantly however, this was a comparative study not attempting to establish the 
absolute decline in performance of individuals undergoing cardiac surgery but to see 
whether a difference could be detected within the context of a randomised control trial of 
the use of two types of filter. 
Parsonnet 
When the author was designing this study the Parsonnet score209 was the most popular 
method of risk stratifying patients, that is: predicting their 30 day mortality from pre- 
operative characteristics. Although the Parsonnet score was developed in North America, it 
has been shown to be applicable to UK patients228'229. Bridgewater et al in 1998 stated "the 
Parsonnet score and preliminary version of the UK national scores seem to be the best 
available scores at present "229. However the Parsonnet score has also been shown to 
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overestimate mortality, especially in high risk patients230. The "Euroscore" was 
subsequently developed by Sam Nashef and better predicts mortality in the UK23 i "233. The 
Euroscore has become more popular due to its superiority and would therefore be the risk 
stratification method of choice in future studies. However the Parsonnet score was useful 
and available at the time of planning this study and was an acceptable method to use. 
Moreover, the purpose of using a risk stratification system in this study was to compare 
groups, not accurately predict mortality . 
Carotid bruit screening 
The method used in this study to screen for carotid artery stenoses was auscultation for 
carotid bruits. If a bruit was heard, the patient proceeded to have carotid artery Duplex 
scanning. Auscultation is a less sensitive method than Duplex scanning for detecting 
carotid stenoses and it is thus possible that patients with stenoses were missed and therefore 
included in the study. The method of the present study was the practice at the institution of 
the study and it was not possible to routinely screen all patients with Doppler scans of the 
carotid arteries before inclusion in the study. To have done so would, however, have been 
ideal. It should be stressed that the same criteria were applied to all three groups in this 
randomised controlled trial. Duplex scanning has a sensitivity of approximately 85% and a 
specificity of 90 %234 whereas others have found the sensitivity of auscultation was 56% 
and specificity was 91%235. 
Diabetics 
The present study only excluded insulin dependent diabetics. The effect on 
neuropsychological outcome of diabetes and blood sugar management in the peri- operative 
period is unknown. This study could be criticised if all diabetics or no diabetics were 
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excluded. There is no perfect study. 
Aspirin 
In this study all the patients from home stopped aspirin seven days before surgery. It was 
not possible to stop aspirin so far in advance in all the inpatients included in the study. This 
could have had an effect on platelet function and microemboli generation. 
AF/ warfarin 
Patients with AF were not excluded from this study. The effect of AF on microemboli 
generation is not known but Stanley et al in 200227 found that patients with AF had worse 
NP outcome. This was published three years after the present study was designed but it 
would have been useful, if not to exclude patients with AF, to record the number of patients 
in each group with AF. 
Neuropsychological testing 
As stated in the methods section, all pre- operative NP testing was performed by the same 
trained psychologist. If this psychologist was not available no patients were recruited pre- 
operatively. At the six week return visit, the patients had to have the tests done on this set 
day. It was very rare (6/162 = 3.7 %) for the post- operative testing to be done by a 
psychologist other than the one who had performed the pre- operative testing. When it did 
occur, it was unavoidable. 
Switching of control filters 
At the start of the study the potential difference between auto -venting and vent -line filters 
was not appreciated and so a leucocyte depleting auto vent filter was being compared with 
a conventional screen and vent -line filter. This is a potential flaw. Fortunately it was 
possible to include a more appropriate second control filter that was auto -venting as well as 
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having the conventional screen filter. The inclusion of this second control filter also had the 
positive aspect of enabling a comparison to be made between the effects of auto- venting 
versus vent -lines on microemboli. In fact, there was no difference between the vent -line 
and auto -venting filters in terms of microemboli count, although the study was not initially 
powered to test this hypothesis. Switching of the filters also led to an uneven distribution of 
recruitment such that 82 patients were recruited to the LD group, 73 to the AV group and 
37 to the AV -6 group (Table 8.3). 
Study population 
Potential differences between the at home patients and the inpatients were not analysed. 
Before drawing some conclusions it is worth commenting on the strengths and weaknesses of 
the study and discussing how this should limit interpretation. A prospective randomised trial is 
the most scientifically valid of the various types of clinical study. However such clinical trials 
have inherent limitations because, however rigorous the attempts are to standardise procedure, 
there will be events and variables beyond the investigators' control. For example, although we 
devised a standard protocol for anaesthesia it was necessary to leave some choices of 
anaesthetic drug usage to the anaesthetists' discretion. Approximately l0 anaesthetists were 
involved and they each had individual preferences for types and amounts of drugs used. It 
would not have been practical to have only one anaesthetist performing all the anaesthetics for 
the trial patients, although this would have been the ideal. Also there are limitations to the 
extent one can impose protocols on clinicians however willing they are to participate in trials. 
In this study, we believed it important to avoid the uncontrolled use of Propofol, which is a 
popular intravenous anaesthetic agent, because it may have neuroprotective effect. It was 
possible to incorporate this restriction into the trial protocol and achieve compliance from those 
anaesthetists who would ordinarily have used Propofol. Moreover, it is not known how 
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anaesthesia affects NP outcome and the only way the effect of surgery could be distinguished 
from the effect of anaesthesia would be to perform anaesthesia without surgery or surgery 
without anaesthesia, both of which would be unethical. Randomisation should deal with the 
uncontrollable variables if numbers are adequate and this has been the case in the present study. 
Power calculations showed that the reduction in the Z scores after cardiac surgery required 197 
patients, a relatively large sample size for a single centre prospective clinical study. In order to 
recruit these patients within a realistic time period it was necessary to recruit widely. We 
therefore recruited patients operated on by six different consultant surgeons whereas ideally 
this should have been kept to fewer. As with the anaesthetists, the surgeons had an agreed 
protocol and all used cross clamp fibrillation for myocardial protection. Other minor 
differences in operative procedure such as use of a side -biting clamp for cannulation could not 
be controlled, but were recorded and so available for analysis. At the beginning of the study 
there were three consultants working in the unit. By the end one had left, and a further three 
had joined. 
There were therefore some unavoidable limitations to this study. In addition, some aspects 
could be criticised. In an attempt to reduce confounding variables we did not recruit patients 
who had had previous cerebral injury, including previous CABG and patients with insulin 
dependent diabetes. We also excluded particularly elderly patients over the age of eighty as it 
was thought these would have been more difficult to follow up. However, it could be argued 
that although we were attempting to reduce variables outside our control, we were actually 
excluding the very patients who could potentially derive more benefit from neuroprotection. 
Excluding both these types of patient will have reduced further the expected incidence of 
deficit and will have reduced the statistical power of the study. The strict selection criteria may 
also mean that the present study is not representative of the whole CABG surgery population 
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and thus limit the ability to generalise from its results. The UK society database has shown that 
15 -20% of UK patients having CABG have diabetes10. 
The aim of randomisation is to have similar variability between groups. In this randomised 
controlled study we are able to demonstrate the similarity of test and control groups' pre- 
operative patient characteristics (Table 8.4). There was a trend towards a slightly younger age 
in the AV -6 group compared to the Avecor group (p = 0.07), but there were no statistically 
significant differences in demographic and preoperative characteristics of the three groups. 
The age and sex ratio was representative of the UK population reported in the National Adult 
Cardiac Surgical Database Report 2000 -200110 and mortality was as predicted using the 
Parsonnet score236. Intra- operatively, all groups had similar number of grafts performed and a 
corresponding similarity of cross clamp and bypass times. The proportion of patients who had 
left internal mammary artery grafts used was similar between groups meaning that all patients 
would have had a similar number of proximal aorto- coronary anastamoses (with attendant side 
biting clamp usage). The LG -6 group did have a lower incidence of aortic atheroma or 
calcification detectable by relatively crude methods (Table 8.6). However, analysis of both 
presence of atheroma/calcification and whether or not a side -biting clamp was used showed 
that neither had a statistically significant effect on microemboli production (Table 8.18). There 
was only a trend towards use of the side -biting clamp at cannulation leading to more 
microemboli. It is worth emphasising the benefits of full randomisation because many studies 
measuring microemboli have not been randomised, especially those testing the effect of a 
particular technique such as off pump surgery117 or epiaortic scanning and exclusive Y- 
grafting95. 
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9.6 Conclusions of Discussion 
The main findings of the present study have now been discussed and are summarised in Fig 9.1 
below:- 
Figure 9.1 Summary of Results Discussed 







Improved NP Outcome 
White Cell Count 
S100b 
Coloured results indicate results from randomised trial. Black results indicate secondary 
analysis. 
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The null hypotheses tested were: - 
1) There will be no significant difference in the neuropsychological outcome when leucocyte - 
depleting filters are used. 
2) There will be no significant difference in the microemboli count or inflammatory response 
when leucocyte- depleting filters are used. 
This study has found the first null hypothesis to be true. No significant difference in NP 
outcome was found when the LD filter group were compared to the standard filter group (Table 
8.9). Using both incidence of deficit and standardised Z change scores, this randomised 
controlled clinical trial of 192 patients has not found conclusive evidence of a neuroprotective 
effect of leucocyte depleting arterial line filters compared to standard arterial line filters. 
However in eight out of a battery of nine tests there was a non -significant trend towards 
improved neuropsychological outcome. The incidence of neuropsychological deficits was 
lower in the present study than in most studies previously reported. As discussed, this is 
probably the result of strict inclusion criteria in the present study. The study may thus have 
been underpowered despite adequate statistical planning. 
The second null hypothesis has been disproved because differences were found between the 
LD and standard filter groups for both microemboli and for the inflammatory response. 
This study has found that leucocyte- depleting filters reduce the number of microembolic events 
detected by transcranial Doppler in the right middle cerebral artery (Tables 8.14 and 8.15). 
There was no direct correlation of microemboli with NP outcome (Table 8.19), but using a 
median split patients with lower numbers of microemboli had a better neuropsychological 
outcome (Fig 8.5). This is therefore further indirect evidence that the LD filters, by reducing 
microemboli, can improve NP outcome. LD filtration had no effect upon cerebral blood flow 
velocity (Table 8.13) nor was there any correlation of cerebral blood flow velocity and 
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microemboli count (Table 8.16). Altering cerebral blood flow is not a mechanism by which the 
LD filters reduce microemboli. 
In terms of the inflammatory response to surgery and cardiopulmonary bypass, it remains 
unclear exactly what effect the LD filters have. The LD filter does not significantly reduce total 
white cell count (Fig 8.17) or neutrophil count (Fig 8.18). The present study has, however, 
found a correlation between increased white cell count and worse NP outcome (Table 8.38). 
There is also a positive correlation between neutrophil count post bypass and microemboli 
count (Table 8.40). The finding of the present study that LD filtration increases serum elastase 
is, as has been discussed, paradoxical. If, by filtering out activated white cells, the LD filters 
are reducing the inflammatory response, the one would expect serum elastase to be lower. It is 
possible that elastase continues to be released by activated neutrophils trapped in the LD filter. 
Elastase is probably not the best inflammatory marker to use in the presence of the LD filter 
because it is not possible to interpret the difference in inflammatory response found. Although 
the LD filter has been shown to have had no quantitative effect on the white cell and neutrophil 
counts, without measuring white cell activation markers it is not possible to determine what 
qualitative effect the filters had on white cells (i.e. it is not known whether the LD filters are 
reducing the proportion of activated white cells). 
This study has found no relationship between peri- operative S100b levels and microemboli 
count or neuropsychological outcome. This study therefore lends weight to the current 
consensus that S100b may not be as useful as a marker of cerebral injury as was once hoped. 
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9.7 Suggestions for Further Research 
Further study would be necessary to determine how much of the mechanism by which the 
leucocyte depleting filters reduce microemboli is mechanical and how much is inflammatory 
mediated. The measurement of white cell activation markers such as CBI 1b and CD18, which 
was not possible in the present study, would determine the qualitative effect of LD filters on 
the white cell population. Measuring additional inflammatory markers such as the interleukins 
or tumour necrosis factor would also give more information on how the LD filters influence the 
overall inflammatory response. 
Newer Doppler techniques may be able to determine whether LD filters differentially reduce 
gaseous or particulate microemboli or whether both are reduced in the same proportion. The 
relative pathogenicicity of particulate, gaseous and lipid microemboli is also yet to be 
determined. 
The low incidence of neuropsychological deficits in this study suggests that future studies will 
need to either have less strict inclusion criteria or have greater numbers of participants. The 
latter suggestion is less practical. Alternatively refinement of existing neuropsychological tests 
may be necessary to make them more sensitive. 
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Mr WB Pugsley 
The University College London Hospitals 
HOLMES SELLORS CARDIOTHORACIC UNIT 
The Middlesex Hospital 
Mortimer Street 
London WIN 8AA 
LEUCOCYTE DEPLETION TRIAL INFORMATION SHEET 
Principal Investigators 
Professor SP Newman Professor MG Harrison Mrs J Stygall Mr DC Whitaker 
Contact: Donald Whitaker, Holmes Sellors Dept of Cardiac Surgery, Middlesex Hospital 
- 0207 679 9419 
You are soon to have coronary artery bypass surgery performed at the Middlesex 
Hospital. In addition you are invited to take part in the following research study. 
Purpose of the Research 
Coronary artery bypass surgery usually involves the use of the heart-lung bypass 
machine which takes over the function of the heart and lungs during the procedure. It is 
known that a small proportion of patients may have subtle changes in memory, 
concentration and attention after such cardiac surgery. The cause of this is unknown. 
However, previous studies conducted at this hospital have shown that arterial line filters 
which filter the blood as it leaves the bypass machine to return to the patient can reduce 
the incidence of changes in memory and so these filters are now used routinely. A 
newer filter is now available which may in theory be superior at filtering the blood. The 
purpose of this study is to evaluate this new filter which, in addition to filtering out 
bubbles and particles which may arise in the blood, also filters out some of the white 
blood cells ( "leucocyte depleting filter "). 
What the Study Involves for You 
If you agree to take part in this study, you will be randomly allocated to receive either 
the standard filter or the leucocyte depleting filter. The doctors looking after you nor you 
will be able too know which filter is used. If you agree to take part in this study, we will 
ask you to have some tests of memory and concentration before your surgery and these 
will then be repeated when you return to clinic about six weeks after surgery. The tests 
are conducted in the hospital by a friendly psychologist and they take about one to one 
and a half hours. During surgery blood flow to your brain will be monitored using a 
Doppler probe. This probe uses ultrasound similar to the probes which are used to scan 
The University College London Hospitals 
HOLMES SELLORS CARDIOTHORACIC UNIT 
The Middlesex Hospital 
Mortimer Street 
London WIN 8AA 
LEUCOCYTE DEPLETION TRIAL INFORMATION SHEET 
pregnant women. The probe simply sits on the side of the head and is not harmful. Some 
extra blood tests will be performed before, during and after surgery at the same time that 
routine blood tests are taken. All other aspects of your medical care will be the same as 
if you were not in the study. 
What if You Do Not Wish to Take Part in the Study 
If you do not wish to take part in the study then you will be treated in the normal way 
and will receive the standard filter. You do not have to take part in the study if you do 
not wish to and you are free to withdraw from the study at any time. Although you will 
be asked to sign a consent form to give us permission to include you in the study this is 
not in any way binding. If you wish to withdraw from the study please inform one of the 
doctors looking after you. 
Benefits of the Study 
It is possible that there are benefits to the leucocyte filter however there is currently no 
information on this and this is why the study is being carried out. 
Risks of the Study 
We are not aware of any risks involved in taking part in this study. However they may 
exist and we will be monitoring any side effects. 
Confidentiality of Records 
Records of you details will be kept only by the study investigators and will be kept 
confidential. The results of the trial may be published but the identity of individuals will 
not be disclosed. 
Further Questions 
If you have any further questions after I have spoken to you, please contact me on the 
ward or on 0207 679 9122. 
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LEUCOCYTE DEPLETION TRIAL 
INDIVIDUAL 
CASE REPORT FORM 
LEUCOCYTE DEPLETION TRIAL 
An investigation into the use of leucocyte depletion during 
cardiopulmonary bypass; Do they reduce the 
neuropsychological deficit and the inflammatory response? 
Patient Initials Trial IN o 
Hospital No. Consultant 
Principal Investigators 
Mr WB Pugsley Professor SP Newman Professor MG Harrison Mrs J Stygall Mr DC Whitaker 
Middlesex Hospital Middlesex Hospital Middlesex Hospital Middlesex Hospital Middlesex Hospital 
Mortimer St Mortimer St Mortimer St Mortimer St Mortimer St 
London London London London London 
WIN 8AA WIN 8AA WIN 8AA WIN 8AA WIN 8AA 
(If found, please return to Donald Whitaker, Holmes Sellors Dept of Cardiac 
Surgery, Middlesex Hospital - 0207 679 9419) 
UCL HOSPITALS, MORTIMER STREET, LONDON W1 N 8AA 
1 
LEUCOCYTE DEPLETION TRIAL 
Index 2 
Informed Consent Form 3 
Assessment Dates 4 
Assessment 1 5 
Assessment 2 13 
Assessment 3 16 
Assessment 4 19 
UCL HOSPITALS, MORTIMER STREET, LONDON WIN 8AA 
2 
LEUCOCYTE DEPLETION TRIAL 
INFORMED CONSENT FORM 
An investigation into the use of leucocyte depletion during 
cardiopulmonary bypass; Do they reduce the 
neuropsychological deficit and the inflammatory response? 
Investigators: Mr Pugsley (Consultant Cardiothoracic Surgeon) 
Professor Newman (Professor of Psychiatry) 
Professor Harrison (Professor of Neurology) 
Mrs Stygall (Lecturer in Health Psychology) 
Mr Whitaker (Research Fellow In Cardiac Surgery) 
1) HAVE YOU READ THE INFORMATION SHEET ABOUT THIS STUDY? YES /NO 
2) HAVE YOU HAD AN OPPORTUNITY TO ASK QUESTIONS AND DISCUSS 
YES /NO 
3) HAVE YOUR QUESTIONS BEEN ANSWERED SATISFACTORILY? YES /NO 
4) HAVE YOU BEEN GIVEN ENOUGH INFORMATION ABOUT THIS STUDY? YES /NO 
5) I HAVE SPOKEN TO DR /MR ABOUT THIS STUDY YES /NO 
6) DO YOU UNDERSTAND THAT YOU ARE FREE TO WITHDRAW FROM 
THIS STUDY AT ANY TIME? YES /NO 
7) DO YOU AGREE TO TAKE PART IN THIS STUDY? YES /NO 
THIS STUDY? 
Doctors Declaration 




The nature and purpose of the study has been explained to me and I agree to 
participate 
Signed Date Time 
UCL HOSPITALS, MORTIMER STREET, LONDON W1 N 8AA 
3 
LEUCOCYTE DEPLETION TRIAL 
Assessment Dates 
Assessment 1 
Outpatient or Inpatient 
Prior to scheduled surgery 
date 












d d m m y y 
UCL HOSPITALS, MORTIMER STREET, LONDON W1 N 8A 
4 
LEUCOCYTE DEPLETION TRIAL 
Assessment 1 
Inpatient or Outpatient prior to surgery 
Inclusion and Exclusion criteria 
Informed Consent 
Demographic Data 
o General Medical History 
o CcTdiovascular History 
o oEmonnet Score 
GeD1 FS Clinical Exam 
o 1caurr orj sychological Testing 
o Mood as to, FBC 
11 and Es 
S100 
astase 
UCL HOSPITALS, MORTIMER STREET, LONDON W1 N 8A 
I 
LEUCOCYTE DEPLETION TRIAL 
INCLUSION CRITERIA 
1. Able to speak and read English 
2. Aged 80 or less 
3. Elective 1st time CABG 
4. No history of TIA or CVA 
5. No history of renal failure 
6. White cell count 3 -11 X 106 
7. Has signed the consent form 
8. Is not enrolled in another study 
YES NO 
NOTE 
IF ANY "NO" BOX IS TICKED, THE PATIENT IS NOT ELIGIBLE 
FOR THE STUDY 
Is the patient eligible for the study? 
YES 
If yes, 
Complete details of scheduled date of surgery and 
assessment dates at front of file. 
Inform Perfusionists 
Inform Anaesthetists ( theatre list) 
J Continue with demographics and medical exam. 
NO 
UCL HOSPITALS, MORTIMER STREET, LONDON W1 N 8AA 
6 
LEUCOCYTE DEPLETION TRIAL 
DEMOGRAPHICS 
Date of Birth 
Age 








a Sex male 
female 
o 
Years of Education 
(5 onwards) os 
Height (m) Weight 
(kg) 
BMI 
UCL HOSPITALS, MORTIMER STREET, LONDON WIN 8AA 
7 
LEUCOCYTE DEPLETION TRIAL 
GENERAL MEDICAL HISTORY 
Enter any significant medical /surgical history 
Tick if none 
DESCRIPTION DATE OF ONSET DATE CEASED 
MEDICATION DOSE 
UCL HOSPITALS, MORTIMER STREET, LONDON W1 N 8AA 
s 
LEUCOCYTE DEPLETION TRIAL 
PARSONNET SCORE 
Female 1 
Obesity (BMI > 30) 3 
Diabetes 3 
Hypertension (Systolic BP > 140mmHg) 3 
Ejection Fraction Good ( >50 %) 0 
Mod ( 30-49) 2 
Poor ( <30 %) 4 
Age 70 -74 7 
75 -79 12 
80 + 20 
Re- operation First 5 0 
Second 10 0 
Pre -operative IABP 2 
Left Ventricular Aneurysm 5 
Emergency Surgery 10 0 
Dialysis Dependency 10 0 
Catastrophic States 10 -50 0 
Other Rare Circumstances (eg severe asthma) 2 -10 
Valve Surgery N/A 0 
Total 
UCL HOSPITALS, MORTIMER STREET, LONDON W1 N 8AA 
9 
LEUCOCYTE DEPLETION TRIAL 
CARDIOVASCULAR HISTORY 
EVENT YES NO START DATE FINISH DATE 
Stable Angina 
grade: 
D D W P J I Y Y D D W W Y Y 
Unstable Angina 
grade: 
D D NMYYDDNMYY 
MMYY`DDMMYY Myocardial Infarction D D 
Dyspnoea 
grade: 
D D IV MYYDDIVMYY 
Angiogram D D NMYYDDNMYY 
Angioplasty or Stenting D D N M Y Y D D N M Y Y 
HYPERTENSION D D W R A Y Y D D I V I I M Y Y 
LVAneurysm D D NMYYDDNMYY 
Peripheral Vascular Disease D D W M Y Y D D I V N I Y 
Time of Angio months 
aao : 
Time on waiting list months 
? Working at present 
If Not working, due to 1)normal retirement pre- symptoms, 2)early retirement 
due to symptoms or 3)off sick due to symptoms 
Smoker Yes No Ex PACK YEARS D D N M Y Y D D N M Y Y 
EJECTION 
FRACTION 
Good ( >50 %) Moderate (30 -49 %) Poor ( <30 %) 
UCL HOSPITALS, MORTIMER STREET, LONDON W1 N 8AA 
10 
LEUCOCYTE DEPLETION TRIAL 
GENERAL PHYSICAL EXAM 
SYSTEM NORMAL ABNORMAL NOT KNOWN 
1. CARDIOVASCULAR 






DETAILS OF ABNORMALITIES FOUND 
SYSTEM NO. FINDINGS 
UCL HOSPITALS, MORTIMER STREET, LONDON W1N 8AA 
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LEUCOCYTE DEPLETION TRIAL 
Neuropsychological Tests 
NART 
Rey Auditory Verbal Learning Test 
Score 1: 2: 3: 4: 5: 6: 7: 
Trail Making Test A Trail Making Test B 
Time to Completion Time to Completion 
Grooved Pegboard Test 
Time to Completion, dominant hand 
Time to Completion, on- dominant hand 
Symbol Digits Modalities Test 
Total time Number correct answers 
Non -verbal Memory Test 
Number correct Time to completion 
Letter Cancellation Test 
Number of Intrusion Errors Made 
Number of targets missed Time to completion 
Choice Reaction Time Test 
A Accuracy A Time 
B Accuracy B Time 
Speilberger state Speilberger trait 
CESD 
UCL HOSPITALS, MORTIMER STREET, LONDON WIN 8AA 
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LEUCOCYTE DEPLETION TRIAL 
Assessment 2 
Inpatient - intra -operative 
Transcranial Doppler Data 
Blood tests 
Anaesthesia Protocol Check 
Intra -operative Vital Signs 
Record of Intra -operative Events 
UCL HOSPITALS, MORTIMER STREET, LONDON W1 N 8AA 
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LEUCOCYTE DEPLETION TRIAL 
START 






TRACE OBTAINED RIGHT Gmood  
poor 




DEPTH POWER GAIN 
TIME ACTUAL TIME MCA BLOOD VELOCITY 
Pre CPB (just before 
cannulation) 
Pre -CPB (immed prior to 
CPB) 
During CPB (15mins into 
CPB) 
Post -CPB (10mins after 
stopping) 
TIME MICROEMBOLI COUNT 
For 15mins after sternotomy 
During CPB 









S100 (3mIs) * 
Elastase (3mIs)** 
* LITH HEP TUBE ** Na CITRATE TUBE 
mis of blood needed 9 9 12 
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LEUCOCYTE DEPLETION TRIAL 
INTRA -OP VITAL SIGNS 












ON CPB OFF CPB 
CPB TIME 















CLINICAL SIGNS OF AORTIC NO 
ATHEROMA OR CALCIFICATION 
METHOD OF CANNULATION YES NO 
SIDE CLAMP OR NOT? 
TIME OF CANNULATION TIME OF DE- CANNULATION 
TEMPERATURE DATA 
MINIMUM TEMP MAXIMUM TEMP 
TIME OF START OF REWARM 
TIME TAKEN TO REACH 37 °C FROM MINIMUM 
UCL HOSPITALS, MORTIMER STREET, LONDON WIN 8AA 
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LEUCOCYTE DEPLETION TRIAL 
Assessment 3 
Inpatient - immediately post op until discharge 
o Cardiovascular and Respiratory Vital Signs 
o flood Loss 
o Adverse Events and Complications 
UCL HOSPITALS, MORTIMER STREET, LONDON W1 N 8AA 
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LEUCOCYTE DEPLETION TRIAL 













Pulse SBP DBP Resp 
Rate 
p02 02 SATS Fi02 Temp 
NOTROPES YES/NO 
idren / norad / dopamine / other DURATION (HRS) 
TIME OF EXTUBATION 
II:VIE TO EXTUBATION 
}IRS) 
UCL HOSPITALS, MORTIMER STREET, LONDON WIN 8AA 
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LEUCOCYTE DEPLETION TRIAL 
BLOOD LOSS 






TRANSFUSIONS (RCC) GIVEN 
DATE TIME DEPLETED OR NOT 
UCL HOSPITALS, MORTIMER STREET, LONDON WIN 8AA 
18 
LEUCOCYTE DEPLETION TRIAL 
Assessment 4 
Out -patient at 6 weeks 
Neuropsychological Tests 
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LEUCOCYTE DEPLETION TRIAL 
Neuropsychological Tests 
Rey Auditory Verbal Learning Test 
Score 1: 2: 3: 4: 5: 6: 7: 
Trail Making Test A Trail Making Test B 
Time to Completion Time to Completion 
Grooved Pegboard Test 
Time to Completion, dominant hand 
Time to Completion, non -dominant hand 
Symbol Digits Modalities Test 
Total time Number correct answers 
Non -verbal Memory Test 
Number correct Time to completion 
Letter Cancellation Test 
Number of Intrusion Errors Made 
Number of targets missed Time to completion 
Choice Reaction Time Test 
A Accuracy A Time 
B Accuracy B Time 
Speilberger state CESD 
UCL HOSPITALS, MORTIMER STREET, LONDON WIN 8AA 
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LEUCOCYTE DEPLETION TRIAL 
SUBJECTIVE COGNITION SCALE 
Since your operation are you: More No Change Less 
More or less alert and thinking more or less 
clearly 
Forgetting things, for example, things that 
have happened recently, where you put 
things or keeping appointments 
Have more or less minor accidents, for 
example dropping things, tripping 
Reacting more or less quickly to things that 
are said or done 
Having more or less difficulty in solving 
problems and learning new things 
Having more or less difficulty in making 
decisions 
Able to keep your attention to a task for 
more or less time 
Making more or less mistakes 
Having more or less difficulty in doing 
things which involve thought and 
concentration 
UCL HOSPITALS, MORTIMER STREET, LONDON W1N 8AA 
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The effect of leucocyte- depleting arterial line filters on cerebral 
microemboli and neuropsychological outcome following 
coronary artery bypass surgery's 
Donald C. Whitaker, Stanton P. Newman *, Jan Stygall, Chris Hope- Wynne, 
Michael J.G. Harrison, Robin K. Walesby 
Unit of Health Psychology, Centre for Behavioural and Social Sciences in Medicine, University College London. 
2nd Floor, Wolfson Building, 48 Riding House Street, London W1W 7EY, UK 
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Abstract 
Objective: A randomised clinical trial sought evidence as to whether leucocyte- depleting (LD) arterial line filters added a further degree of 
neuroprotection in patients undergoing elective coronary artery bypass graft (CABG) surgery. Methods: One hundred and ninety-two 
patients were randomised to the use of a Pall Leukoguard -6 LD filter or either an Avecor Affinity or Pall Autovent -6 control filter. Cerebral 
microemboli during surgery were recorded by transcranial Doppler (TCD) monitor over the right middle cerebral artery. Evidence of cerebral 
impairment was obtained by comparing patients' performance in a neuropsychological (NP) test battery (nine tests) administered 6 -8 weeks 
post- operatively with their pre -operative scores. Results: The groups proved well balanced in pre- operative variables. During 
cardiopulmonary bypass (CPB) the median number and range of microemboli was 15 (3 -180) in the LD group compared to 67 (5 -846) 
and 55 (2 -773) for the Avecor and AV6 groups, respectively (P < 0.0001). One hundred and sixty -two patients completed all the NP tests. 
The LD group showed better post -operative performance in all but one of the nine tests although the difference in a total change score just 
failed to reach significance (P = 0.07 one -tailed t- test). Conclusions: LD filtration during CABG reduced the number of cerebral 
microemboli recorded by TCD and showed a strong trend towards improving NP performance post -operatively. These findings suggest that 
the use of such filters in CABG surgery may offer increased neuroprotection. 
© 2003 Elsevier B.V. All rights reserved. 
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1. Introduction 
Diffuse cerebral injury leading to cognitive dysfunction 
remains a concern associated with coronary artery bypass 
graft (CABG) surgery. Defined by a reduction in test 
performance it affects approximately 20 -40% of patients 
followed up 2 -3 months after surgery [1]. Its cause is 
probably multi- factorial involving poor cerebral perfusion, 
inflammatory responses to surgery, and particularly cerebral 
microembolism, as detected by transcranial Doppler (TCD). 
Pugsley et al. [2] have demonstrated a correlation 
between the number of microemboli recorded during 
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surgery and the incidence of post- operative neuropsycholo- 
gical (NP) deficits. Clark [3] subsequently also found that 
patients with highest counts of emboli had the worst NP 
outcome. A study by Neville et al. [4] however found that 
more microemboli accompany valve surgery than CABG 
but without a comparable difference in cognitive outcome. 
The weight of evidence has been sufficient to lead to 
widespread use of arterial line filters especially as Pugsley's 
randomised study demonstrated both reduced microemboli, 
and improved NP performance when an arterial line filter 
was added to the cardiopulmonary bypass (CPB) circuit. 
More recently, the screen filter with an additional leucocyte - 
depleting (LD) element (the Pall Leukoguard -6 or LG -6 
filter) has been introduced following experimental studies in 
animals showing protection from inflammatory mediated 
damage to a number of organs after CPB [5]. In the clinical 
268 D.C. Whitaker et al. / European Journal of Cardio -thoracic Surgery 25 (2004) 267 -274 
situation there is some suggestive evidence of improved 
post -bypass pulmonary function in particular [6,7]. 
The purpose of this study was to test the effect of LD 
filters on intra- operative microembolic load to the brain and 
NP sequelae when compared with conventional arterial line 
filters. To this end we performed a randomised controlled 
clinical trial of patients undergoing elective CABG surgery. 
2. Materials and methods 
Between May 1999 and September 2001, 198 patients 
were prospectively randomised to three groups. The initial 
plan was to compare two filters namely the LG -6 as the test 
filter and our unit's routine arterial line filter, the Avecor 
Affinity as a control. Both have a 40 p.m screen polyester 
element and the LG -6 has an additional non -woven 
polyester mesh downstream of the screen which gives it 
its LD properties. However, the LG -6 is an autoventing filter 
which allows the LG -6 to vent air filtered by the screen 
directly to the atmosphere. In contrast, the Avecor filter 
vents any air back to the oxygenator through a closed vent 
line. From the midpoint of the trial we therefore used a 
second control filter, the Pall Autovent -6 (AV -6), which is 
autoventing in an identical manner to the test filter but has 
no LD element. 
Patients scheduled for elective CABG surgery in the 
department of cardiothoracic surgery at The Middlesex 
Hospital (University College London Hospitals NHS Trust) 
were invited to participate. We recruited patients of all six 
consultants from the elective waiting list and inpatients 
awaiting urgent surgery. Prior approval was obtained from 
the hospital ethics committee and all patients gave written 
informed consent before participation. The following 
patients were excluded from recruitment. 
Patients over 80 years or having re -do procedures 
were excluded as were any with a history of transient 
ischaemic attacks or strokes or if they had a cardiac 
arrest in the preceding month. All patients with carotid 
bruits were excluded. Patients with insulin -dependent 
diabetes mellitus, pre -operative renal failure (defined as 
creatinine > 150 mmolll) or a pre- operative leucocyte 
count outside the normal range of 3 -11 X 106 /mm3 were 
also excluded. 
Randomisation was achieved with sealed envelopes 
given to the perfusion department, whose staff then set up 
the bypass circuit using the appropriate filter. The 
perfusionists kept a record of the filter used for each patient 
and all other investigators were blinded to the patients' 
assignment. 
2.1. Surgical and anaesthetic technique 
Anaesthesia, surgical technique, CPB, control of blood 
pressure and perfusion pressure, control of pH and paCO2 all 
followed a set protocol. 
Pre- medication consisted of morphine (5 -10 mg) and 
hyoscine (0.3 -0.4 mg). Diazepam (5 -10 mg) or temaze- 
pam (10 -20 mg) was given according to the anaesthetist's 
preference. Intravenous midazolam was used during inser- 
tion of peripheral and central cannulae, as necessary. 
Induction was carried out with midazolam (2 -10 mg), 
fentanyl (0.5 -2.0 mg), pancuronium and or suxametho- 
nium. Maintenance was with nitrous oxide and oxygen and 
then isoflurane. 
All surgeons used the technique of intermittent cross 
clamp fibrillation for myocardial protection. 
The details of the CPB technique included crystalloid 
prime, non -pulsatile flow, using a flat membrane oxy- 
genator, a flow rate of 2.4 1/m2 per min at 37 °C reducing 
to 1.8 1/m2 per min at 32 °C. Perfusion pressure was 
maintained between 50 and 70 mmHg using phenyl - 
ephrine and phentolamine. paCO2 was maintained at 
5.3 kPa (alpha stat). 
Intra- operative TCD was used to record cerebral blood 
flow and monitor microembolic events. Records were taken 
from the right middle cerebral artery through the temporal 
window using a Nicolet EME Pioneer 4040 system and a 
2 MHz pulsed wave transducer secured by a headband. All 
subsequent measurements were made off -line, using 
international consensus criteria [8] and the second observer 
reviewed 10% of tapes to assess inter -rater reliability. 
Recordings of velocity were made 10 and 1 min before 
bypass, 15, 30 and 60 min into CPB and 10 min after 
discontinuing bypass. Microembolic events were counted 
throughout CPB and for 10 min after bypass. 
2.2. Blood tests 
EDTA blood samples for full blood count (haemoglobin, 
platelets, white cell count and differential) were taken 
(1) pre -operatively, (2) at cannulation, (3) after 30 min of 
CPB, (4) 10 min after coming off CPB, (5) first post- 
operative day and (6) second post- operative day. 
2.3. Neuropsychological assessments 
One psychologist administered the battery of nine NP 
tests. The assessments were conducted during the pre- 
operative week, usually on the day before, and 6 -8 weeks 
later during a routine clinic. On each occasion the patient 
was tested in the same quiet room. The test battery consisted 
of the Rey Auditory Verbal Learning Test, Trailmaking 
A and B, Grooved Pegboard (dominant and non -dominant), 
Symbol Digit Replacement Test, Non -verbal Memory, 
Letter Cancellation and Choice Reaction Time as previously 
described [9].The Center for Epidemiologic Studies 
Depression Scale (CES -D) [10] was used to assess 
depression and the Spielberger state and trait anxiety 
inventory (STAI) [11] was used to measure state anxiety 
on each occasion of NP testing and trait anxiety pre- 
operatively. 
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Table 1 
Clinical outcomes and attendance at follow -up 
All, n - 192 % LD, n = 82 % Av,n=73 % AV-6,n=37 % 
Dead 9 4.6 4 4.9 4 5.5 1 2.7 
CVA 2 1.1 0 0 2 2.7 0 0 
Medically unable to FU 11 5.7 5 6.1 4 5.5 2 5.4 
Unwilling to attend FU 8 4.2 2 2.4 4 5.5 2 5.4 
Completed 162 84.4 71 86.6 59 80.8 32 86.5 
Total 192 100 82 100 73 100 37 100 
LD, LG- 6leucocyte- depleting filter group; Av, Avecor conventional filter group; AV -6, AV -6 conventional filter group. There were no differences between 
groups (2- test). 
To make optimal use of the NP data each patients pre - 
and post -operative scores were compared to create a change 
score. Z scores were thus obtained for individual tests and 
for an overall score. (Z score was calculated as 
(X2 - Xt) /µSD1). A positive Z score indicates an improved 
performance and the higher the Z score the better the 
improvement, whereas a negative score indicates a 
deterioration. Differences were analysed between groups 
using the one -tailed t -test. 
In addition a secondary endpoint for neuropsychology 
was the proportion of patients showing a drop in score of 
1 SD from their pre -operative performance in two or more 
tests were compared (,ÿ). This is a conventional incidence 
analysis method but is relatively crude as it reduces a score 
to a binary outcome [1]. 
3. Results 
3.1. Recruitment 
One hundred and ninety -eight patients were recruited 
and randomised to one of the three groups. Six patients 
were removed from the study between the time of 
recruitment/randomisation and surgery either because 
their surgery was performed without CPB (4), because 
the protocol was broken by using Propofol (1) or because 
the patient was found to have carotid artery stenosis (1). Of 
those 192 who were randomised, completed pre- operative 
NP assessment and successfully completed theatre protocol 
162 (84%) returned for repeat NP assessment at 6 -8 
weeks. One hundred and twenty -seven received intra- 
operative TCD monitoring. There were no significant 
differences in patients lost to follow -up between the filter 
groups (Table 1). 
The demographic and operative details of all the 
randomised patients are shown in Table 2. The AV -6 
group had the lowest Parsonnet scores, which measures 
surgical risk profile, but neither this or any other difference 
was significant, and the groups proved well balanced. 
Fig. 1 shows the characteristic drop in neutrophil count 
during CPB and post- operative neutrophils in all three 
groups. The count was lowest 30 min into bypass. An 
ANOVA on the difference in count between the LG -6 group 
[2.54 (SD 1.46) X 109/1] and the AV -6 [3.26 (SD 
1.39) X 109/1] was not significant. 
The cerebral blood velocity data (Fig. 2) revealed the 
expected slight fall during bypass, and increase with 
rewarming and end of bypass. There were no significant 
differences between the different filter groups. 
Significantly fewer microemboli were detected in 
patients randomised to LD filters (Fig. 3). The median 
number and range of microemboli was 15 (3 -180) in the 
LD group compared to 67 (5 -846) and 55 (2 -773) for 
the Avecor and AV6 groups, respectively (P < 0.0001). 
There was no difference between the two control filters. 
Table 2 
Demographic and intra- operative data 
All (198) LD (82) Avecor (73) AV-6 (37) 
Age (years) 64.1 (8.7) 63.6 (8.7) 65.5 (8.3) 62.3 (9.1) 
Sex (% m:f) 86:14 84:16 89:11 81:19 
Body mass index (kg/m2) 27.8 (4.5) 27.9 (4.9) 27.6 (4.1) 28.1 (4.2) 
Parsonnet score 6.13 (5.6) 6.21 (5.9) 6.46 (5.5) 5.26 (4.9) 
Operation time (min) 169 (30.5) 166 (33.9) 172 (29.1) 171 (25.0) 
CPB time (min) 67.7 (19.1) 66.5 (22.1) 68.7 (17.0) 68.4 (15.5) 
Cross clamp time (min) 30.9 (9.2) 30.6 (10.1) 31.9 (8.9) 29.5 (7.0) 
Number of grafts 2.88 (0.7) 2.86 (0.7) 2.95 (0.7) 2.78 (0.6) 
Figures are expressed as means with SD in brackets. There were no significant differences found in demographic data between groups. Mann - Whitney 
U -test. 
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Fig. 1. Perioperative neutrophil count. Time points (1) pre- operatively, (2) 
at cannulation, (3) after 30 min of CPB, (4) 10 min after coming off CPB, 
(5) first post- operative day and (6) second post -operative day. ANOVA 
showed no statistically significant differences between groups at any time 
point. 
3.2. Neuropsychological outcome 
There were no differences in the pre -operative NP scores 
between the three groups. There were also no differences in 
CES -D or STAI scores pre- or post -operatively. Analysis of 
post -operative Z change scores showed no difference 
between the two control groups. These two groups were 
therefore merged to a single group to increase power of 
analysis. At 6 weeks post -surgery there was a trend towards 
greater improvement in NP performance expressed as Z 
scores in the LD group compared to the control group. The 
LD group showed better performance in all tests of the 
battery apart from the non -verbal memory test (see Fig. 4) 
The total Z score for the LD group was 1.55 (SD 2.71) 
compared to 0.84 (SD 2.70) in the control group (P = 0.07 
one -tailed t- test). 
Using the definition of a deficit as a decline by more than 
1 SD in two or more tests, there was an incidence of 7.8% 
(7/90) in the standard filter group and 5.6% (4/71) in the LD 
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Fig. 2. Middle cerebral artery blood velocity. Time points (1) 10 min pre - 
bypass, (2) 1 min pre -bypass, (3) 15 min into CPB when the patient has 
cooled to 32 °C, (4) 30 min into CPB, (5) 60 min into CPB, and (6) 
10 minutes after discontinuing CPB. ANOVA showed no statistically 
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Fig. 3. Microemboli counts on CPB for filter groups. See text for medians 
and range for each group. Mann -Whitney test: LG -6 vs. Avecor 
P < 0.0001, LG -6 vs. AV -6 P < 0.0001 and Avecor vs. AV -6 P = 0.79. 
group. This difference in incidence of 2.8% did not reach 
statistical significance (x2 = 0.18). 
As the LD filters significantly reduced microemboli but 
had a non -significant effect on NP outcome, the data were 
looked at within each group to detect any relationship 
between emboli counts and NP scores. The correlation 
coefficients ranged from 0.03 to 0.16 none being significant. 
Combining all three groups however showed that those with 
less than the median count of 35 microemboli had a higher Z 
change score than the others (Z = 1.98, SD 2.11 compared 
to Z = 0.74, SD 1.35, P < 0.005 one -tailed t- test). Using 
the median split is somewhat arbitrary but it suggests that a 
lower total microemboli count is associated with a better NP 
performance. 
4. Discussion 
This study has shown that LD filters further reduce the 
number of microembolic events recorded by TCD during 
CABG, and that NP test results strongly suggest an 
accompanying degree of neuroprotection. 
The study has the advantage of a randomised format with 
demonstrated matching of pre- and intra- operative par- 
ameters which can influence cerebral outcome (age, 
operation time, bypass time). Recent studies of new surgical 
techniques such as off -pump surgery [12] and epiaortic 
scanning with Y- grafting [ 13], for example have lacked this. 
Interpretation of the TCD records however must be 
circumspect. The monitoring of one vessel can only be a 
very incomplete measure of total cerebral embolic load 
although there is little difference between sides [14], and 
more emboli enter the middle cerebral artery than the 
anterior cerebral artery [15]. Also the consensus criteria for 
embolus detection are set on an arbitrary size limit which 
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Fig. 4. Neuropsychological outcome as mean Z score changes. 
may not reflect the most pathologically important dimen- 
sions. Furthermore the methodology current at the time of 
this study cannot distinguish between solid and gaseous 
particles. Histological study suggests many emboli which 
enter cerebral capillaries are lipid rich. Brooker [16] showed 
that such emboli were more common in dogs put on bypass 
when cardiotomy suction was used, and Kincaid [17) 
confirmed these results by reducing their number by 
processing the suction blood with a cell saver. Arterial 
line filtration, including leucocyte filters did not reduce the 
histological evidence of embolism however. This is of 
interest in the present context where leucocyte filters 
reduced the total number of microemboli. It is unlikely 
that the LD filter removed more gaseous microemboli as it is 
the screen filter in both types of filter that is designed to 
remove bubbles. However, it is theoretically possible that 
the LD mesh traps some bubbles that pass through the 
screen. Although repeated cross clamping can theoretically 
increase microemboli production there is no reliable 
evidence that intermittent cross clamp fibrillation produces 
more microemboli than cardioplegic techniques. Indeed, it 
is possible that since intermittent cross clamping tends to 
result in shorter cross clamp and bypass times, total 
microemboli production could be less than with cardio- 
plegia. The two methods have only ever been compared in 
one randomised study in terms of microemboli production 
or NP outcome. This study reported no difference but was 
underpowered [18]. 
The next question to consider is whether the reduction in 
microemboli seen with the LD filter can confer a reduction 
in NP deficit post -operatively. Although a number of 
studies have linked microemboli to NP outcome, 
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the relationship between the two remains unclear. Pugsley 
initially demonstrated a correlation between number of 
microemboli detected intra- operatively and incidence of 
post -operative NP deficits. In his study 8.6% of patients 
with microemboli counts < 200 had deficits compared to 
43% of those with counts > 1000. Four of 49 filtered 
patients had deficits and 12 of 45 non -filtered patients had 
deficits. However, the overall numbers of microemboli in 
Pugsley's study were much greater, probably as a result of 
the use of bubble oxygenators which produce more 
microemboli [19] and pH stat control which may increase 
cerebral blood flow and so microemboli delivery [20]. A 
later study by Clark [21] using alpha stat and membrane 
oxygenators divided patients into microemboli count of 
<30, 30 -60 and >60 and found that those with higher 
counts had worse NP outcome. Barbut [22] showed that 
perioperative stroke was associated with a higher micro - 
emboli count. Fearn et al. [23] found a weak but significant 
(r = 0.3, P< 0.01) correlation between emboli and 
memory loss in a group of 70 patients who had NP testing 
pre -operation and at 2 months post -operation. Neville et al. 
[24] seem to provide evidence to the contrary. In a non - 
randomised study, 193 patients having CABG were 
compared to 73 patients having valve replacement surgery. 
NP testing was performed pre -surgery and at 5 -7 days, 1 
and 6 months post- surgery and infra- operative left common 
carotid Doppler detection of microemboli was performed. 
Neville et al. confirmed previous findings that there were 
more microemboli detected during valve surgery but there 
was no difference found in NP outcome. Their result 
suggests that the number of microemboli may not always 
be the most significant determinant of NP outcome. 
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Fig. 5. Z scores for <34 and >34 microemboli. 
In our study it can be seen that the effect of the LD filter 
on NP outcome is less striking than the effect on 
microemboli. Fig. 4 shows that although there is a trend 
towards an improvement in NP outcome with the LD filters 
compared to controls, this does not reach statistical 
significance (P = 0.07). However, the fact that this trend 
extends across almost all the tests in the battery suggests 
that this is a real effect that has not reached significance due 
to statistical under powering, rather than an insignificant 
effect. Power calculation for this study using NP outcome 
were calculated and based on an estimated deficit incidence 
of 20%. This was based on current studies but turned out to 
be an overestimate as the incidence was found to be much 
lower. The incidence of deficits was 7.8% in the control 
group and 5.6% in the LD group. The low incidence may 
have been due both to improvements in operative, 
anaesthetic and perfusion techniques as well as strict 
inclusion criteria of this study. Excluding patients with 
insulin -dependent diabetes or a history of previous stoke or 
TIA will have reduced the risk of poor NP outcome in our 
study population. The finding that increased microemboli is 
associated with worse NP outcome (Fig. 5) suggests that at 
least some of the neuroprotective effect of the LD filters is 
due to a reduction in microemboli. 
Loss of patients to follow -up may also lead to an 
underestimate of the true deficit rate. If there is selective 
attrition of those patients with the worse deficits then the NP 
performance of those returning will be higher than that of 
the study population as a whole. As can be seen from Table 
1, the follow -up rate in our study was good (84 %) with no 
difference in follow -up rates or complication rates between 
filter groups. 
In conclusion, this study shows that LD filters are able to 
reduce the number of cerebral microemboli detected by 
TCD. However, due to the limitations of TCD, we do not 
know the type or size of the microemboli affected. 
Elucidation of the mechanisms by which the LD filters 
reduce microemboli will require further study. The 
reduction in microemboli associated with the LD filters 
has not been shown to lead to a statistically significant 
neuroprotective effect but the data show that all but one of 
the tests were in the direction of improved performance with 
the LD filter. It is likely that in the presence of low 
morbidity the study was underpowered despite recruiting 
198 patients. 
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Appendix A. Conference discussion 
Dr S. Hag! (Heidelberg, Germany): Are these two cohorts of patients 
compared really comparable in terms of bypass time and the severity of 
disease? 
Dr Whitaker: I didn't have time to show you that data, but there was no 
differences in preoperative and intraoperative data. And the cross -clamp 
time was approximately 30 minutes in each group, and the bypass time was 
approximately 60 minutes. 
Dr M. Grimm (Vienna, Austria): Could you identify specific subgroups, 
such as patients with diabetes or patients with a history of a cerebrovascular 
event, who benefit more than others from using such a filter? 
Dr Whitaker: That is certainly possible. In this study we excluded 
patients with diabetes or with previous strokes to reduce confounding 
variables in the study. But future studies should certainly include these 
patients to see if they receive greater benefit. 
Dr R. Bowser (Birmingham, United Kingdom): What was the group 
incidence in each group of neuropsychological deficit by a definition of 
20% reduction in 20% of the tests or by one standard deviation? What was 
the group incidence? 
Dr Whitaker: We used the 20% cutoff level. And it was 5.6 in the 
leukocyte -depleting group and 7.5. This did not reach statistical 
significance on chi -squared testing. So that's a low incidence. 
Dr S. Westaby (Oxford, United Kingdom): I know of at least one study 
currently that's looking at neuropsychological testing after cardiopulmo- 
nary bypass versus off -pump surgery versus interventional cardiology. And 
these comparisons are not demonstrating significant changes between these 
groups. You didn't demonstrate statistical significance with your filter or 
not. Given that off -pump work gives you the same element of 
neuropsychological dysfunction, and it's now appearing that catheter 
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techniques do too, could you comment on why you think you were going to 
find a difference in these patients. 
Dr Whitaker: We had two hypotheses, either by reducing the 
inflammatory response with these filters or reducing microemboli. We 
didn't find any difference in inflammatory response in this study. 
Dr P. Boonstra (Groningen, The Netherlands): How did you handle 
cardiotomy suction? Because a lot of microemboli are formed in that area. 
Can you comment on that? 
Dr Whitaker: We used routine cardiotomy suction. But I agree, it is an 
important factor 
Dr Boonstra: And didn't filter it? 
Dr Whitaker: No. Well, there was a routine 20- micron filter in the 
cardiotomy suction line, but this was not leukocyte- depleting filtration. It 
was standard filtration. 
Dr P. Punjabi (London, United Kingdom): According to you there are 
two theories: One was the mechanical theory and the other was the 
activated neutrophils theory. 
I suppose the mechanical theory you don't really need to have an 
activated leukocyte depletion, you can use any proper filter. 
As far as activation, what is your opinion about the pharmacological 
agents, especially as we are working quite a lot on aprotinin where we are 
hoping that we will be able to reduce the inflammatory response and that 
may have an effect on the neuropsychological outcome? 
Dr. Whitaker: There has been a lot of work using pharmacological 
agents over the last 10 years. And as far as I'm aware, there is no 
convincing evidence that any are beneficial. And that was part of the 
reason why we decided to use a physical method to try and reduce 
inflammation. 
Dr Punjabi: I think you're quite right. We are just in the process of 
starting a major study to look at that. 
Dr J. Svennevig (Oslo, Norway): Was the drop in the number of 
circulating leukocytes significant, or was it just transient? 
Dr Whitaker: We did detect a significant reduction in neutrophils at 30 
minutes on bypass. This was only between the leukocyte -depleting group 
and the Avecor group. There wasn't a difference between the leukocyte - 
depleting group and the other control group. 
Dr Svennevig: So in your opinion, the effect that you achieved, is that 
based more on, let's say, physical removal of particles, or do you think it 
has more to do with the inflammation therapy? 
Dr Whitaker: It's difficult to say from the information we have. We 
didn't measure activated neutrophils in this study; although other studies 
have shown a reduction in activated neutrophils with this filter. It's possible 
that we're filtering out activated neutrophils and then the bone marrow is 
replenishing them. And that's the explanation why these filters often don't 
reduce the overall number of neutrophils. 
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Role of the Author in This Study 
Under the supervision of Professor Newman and Professor Harrison, the author designed and 
implemented this study. The author wrote the study protocol and submitted this for ethical 
approval and research and development committee approval. During the design of the study 
the author liaised with Pall Biomedical who manufacture the LG -6 leucocyte -depleting filter 
and the clinical Perfusionists at the Middlesex Hospital. The bypass circuit is manufactured 
as a ready made circuit with the arterial line filters in place and so they had to be ordered and 
made. Discussion was carried out with the cardiothoracic surgeons whose patients were to be 
recruited into the study to ensure that they approved of the protocol. Several previous studies 
investigating various aspects of neuropsychological outcome in cardiac surgical patients had 
been carried out at the Middlesex hospital and so the surgeons were familiar with this type of 
study. The author made contact with the collaborating physicians Dr Green and Dr Mackie 
who carried out the S100b and neutrophil elastase assays. 
At the beginning of the project the author was employed as a part time (one day per week and 
one weekend per month) resident medical officer in a nearby private hospital so as to have a 
salary. The author therefore applied to a variety of sources for funding for the project. All 
applications were written by the author and submitted to The British Heart Foundation, The 
Royal College of Surgeons of Edinburgh, The British Medical Association, The Medical 
Research Council, The Welcome Institute, The Stroke Association (UK), The Jules Thorn 
Institute among others. Following the award of grants from The Royal College of Surgeons 
of Edinburgh, The British Medical Association and The Stroke Association (UK) the author 
worked on the project full time for two years. 
The author constructed the case report files (CRFs) for recoding the study data, designed the 
patient information sheet and once ethical approval was given, began recruiting patients. 
The author wrote to all patient scheduled for surgery informing them of the study, enclosing 
the information sheet. When patients arrived the day prior to surgery the author introduced 
himself and explained the study verbally. Patients were invited to ask questions and take part 
if they wished. The author consented all patients who agreed to participate and then 
introduced them to Mrs Stygall who was the psychologist performing the neuropsychological 
tests. At this stage the author made cups of tea or coffee as requested by the patients and Mrs 
Stygall. When a patient had been recruited it was necessary for the author to inform the 
perfusionists so that they could set up the bypass circuit, the anaesthetists so that they were 
prepared for the study anaesthetic protocol (and did not for example prepare Propofol). The 
author examined all patients and took the required pre- operative blood samples. 
On the day of surgery, the author recorded all data into the CRF, set up the transcranial 
Doppler machine as the patient left the anaesthetic room and entered theatre. This had to be 
done in the short period of time before the patient was prepped and draped for surgery. The 
author had to monitor the probe to ensure that it was not dislodged during recording and also 
take the intra- operative blood tests as described in Materials and Methods. All peri- operative 
blood samples were spun in the centrifuge by the author, decanted into small tubes and then 
placed in the freezer. The author then monitored the inpatient post- operative progress of all 
patients. When discharged, the author was responsible for coordinating the return outpatient 
visit with an appointment to see the psychologist. The author wrote to all patients again to 
confirm this and also phoned all patients himself to encourage attendance. 
The author recorded all the data from the CRFs onto a personal computer for the subsequent 
analysis. The author also reviewed all the transcranial Doppler tapes. With supervision, the 
author performed all the statistical analysis of the results and wrote this thesis. 
